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Abstract
Flt3 is the most recently discovered member of the platelet-derived growthfactor receptor (PDGFR) subfamily of receptor tyrosine kinases (RTKs).
It is expressed on early hematopoietic progenitor cells and is involved in their
growth. Activating mutations of Flt3, such as internal tandem duplica-
tions (ITD) in the juxtamembrane (JM) region of Flt3, are among the most
common genetic alterations found in patients with acute myeloid leukemia
(AML). For this reason Flt3 is an attractive target for specific tyrosine ki-
nase inhibitors, and a number of such compounds are currently being tested
in clinical trials. However, the mechanisms of Flt3-mediated signal trans-
duction are poorly understood.
Src family tyrosine kinases (SFKs) are involved in the signaling processes
of various RTKs, including those of the PDGFR subfamily . Most SFKs are
expressed predominantly or exclusively in hematopoietic cells, and at least
Hck and Lyn were found to be activated in AML patients. These observa-
tions indicate that SFKs could also be involved in Flt3 signaling. In this
work the role of SFKs in signal transduction of the Flt3 receptor was in-
vestigated. A panel of Hck and Flt3 mutants was used in biochemical and
biological assays to deduce the contribution of kinase activity, SH2 and SH3
binding domains and tyrosine phosphorylation status to Flt3-SFK interac-
tion.
The work presented shows that SFKs interfere with the maturation of
wild type and Flt3 ITD receptors in human embryonic kidney 293 (HEK-
293) cells in a kinase-dependent manner. The SFK-mediated effect on recep-
tor maturation is reflected by accumulation of the immature, intracellular
form of Flt3 at the expense of the mature, plasma membrane-inserted form
of the receptor. This effect of SFK kinase activity on receptor maturation is
not limited to Flt3, because analogous results were also obtained for the Kit
receptor, another member of the PDGFR subfamily. The demonstration of
the role of SFKs in regulation of receptor maturation is novel and the exact
mechanism underlying this effect requires further investigation.
XVI Abstract
Using the HEK-293 cells it was also shown that Hck is able to phospho-
rylate Flt3 on tyrosine residues and to associate with autophosphorylated
Flt3 in an SH2 domain-dependent manner. Hck-mediated tyrosine phos-
phorylation occurs in the JM region of Flt3. Tyrosine residues 589 and 591
in the JM region, when phosphorylated, were also identified as the dock-
ing sites for Hck. Although Hck phosphorylation and binding sites on Flt3
overlap, Hck-mediated phosphorylation of Flt3 is not sufficient for Flt3-Hck
association.
In contrast to the situation in HEK-293 cells, Hck neither interferes with
Flt3 maturation nor phosphorylates Flt3 on tyrosine residues, and does not
detectably associate with the Flt3 receptor in the hematopoietic murine cell
line 32D clone 3 (32D cl.3). However, the level of the ectopic expression of
Hck in 32D cl.3 cells was lower than in HEK-293 cells. This difference in
Hck expression level probably accounts for both the lack of the Hck-mediated
phosphorylation of Flt3 and the interference with its maturation in 32D cl.3
cells. The lower Hck expression level, however, does not account for the lack
of detectable association of Hck with Flt3 in 32D cl.3 cells. Using biological
assays in which activation of Flt3 can partially overcome the requirement
for cytokine stimulation in 32D cl.3 survival and proliferation, it was shown
that Hck is not involved in Flt3 signal transduction leading to Flt3-mediated
cell survival and Flt3 ITD-dependent cell growth. Therefore, biological rel-
evance of SFKs in Flt3 signaling remains unclear.
In summary, although the binding and phosphorylation of Flt3 by Hck
can be shown, the biological relevance of Hck in Flt3 signaling remains
to be formally demonstrated. This research led to the novel finding that,
at least when over-expressed or hyperactivated, SFKs interfere with the
maturation process of RTKs. Various studies have shown that the ligand-
independent activation of RTKs as well as their premature phosphorylation
can interfere with maturation of RTKs. This study reveals that, by virtue
of their phosphorylating of Flt3, Kit and possibly other RTKs, SFKs can
regulate maturation of these RTKs and consequently alter their transport
to the plasma membrane. Further studies are required to investigate the
biological relevance of this function of SFKs.
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2 Chapter 1. Introduction
1.1 Protein phoshorylation in signal transduction
The ability of cells to perceive and act upon a signal is essential for thedevelopment and functioning of multicellular organisms. Deregulation
of this process leads to abnormal activities of cells, which underly the de-
velopment of various diseases, including cancer and diabetes. Such deregu-
lations are often associated with mutations in genes encoding proteins that
are involved in signal transduction - a process during which an extracellular
signal is converted to an intracellular event, like onset of expression of spe-
cific genes, leading to cell growth, differentiation or apoptosis. One group
of signal transducing proteins includes protein kinases and phosphatases.
These enzymes regulate phosphorylation of proteins - a post-translational
modification that represents a key switch in the process of signal transduc-
tion.
1.2 Receptor tyrosine kinases (RTKs)
1.2.1 Diversity of RTKs
There are more than 520 protein kinases and 130 protein phosphatases en-
coded by the human genome [20]. Both types of proteins can be divided
into phospho-tyrosine or phospho-serine/threonine specific enzymes based
on their substrate amino acids. Receptor tyrosine kinases (RTKs) are trans-
membrane proteins which transduce an extracellular stimulus into an in-
tracellular signal, which is then further propagated intracellularly. RTKs
regulate almost all fundamental cellular processes including metabolism, di-
vision, differentiation, migration and death. There are currently 58 known
RTKs, which can be classified on the basis of their primary structure into 20
subfamilies (Figure 1.9). The structure of RTKs usually includes an intracel-
lular kinase domain, transmembrane domain and several immunoglobulin-
like domains, Cystein-rich domains, epidermal growth factor (EGF)-like do-
mains, fibronectin type III domains or other domains in the extracellular
part.
1.2.2 Regulation of RTKs
Regulation of RTK activity by dimerization
In normal resting cells the activity of RTKs is tightly controlled and only
a small fraction of active RTKs is present. This accounts for a basal level
of RTKs activity in non-stimulated cells. The active state of the receptor
is characterized by an ”open” conformation of an activation loop (A-loop),
which in most cases requires phosphorylation of one or more of its tyrosine
residues, usually achieved by trans-autophosphorylation. In the inactive
state of most RTKs, the A-loop assumes a so called ”closed” conforma-
tion, which prevents substrate binding. Stimulation by the ligand leads
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Figure 1.1: Family of human RTKs. The prototypic receptor for each family is indicated
above the receptor, and the known members are listed below. Abbreviations of the
prototypic receptors: EGFR, epidermal growth factor receptor; InsR, insulin recep-
tor; PDGFR, platelet-derived growth factor receptor; VEGFR; vascular endothelial
growth factor receptor; FGFR, fibroblast growth factor receptor; KLG/CCK, colon
carcinoma kinase; NGFR, nerve growth factor receptor; HGFR, hepatocyte growth
factor receptor, EphR, ephrin receptor; Axl, a Tyro3 PTK; TIE, tyrosine kinase
receptor in endothelial cells; RYK, receptor related to tyrosine kinases; DDR, dis-
coidin domain receptor; Ret, rearranged during transfection; ROS, RPTK expressed
in some epithelial cell types; LTK, leukocyte tyrosine kinase; ROR, receptor or-
phan; MuSK, muscle-specific kinase; LMR, Lemur. Other abbreviations: AB, acidic
box; CadhD, cadherin-like domain; CRD, cysteine-rich domain; DiscD, discoidin-like
domain; EGFD, epidermal growth factor-like domain; FNIII, fibronectin type III-
like domain; IgD, immunoglobulin-like domain; KrinD, kringle-like domain; LRD,
leucine-rich domain. The symbols α and β denote distinct RTK subunits. RPTK
members in bold and italic type are implicated in human malignancies. An asterisk
indicates that the member is devoid of intrinsic kinase activity. (Adopted from [20].)
to dimerization of the receptor subunits, which increases the local concen-
tration of the kinase domains. This in turn increases the probability of
trans-autophosphorylation and increases the fraction of the active recep-
tors (shown in Figure 1.2). Activated RTKs trans-autophosphorylate ad-
ditional tyrosine residues in the cytoplasmic domains, which serve as bind-
ing sites for Src homology 2 (SH2)- and phospho-tyrosine binding (PTB)
domain-containing signaling proteins [97]. The specificity of binding of SH2
domain-containing proteins is defined by 1-6 amino acids C-terminal of the
phospho-tyrosine residue [205], while PTB domain-containing proteins bind
to phospho-tyrosines in the context of 3-5 N-terminal amino acids [135].
Binding of these proteins to RTKs leads to the assembly of signaling com-
plexes containing multiple signal transduction molecules. Over-expression
of RTKs leads to their activation due to an increase in the concentration of
dimers and is often associated with cancer development [20].
Regulation of RTKs by autoinhibition
In the absence of ligand stimulation RTKs are kept in the inactive state by
various autoinhibitory mechanisms. Intracellular and extracellular regions
of the RTKs can participate in the negative regulation of RTK activity. For
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example, intramolecular interactions in the extracellular part of the EGFR
prevent high affinity binding of the EGFR to its ligand [197]. Another ex-
ample is fibroblast growth factor receptor (FGFR), which takes advantage
of intramolecular interactions in the extracellular domain to keep the re-
ceptor in the inactive state. In FGFR the extracellular acid box domain
binds to the D2 domain, which blocks D2 domains from binding heparin.
As FGFR requires binding of both ligand and heparin for its full activa-
tion, this intramolecular interaction prevents the receptor activation [197].
In addition to extracellular domains, different regions in the cytoplasmic
part of the receptors can have an autoinhibitory function (Figure 1.2). In
the endothelium-specific receptor tyrosine kinase, Tie2, the C-terminal tail
occludes the substrate binding site [201]. In other subfamilies of RTKs,
the JM region participates in auto-inhibition of the kinase activity, though
the mechanisms of autoinhibition vary among different receptor subfami-
lies. In Ephrin receptors, the JM region interacts with an αC helix in the
N lobe of the kinase stabilizing its inactive conformation [14], [235]. Re-
ceptors of the PDGFR subfamily are also negatively regulated by the JM
region. The mechanism of auto-inhibition for these receptors is described in
detail in 1.3.4. In all cases described above, auto-inhibited receptors exist
in an equilibrium with a small fraction of active receptors. Ligand binding
to the active receptors stabilizes the receptors in their active conformation
and thus shifts the equilibrium towards active receptors. Additionally, mu-
tations in the autoinhibitory regions and their modifications by intracellular
factors could relieve autoinhibitory constraints and increase the basal level
of receptor activity.
Regulation of RTKs by intracellular kinases and phosphatases
As described above, activation of RTKs results in phosphorylation of multi-
ple tyrosine residues in the intracellular part of the receptor. These phospho-
rylation events are required to achieve maximum catalytic activity, relieve
autoinhibitory constraints and to create binding sites for signal transduc-
tion molecules. In addition to autophosphorylation, some of these tyro-
sine residues can also be phosphorylated by intracellular kinases. On the
other hand, phoshatases can negatively regulate the activity of RTKs by
de-phosphorylating these tyrosine residues. As a result, treatment of cells
with tyrosine phosphatase inhibitors almost always leads to the activation
of RTKs [197], [55]. It is therefore likely that the balance of kinases and
phosphatases in the cell provides an additional level of control of RTKs
activity.
1.2.3 Activation of signaling cascades by RTKs
As described above, phosphorylation of RTKs on tyrosine residues, leads to
an increase in the catalytic activity of RTKs and generates binding sites for
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Figure 1.2: Activation of RTKs by dimerization and relief of autoinhibition. In the
resting cells, majority of the receptors are present in the inactive state in which
conformation of the A-loop (red) interfere with protein substrate binding and per-
haps ATP binding. However, in a subset of receptors, conformation of the A-loop
(green) is compatible with substrate binding. Ligand binding induces dimerization
of receptor subunits and increases the probability of trans-autophosphorylation of
the tyrosine residues in the A-loop, which stabilizes its active conformation. Au-
tophosphorylation on additional tyrosine residues relieves autoinhibitory constrains
and creates binding sites for downstream signaling proteins. (Adopted from [97].)
phospho-tyrosine-binding proteins. Binding of these proteins to an activated
RTK mediates an assembly and recruitment of signaling complexes which
participate in the signal transduction of an activated RTK [196].
A signaling programm initiated by RTKs involves a number of signal-
ing pathways whose general principle of regulation and functions are highly
conserved in evolution. The important rule is that these signaling path-
ways do not act separately in a linear fashion, but rather form a complex
network which takes positive and negative inputs and employs various feed-
back regulatory mechanisms. RTKs induce activation of signal transduction
molecules that trigger activation of the signaling pathways by three types
of mechanisms: membrane translocation, conformational changes and phos-
phorylation on tyrosine residues.
Signaling pathways activated by RTKs are shown in Figure 1.3. Major
signal transduction pathways activated by most RTKs include: Ras/Mitogen-
activated protein kinase (MAPK) pathway, phospholipase C (PLC)-γ and
Phosphatidylinositol 3-kinase (PI3-K) pathways and the signal transducers
and activators of transcription (STAT) pathway. Principles of activation of
these pathways are described below.
Ras/MAP Kinase signaling cascade
Activation of the small GTPase Ras in this pathway is achieved through
recruitment of its guanine-nucleotide exchange factor Sos to the membrane,
where Ras is located. Sos is recruited to the plasma membrane through its
association with the SH2 domain-containing adaptor protein Grb2, which
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binds to phosphorylated tyrosine residues on RTKs or other adaptor or
docking proteins in the signaling complex. Once in its GTP-bound active
state, Ras activates several effector molecules, including Raf, PI3-K and
Cdc42. Raf activates MAPK kinase (MAPKK/MEK) by phosphorylating
serine residues in the A-loop of the kinase. The activated dual specific Tyro-
sine, Serine/Threonine MAPKK then phosphorylates MAPK on threonine
and tyrosine residues in the A-loop leading to its activation. MAPK phos-
phorylates a number of cytoplasmic and membrane bound targets. It also
translocates to the nucleus where it phosphorylates and activates a number
of transcription factors.
Pathways regulating Phosphoinositol metabolism
Activation of PLC-γ and PI3-K pathways involves activation of phophoinos-
itol (PtdInst) metabolism and generation of second messengers. PLC-γ is re-
cruited to the plasma membrane through binding of its SH2 domain to phos-
phorylated tyrosine residues on some RTKs. Activated PLC-γ cleaves its
substrate PtdInst 4,5-biphosphate (PtdInst(4,5)P2) to generate two types of
second messengers: diacylglycerol (DG) and Inositol (Inst) 1,4,5-triphosphate
(Inst(1,4,5)P3 or IP3). The latter binds to Ca2+ channel proteins on the sur-
face of the endoplasmic reticulum (ER) and stimulates the release of Ca2+
from the ER into the cytoplasm. Calcium binds to Calmodulin, which acti-
vates a family of Ca2+/Calmodulin-sensitive kinases (CaMK). In addition,
together with DG, an elevated cytoplasmic Ca2+ level is required for activa-
tion of protein kinase C (PKC). So, through generation of second messengers,
activation of PLC-γ leads to stimulation of various intracellular responses
[98].
The PI3-K pathway is activated by binding of the SH2 domain of its
regulatory subunit p85 to phosphorylated tyrosine residues in the acti-
vated RTKs or adaptor proteins in the signaling complex. Activated PI3-K
phosphorylates PtdInst 4-phosphate (PtdInst(4)P) and PtdInst(4,5)P2 to
yield two kinds of membrane-bound second messengers: PtdInst(3,4)P2 and
PtdInst(3,4,5)P3, respectively. These second messengers attract signaling
proteins containing pleckstrin homology domains (PH) to the plasma mem-
brane, including PDK-1 and Akt (also known as Protein kinase B (PKB)).
PDK-1 phosphoryalates Akt on Thr 308 in the A-loop which is a prerequisite
for activation of Akt. Akt phosphorylates a variety of target proteins in-
cluding Forkhead transcription factors, Bad, S6-Kinase (S6-K) and glycogen
synthase kinase-3 (GSK-3). Phosphorylation of Forkhead transcription fac-
tors (e.g FKHR1) by Akt results in their cytoplasmic retention and inactiva-
tion, which blocks the expression of their target genes involved in the control
of the cell cycle, cell death and cell metabolism. Another substrate of Akt is
pro-apoptotic Bcl-2-related protein, BAD. Phosphorylation of BAD by Akt
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blocks its complex formation with with Bcl-2 and Bcl-xL thereby preventing
apoptotic cell death. PI3-K also induces activation of small GTPases Cdc42
and Rac1 via yet unknown mechanism [118], [230]. PI3-K activation (prob-
ably in a Rac1-dependent fashion) also stimulates generation of hydroxide
peroxide (H2O2), which is catalyzed by NADPH synthase enzyme complex.
H2O2 oxidizes active site cysteines in phosphatases, thereby inactivating
them. Inactivation of the phosphatases leads to sustained phosphorylation
of RTKs on tyrosine residues and their activation. Mutations in several
proteins in PI3-K pathway have been associated with the development of
cancers [225].
STAT-mediated signaling pathway
STAT transcription factors are activated by two types of receptors: those
that lack intrinsic tyrosine kinase activity, but are constitutively associated
with Janus kinases (JAKs) and by RTKs. Activation of STATs involves
their phosphorylation on a single tyrosine residue in the C-terminus. Once
phosphorylated, this tyrosine residue serves as a binding site for the SH2
domain of another STAT protein and induces formation of homo- or hetero-
dimers. Phosphorylation of STATs upon RTK activation can be achieved
directly or indirectly by intracellular tyrosine kinases. In the latter case,
SFKs have been suggested to play a role [163], [226]. Dimerized STAT
proteins translocate to the nucleus, where they bind to DNA and other
transcription factors and modulate transcription of target genes [45] which
results in growth related cellular responses.
Figure 1.3: Signaling pathways activated by RTKs. Different signaling pathways are pre-
sented as distinct signaling cassettes (colored boxes). In several cases the signaling
cassettes do not include all the known components of a given pathway. (Adopted
from [196])
.
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1.2.4 Attenuation and termination of RTK activation
As described in 1.2.2, de-phosphorylation of RTKs by tyrosine phosphatases
can negatively regulate the activity of RTKs. In addition, internalization
and degradation of RTKs represents an important mechanism of down-
regulation of RTK signaling.
Internalization and degradation of RTKs
Activated receptors are removed from the cell surface by endocytosis. Receptor-
mediated endocytosis occurs via clathrin-coated pits and vesicles [176]. Clathrin
polymerizes around the region of the membrane that contains a receptor tar-
geted for internalization. This membrane region then invaginates to form a
clathrin-coated pit and eventually pinches off in a form of a clathrin-coated
vesicle (CCV). Protein complexes called assembly particles (AP) are located
between clathrin and the membrane and determine whether membrane pro-
teins would be included into the CCVs. In addition to clathrin and proteins
in APs, many other proteins participate in endocytosis. For example, GT-
Pase dynamin self-assembles into rings or spirals to wrap around the necks
of the budding vesicles and is required for endocytosis [164]. Upon inter-
nalization, CCV shed clathrin and fuse with the internal vesicles to form
early endosomes, which maturate into late endosomes. Upon internalization,
RTKs are either recylced back to the plasma membrane or are internalized
by the late endosomes into the internal vesicles. The latter process results
in the formation of the multivesicular bodies (MVB), which eventually fuse
with lysosomes where RTKs are degraded. RTKs can activate signal trans-
duction pathways even after endocytosis, possibly through a different subset
of signaling molecules and a termination of RTKs signaling takes place only
upon incorporation of RTKs into MVBs and lysosomes [138].
1.2.5 Class III of RTKs
Genomics and structure
Class III of RTKs includes PDGFR α and β, Fms-like tyrosine kinase 3
receptor (Flt3), colony stimulation factor-1 receptor (CSF-1R) and the Kit
receptor.
The chromosomal location and genomic structure of these receptors sug-
gest their close evolutionary relationship and their origin from a common
ancestor gene by cis and trans duplication. C-kit and PDFRα genes are
located on chromosome 4q11-q13 [77], [70]. The PDGFRβ gene lies about
350 base pairs upstream of the major transcription site of c-fms gene, which
encodes the CSF-1R, on chromosome 5q31-q33 [76], [178]. The Flt3 gene is
located on chromosome 13q12 and is linked in head-to-tail fashion to Flt1,
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a class V receptor tyrosine kinase [186]. In addition, fragments of the genes
coding for intracellular parts of Kit, CSF-1R and Flt3 proteins, share the
same number of exons, which are highly conserved in size, sequence and
exon/intron boundary positions [2].
Members of class III of RTKs share a common structural organization
which is discussed in detail for Flt3 in 1.3.1 and shown in Figure 1.4.
Functions of RTKs of class III in normal and malignant hematopoiesis
RTKs of class III in normal hematopoiesis RTKs of class III are in-
volved in normal hematopoiesis and are associated with the pathogenesis
of hematological disorders [173]. CSF-1R is the receptor for macrophage
colony stimulating factor (M-CSF), which is essential for growth and differ-
entiation of the monocyte-macrophage-osteoclast lineage [200]. Flt3 and Kit
have partially overlapping, but distinct functions in the development of early
hematopoietic progenitor cells [127] and Kit has an additional function in
the development of germ cells and melanocytes, as well as of interstitial cells
of Cajal [30]. The role of Flt3 in normal hematopoiesis is described in more
detail in 1.3.6. PDGF also stimulates hematopoiesis, but unlike ligands of
the CSF-1R, Kit and Flt3 which act directly on hematopoietic cells, PDGF
activates stromal cells that express PDGFR [103]. Among these cells are
fibroblasts, smooth muscle cells, osteoblasts and macrophages that produce
a variety of growth factors which regulate the development of hematopoietic
progenitors.
RTKs of class III in leukemogenesis Consistent with their role in normal
hematopoiesis, deregulation of class III RTKs is associated with the devel-
opment of various types of hematopoietic malignancies. Point mutations in
the c-kit gene that lead to the activation of the tyrosine kinase activity of
the receptor are found in patients with mast cell disease, AML and NK/T
cell lymphomas [173]. PDGFR is often found as a translocation partner in
a number of fusion proteins expressed in patients with AML and chronic
myeloid leukemia (CML) [173]. In these fusion genes, PDGFR usually pro-
vides the kinase domain and the partner gene encodes a protein-protein
interacting domain which leads to constitutive dimerization and activation
of the PDGFR kinase activity. The role of mutations in the c-fms gene in
leukemogenesis is not clear. Even though some early studies have identi-
fied point mutations in patients with AML and Myelodysplastic syndrome
(MDS), further analysis was not able to confirm these findings [173]. Muta-
tions in the Flt3 gene are the most common genetic lesions in patients with
AML. The role of the Flt3 gene mutations in leukemogenesis is described in
more detail in 1.3.7.
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1.3 Flt3 and its ligand
1.3.1 Structure of the Flt3 receptor
The structure of the Flt3 receptor is characteristic of other RTKs of class III
and is shown schematically in Figure 1.4. The extracellular part of the Flt3
receptor contains five immunoglobulin (Ig) domains, and is heavily glycosy-
lated on asparagines (described in detail in 1.3.2). Ig domains are followed
by a single transmembrane (TM) domain, JM region, kinase domain, inter-
rupted by a kinase insert and C-terminal tail (C-tail).
TM JM Kinase domainIg domains C-tail
Figure 1.4: Domain structure of Flt3. Flt3 contains five Ig domains (light green), followed
by a TM domain (dark green), JM region (red), kinase domain (blue) interrupted
by a kinase insert (yellow) and C-tail (gray).
1.3.2 Maturation of Flt3 in the ER and Golgi complex
N-glycosylation of Flt3
Predicted molecular weight of Flt3 protein based on its primary sequence
is about 110 kDa. However, Western blot analysis of Flt3 results in the
two bands of 130-143 kDa and 155-160 kDa [131], [139]. Various studies
showed that the difference in the calculated and actual molecular weight of
Flt3 is due to its N-glycosylation. Treatment of immuno-precipitated Flt3
with tunicamycin, an agent that blocks the first step in the assembly of
core oligosaccharide and therefore inhibits synthesis of all N-linked glyco-
proteins, results in a disappearance of both forms of the receptor and in
the appearance of a new 110 kDa form [139]. Treatment of Flt3 immuno-
precipitates with endo H, a glycosydase which cleaves only high mannose
N-linked structures of glycoproteins, results in the reduction of the amount
of lower, but not higher molecular weight form of Flt3 [139]. In contrast,
no differences are observed when immuno-precipitates are treated with O-
glycosidase [139]. Pulse chase experiments show that the higher molecular
weight band arises from the lower molecular weight form [131]. In addition,
labeling of cell surface proteins with 125I detects only the higher molecular
weight form on the cell surface [131]. Together, these studies suggest that
the lower molecular weight form of Flt3 represents immature high mannose
form of the receptor, which is probably confined to ER or ER-Golgi transi-
tion, while the higher molecular weight form of Flt3 represents mature cell
1.3. Flt3 and its ligand 11
surface receptor which contains complex N-linked oligosaccharides.
Maturation of N-glycosylated proteins in the ER and Golgi complex
The maturation process of Flt3 has not been analyzed in detail. However,
Flt3 most likely undergoes classical maturation steps in the ER and Golgi
complex described in detail for other N-glycosylated proteins. The work
described in this thesis shows that SFKs interfere with the maturation of
Flt3. For this reason, detailed analysis of the maturation steps of a typical
N-glycosylated protein is presented below.
The presence of the hydrophobic stretches of amino acids at the N-
terminus (signal sequence) and in the middle of the polypeptide chain (trans-
membrane domain) ensures that the growing polypeptide is penetrating the
ER membrane co-translationally. The protein spans the ER membrane in
the same orientation it would have on the plasma membrane: the extracellu-
lar part is localized inside the ER lumen and the intracellular part is facing
the cytosol [231]. At the same time N-glycosylation of the extracellular part
of the growing polipeptide chain begins in the ER lumen. The first step
in N-glycosylation of proteins is an assembly of the 14-saccharide ”core”
unit on a dolicholphosphate carrier by the addition of sugars one by one.
The core oligosaccharide is then transferred en bloc to an asparagine residue
that is part of Asn-X-Ser/Thr consensus sequence and is coupled to its side
chain through an N-glycosidic bond. After coupling of the oligosaccharide
to the polypeptide, all three glucose and one specific mannose residues are
removed from the oligosaccharide by the action of glucosidases and mannosi-
dases, which are resident enzymes of the ER. Then the glycoprotein moves
to the Golgi complex, where further trimming and addition of sugars takes
place. Terminal glycosylation in Golgi prepares the proteins for their spe-
cific functions. A typical maturation pathway of N-glycosylated proteins is
shown on Figure 1.5.
In the ER, the most important function of N-glycosylation is the promo-
tion of folding of newly synthesized proteins [87]. N-glycosylation-assisted
folding of glycoproteins involves a unique chaperone system found in the ER,
the so-called calnexin-calreticulin cycle. Calnexin (CNX) and calreticulin
(CRT) are homologous ER lectins that bind specifically to monoglucosy-
lated core oligosaccharides on glycoproteins. CNX or CRT bind to another
folding factor thiol oxidoreductase ERp57. The complex of CNX or CRT
with ERp57 modulates protein folding by promoting the formation of disul-
phide bonds [92].
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Figure 1.5: Typical steps of protein N-glycosylation in the ER and Golgi complex.
Synthesis of the core olygosacharide takes place at the cytosolic face of the ER mem-
brane by an addition of sugars to a dolichylphosphate carrier. A partly assembled
oligosaccharide is flipped to the lumenal side of the membrane, where further sugars
are added to generate a complete core oligosacharide. The core oligosacharide is then
transfered to the asparagine residues of nascent, growing polypeptide chains. The
three glucoses and terminal mannoses are trimmed away in the ER. The ER also
contains a glucosyltransferase that can re-glucosylate glucose-free chains and thus
establish, with glucosidase II, a deglucosylation-reglucosylation cycle. When the gly-
coprotein has folded (gray oval) and reached the Golgi complex, further trimming
and terminal glycosylation occurs. Only one of many possible terminal glycosylation
pathways is shown.(Adopted from [88].)
Role of N-glycosylation of class III RTKs
The role of N-glycosylation in the function of Flt3 and other class III RTKs
is not clearly established. PDGFR is able to bind PDGF and is kinase active
in the absence of the N-glycosylation, suggesting that N-glycosylation per
se is not required for ligand-induced receptor activation [106]. Treatment of
cells transformed by v-fms (viral oncogene derived from cellular c-fms gene)
with the mannosidase inhibitor swaisonine, which results in the expression
of abnormally glycosylated v-fms protein on the surface of the cells, does not
interfere with their transformed phenotype [157]. In contrast, treatment of
these cells with two glucosidase inhibitors which block glycosylation of v-fms
protein at an early stage, prevents translocation of the oncogenic protein to
the plasma membrane and reverts v-fms-transformed cells to the normal
phenotype [157]. The latter results suggest that while proper glycosylation
is not necessary for v-fms oncogenic potential, its glycosylation is required
for membrane localization which is necessary for cellular transformation.
Presence of RTKs in the plasma membrane and their exposure to the lig-
ands is most likely required for ligand-dependent activation of RTKs. On the
other hand, hyperactivation due to the presence of mutations or overexpres-
sion of RTKs might result in the premature dimerization and/or activation
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of RTKs in the secretory pathway and subsequent activation of the intracel-
lular signaling processes. For example, premature auto-phosphorylation of
Flt3 in Flt3 ITD impairs its maturation [198].
1.3.3 Expression of Flt3 in hematopoietic cells
Flt3 expression in normal human bone marrow cells was analyzed by var-
ious groups either by staining of cells with specific antibodies generated
against the epitopes in the extracellular part of the receptor and subsequent
fluorescence-activated cell sorting (FACS) analysis [185] or by Northern blot
analysis of Flt3 mRNA [203]. Similar approaches were also applied to ana-
lyze Flt3 expression in murine bone marrow [82], [142], [50], [1].
Staining of human bone marrow cells with antibodies revealed that only
a small fraction of bone marrow cells (about 2%) are Flt3 positive [185].
Most of these positive cells represent early progenitor or stem cells [185].
However, the most primitive human hematopoietic stem cells do not express
Flt3 [185]. On the other hand, myeloid and B cell precursors in human bone
marrow are Flt3 positive [185]. A study of murine Flt3 also showed that
up-regulation of Flt3 expression is accompanied by a loss of self-renewal ca-
pacity of stem cells and that Flt3 positive cells have a prominent lymphoid
reconstitution potential [1]. Expression of Flt3 on human T cell progenitors
requires further analysis, but most of the studies in mice suggest that Flt3
is expressed on T cells and is required for their development [82], [1]. Flt3
expression in normal hematopoietic cells is summarized in Figure 1.6.
Analysis of Flt3 expression on human hematopoietic cell lines shows that
most myeloid, monocytic, pro-B and pre-B cell lines are Flt3 positive, while
erythroid, myeloma, NK and T cell lines are negative [185], [46], [27], [145].
1.3.4 Regulation of the kinase activity of Flt3 by the JM region
As described in 1.2.2, in the absence of ligand stimulation, RTKs are kept
inactive by a number of autoinhibitory mechanisms.
Various genetic and biochemical studies suggest that the JM region of
Flt3 could play an autoinhibitory role [156], [111], [110]. However, only the
determination of the crystal structure of the autoinhibited form of Flt3 con-
firmed this hypothesis and revealed the mechanism of autoinhibition of the
kinase activity by the juxtamembrane region [75].
The structure of the kinase domain of Flt3 in the inactive conforma-
tion is consistent with that of other Tyrosine and Serine/Threonine kinases
(shown in Figure 1.7). It consists of N and C lobes with an ATP binding site
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Figure 1.6: Expression of Flt3 in normal hematopoiesis Schematic view of maturation
and differentiation of hematopoietic cells and Flt3 expression on these cells (+, +/-
or -) is shown. Colony forming units for the erythroid (CFU-E), megakaryocytic
(CFU-MK), granulocytic-monocytic (CFU-GM), basophilic (CFU-B), granulocytic
(CFU-G), monocytic (CFU-M), and dendritic lineages are shown. NK cells are
natural killer cells; RBC, red blood cells. (Adopted from [212].)
being situated in the cleft between the lobes and the activation loop folded
between two lobes. The distinct feature of the Flt3 kinase domain structure
is the position of the JM region in a way that it interacts with almost all
key components of the kinase fold to inhibit an activation of the kinase.
The JM region of the Flt3 receptor comprises amino acids 572-603 and can
be divided into three topologically different regions from N- to C-terminus:
juxtamembrane binding motif (JM-B), juxtamembrane switch motif (JM-S)
and juxtamembrane zipper segment (JM-Z). 76% of the total area of the
JM-B binds to the cleft between the N and C lobes where it forms interac-
tions with key components of the kinase fold: glycine-rich P loop, activation
loop and αC helix. In contrast to JM-B, JM-S is not buried in the structure
of autoinhibited Flt3, but the side chains of Tyr 589 and Tyr 591 in this
segment are positioned between the backbone of JM-S and the C lobe of
the kinase. JM-Z folds alongside the N lobe and terminates in the JM hinge
region.
The phosphorylation status of Tyr 589 and Tyr 591 plays a key role
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[75]. Phosphorylation of one of these tyrosine residues is incompatible with
the positioning of their side chains between the backbone of JM-S and the
C-lobe and leads to dislocation of JM-B from its binding site within the cat-
alytic domain. This allows the conformational changes in the kinase domain
that are required for an activation of the kinase. In contrast, when Tyr 589
and Tyr 591 are de-phosphorylated and their side chains are positioned be-
tween JM-S backbone and C-lobe, JM-B fits snugly into its binding pocket,
preventing the kinase domain from assuming an active conformation.
(a) (b)
Figure 1.7: Structure of the autoinhibited Flt3. Surface diagram of Flt3 (a) shows the
structure of the kinase domain of Flt3 and its interaction with the juxtamembrane
region of the receptor. The Flt3 kinase domain consists of the N lobe (red), the C-
lobe (blue) and the activation loop (green), which is located in the cleft between two
lobes. The JM region is shown in yellow. The ribbon diagram of Flt3 (b) highlights
the interactions of the JM domain with the key components of the kinase domain:
A-loop, αC helix, and Glycin-rich loop. (Adopted from [75].)
1.3.5 Structure and expression of Flt3 ligand (FL)
Structure of FL
There are several isoforms of Flt3 ligand (FL) [82], [130], [129], [128], [127].
The most abundant isoform of FL in humans is a transmembrane protein.
Its N-terminal extracellular part contains four helical domains, a spacer re-
gion and a tether region. A single transmembrane domain is followed by a
small C-terminal tail. Transmembrane FL is biologically active on the cell
surface, however it can be cleaved by an unidentified protease to produce
a soluble form of FL. The functional differences of the soluble ligand and
transmembrane ligands are not known. Another isoform of FL arises from
alternative splicing. For example, alternative splicing of the sixth exon gen-
erates a premature stop codon near the end of the extracellular part and
therefore results in the soluble protein. This isoform is less abundant than
the transmembrane isoform, but is also biologically active. In mice, one
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more isoform of FL is known. It is produced by an alternative splicing of
FL mRNA, which results in a frame shift. The resulted protein lacks spacer
and tether regions and terminates in a stretch of hydrophobic amino acids,
that anchor the protein to the membrane. This isoform, though the most
abundant in mice, has not been found in humans.
FL contains two potential sites for N-glycosylation and is N-glycosylated
[127]. Preliminary data suggest that it exists as a non-covalently linked
homo-dimer [127]. The ligand dimer most likely binds to the dimeric form
of the receptor, which leads to the activation of the latter. However, the
exact mechanism of binding of FL to the Flt3 receptor is not known.
Expression profile of FL
Unlike the Flt3 receptor, whose expression is restricted to a small population
of hematopoietic cells, FL is expressed in most tissues except brain [129].
Since FL is only known to stimulate the Flt3 receptor, and FL is the only
known ligand for the Flt3 receptor, the pattern of receptor expression most
likely restricts the biological outcome of receptor-ligand interaction.
1.3.6 Biological function of Flt3 in normal hematopoiesis
Role of Flt3 in growth of primitive hematopoietic progenitors
Early hematopoietic progenitor cells require activation by multiple cytokines
to be recruited into the active cycling state [161]. Analysis of responsiveness
of primary leukemia cells and primitive hematopoietic progenitor cell to FL
have shown that FL acts synergistically with other cytokines to enhance
growth of human and murine primitive hematopoietic progenitor/stem cells
[131], [129], [69], [188], [143], [32]. In the absence of other cytokines, however,
FL stimulation leads to sustained viability, but does increase proliferation
of these cells [216], [224], [127].
Targeted disruption of Flt3 receptor and ligand in mice
The phenotype of Flt3 knock-out mice is in agreement with the suggested
function of Flt3 in the development of primitive hematopoietic progenitors.
Mice carrying a homozygous deletion of most of the gene encoding the Flt3
receptor are healthy animals with normal amounts of mature hematopoietic
cells in peripheral blood [132]. However, the numbers of early B cell progen-
itors in these animals are reduced as compared to normal mice. In addition,
stem cells isolated from Flt3 knock-out mice are deficient in their ability
to repopulate lymphoid and myeloid compartments when introduced into
lethally irradiated animals. Mice lacking FL also have reduced numbers of
early B-lymphoid progenitors [144]. However in contrast to Flt3 knock-out
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mice, these animals have a significant reduction of cells in peripheral blood,
spleen and bone marrow. The numbers of NK cells and dendritic cells (DC)
are also significantly reduced in FL-knock out mice. The reason for the
differences between phenotypes of the Flt3 receptor and ligand knock-out
animals is not clear. Mice strain variation and the depth of the analysis of
animals have been suggested as possible explanations [127].
Role of FL in the immune system
Reduced numbers of NK and DC in mice lacking the FL gene suggests that
FL has a specific function in the development of these cells. In agreement
with this assumption, different groups demonstrated that FL induces expan-
sion of functional mature DC [134], [133]. DC are the most efficient antigen
presenting cells (APS) for T-cells. For this reason, FL-mediated expansion
of DC was suggested for the use in the immunotherapy of cancer. Use of FL
in mouse models of various cancers demonstrated a therapeutic potential of
such an approach. FL treatment resulted in protection of mice from tumor
development and regression of tumor growth [40], [38]. Clinical trials in
humans employing immunization with cancer antigens and stimulation with
FL also showed positive results [62]. However, in other studies no significant
positive effect of FL could be shown and some treated patients developed
autoimmune responses [52].
1.3.7 Role of Flt3 in hematopoietic malignancies
A great interest in understanding the biology of Flt3 is prompted by the
finding that mutations in this gene as well as its over-expression are present
in a large group of patients with AML.
Flt3 internal tandem duplications (ITD)
There are two types of mutations in the Flt3 gene that are associated with
leukemia in humans and lead to constitutive activation of the kinase activity.
The most common type of Flt3 mutation is an internal tandem duplication
(ITD) [156], which is found in about 15-35% of patients with AML and 5-
10% of patients with MDS but not in healthy donors [212]. ITD mutations
result from duplications of a fragment of the JM region of the Flt3 receptor
and its direct insertion in a head-to-tail fashion without a shift in the reading
frame. The length of a duplicated fragment varies from 3 to 400 base pairs
and in some cases insertions of a nucleotide sequence of unknown origin
have also been detected [111]. One mechanism of kinase activation by an
ITD-type mutation could be the dislocation of the JM-B segment of the JM
region from its binding site, which relieves an auto-inhibitory constraint on
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kinase activity [75]. This results in a constitutively elevated kinase activity
of the receptor in the absence of ligand stimulation.
Flt3 tyrosine kinase domain mutations
The second type of Flt3 mutations found in AML patients includes missense
mutations in the tyrosine kinase domain (TKD). TKD mutations occur in
5-10% of patients with AML, 2-5% of patients with MDS and in 1-3% of
patients with acute lymphoblastic leukemia [212]. The most common mu-
tation of this type is substitution of aspartic acid at the position 835 by
tyrosine (D835Y), although other mutations of this codon have also been
described [238]. Aspartic acid 835 is located in the activation loop of the
Flt3 kinase domain and is highly conserved among RTKs. Substitutions of
the corresponding aspartic acid in Kit (D816) were also found in AML and
mast cell leukemia [12], [22].
Relevance of Flt3 mutations to leukemogenesis
Expression of Flt3 containing ITD or TKD mutations leads to transforma-
tion of hematopoietic cell lines characterized by factor-independent growth
[147], [86], [61]. Moreover, Flt3 ITD induces a myeloproliferative disease in a
murine bone marrow transplant model [108]. However, presence of Flt3 ITD
alone is not sufficient to cause leukemia in mice, suggesting that additional
mutations are required [108]. In support of this hypothesis, it was shown
that Flt3 ITD cooperates with PML-RARα (a protein that results from an
aberrant fusion of retinoic acid receptor α and promyelocytic leukemia pro-
tein) in the mouse model system to induce a short latency APL-like disease
[107]. In patients, Flt3 ITD mutations are also often found in conjunction
with other genetic abnormalities, such as translocations that include genes
for transcription factors [71]. Based on these data, the ”two-hit” model of
leukemogenesis is favored by many researchers in the field [71]. According
to this model, two classes of mutations cooperate in the development of
AML: mutations of the first class (e.g Flt3 ITD or TKD, N- or K-Ras mu-
tations) confer proliferative advantage to the cells, while mutations of the
second class (e.g PML-RARα, AML/ETO, MLL fusions) impair differenti-
ation and apoptosis. The presence of at least one mutation from each class
is required for the development of AML.
1.3.8 Flt3-mediated signal transduction
Studies of Flt3-mediated signaling using a chimeric receptor
Before the cloning of FL, signal transduction studies of the Flt3 receptor
were done using a chimeric receptor, which consists of the extracellular part
of the CSF-1R and transmembrane and intracellular parts of murine Flt3
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[139], [187], [13], [53]. The chimeric receptor was introduced into Rat-2, NIH-
3T3 or Baf/3 cells and CSF-1. It was shown that stimulation with CSF-1
induces an increase in phosphorylation of the mature form of the receptor
and enhanced the kinase activity of the receptor [187]. Upon stimulation
with CSF-1, phosphorylation of a number of signal transducing molecules on
tyrosine residues was induced. These molecules include proteins involved in
the Ras signaling pathway: Ras GTPase activating protein (Ras GAP) and
adaptor protein Shc and Vav, as well as proteins involved in phospholipid
metabolism: PLCγ and PI3-K. It was also shown that SH2 domains derived
from p85, Ras GAP, PLCγ and Grb-2, but not Vav or Nck can bind to the
chimeric receptor [187], [53]. The PI3-K binding site on Flt3 was mapped
to Tyr 958. However, mutation of the PI3-K binding site showed that it is
not required for mitogenesis or internalization of the chimeric receptor [13].
A slight increase in phosphorylation of Src, but not Fyn was also detected
upon CSF-1 stimulation. Additionally, both SFKs were also detected in
immuno-precipitates of the chimeric receptor [53].
Studies of Flt3-mediated signaling using Flt3 ligand
After cloning of FL some, but not all, signaling data obtained with the
chimeric receptor was confirmed using native Flt3 receptor. In Baf/3 cells
stimulation of human Flt3 with FL induced auto-phosphorylation of the
receptor, its association with Grb-2 and phosphorylation of Shc [242]. Acti-
vation of the Ras signaling pathway was also shown [242]. In addition, SH2
domain phosphatase-2 (SHP-2), but not SH2 domain phosphatase-1 (SHP-
1), were found to be phosphorylated on tyrosine residues and inducibly
associate with Grb-2 and Shc respectively upon FL stimulation [242]. In
contrast to the data obtained with the chimeric receptor, the regulatory
subunit of PI3-K, p85, did not associate with human Flt3 upon ligand stim-
ulation, but instead formed a complex with SHP-2, SH2 domain-containing
inositol polyphosphate 5-phosphatase (SHIP) and a tyrosine-phosphorylated
100 kDa protein upon stimulation of human Flt3 by FL in Baf/3 cells [242].
Stimulation of the native receptor with FL was also shown to induce phos-
phorylation of Gab1 and Gab2 adaptor proteins and their association with
SHP-2, Grb2 and PI3-K [241]. Other signal transduction molecules involved
in human Flt3-mediated signal transduction have also been identified. Ubiq-
uitin ligase Cbl-b was shown to be phosphorylated on tyrosine residues upon
FL stimulation and to form a complex with the p85 subunit of PI3K in THP-
1 monocytic and JEA2 pro-B cell lines [115]. A novel zinc-finger protein,
Fiz-1, was shown to associate with the catalytic domain of Flt3 in HEK-
293 and Baf/3 cells upon Flt3 ligand stimulation [234]. Association of Flt3
with SFK and their phosphorylation upon FL stimulation of the native Flt3
receptor have not been reported so far.
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Diversity of Flt3 signaling in various cell types
Activation of signaling pathways by Flt3 appears to be cell type specific
[53], [242]. For example, in NIH-3T3 cells stimulation of the chimeric re-
ceptor does not lead to phosphorylation of p85 and leads to only a slight
increase in phosphorylation of Shc, while phosphorylation of both proteins
is strongly induced by Flt3 in Baf/3 cells [53]. Similarly, stimulation of hu-
man Flt3 leads to phosphorylation of SHP-2 and its association with p85 in
Baf/3, but not in THP-1 cells [242]. These findings indicate that recruit-
ment and activation of various signaling pathways by Flt3 depends on the
expression of signaling molecules in a cell. Therefore, the biological outcome
of Flt3 stimulation could also depend on the cell type in which the receptor
is expressed.
Different signaling properties of Flt3 wt and Flt3 ITD
Initial studies showed that stimulation of the chimeric receptor provides an
oncogenic signal and induces the transformation of Rat-2 cells and NIH-
3T3 fibroblasts as well as abrogates IL-3 growth requirement of Baf/3 cells
[139], [53]. However, later studies with human Flt3 receptor demonstrated
that stimulation of Flt3 with FL does not lead to an oncogenic signaling
and cellular transformation, but only sustains cell viability [147], [146]. In
contrast, Flt3 ITD does transform cells and its expression blocks myeloid
differentiation of 32D cl.3 cells into granulocytes [147], [244]. Some studies
suggest that Flt3 ITD induces qualitatively different type of signaling than
Flt3 wt. In support of this hypothesis, it was shown that while Flt3 wt
induces the expression of some genes, Flt3 ITD represses or has no effect
on transcription of the same genes. For example, Flt3 wt induces expres-
sion of myeloid transcription factors C/EBPα and PU.1, while Flt3 ITD
strongly represses C/EBPα expression leaving PU.1 expression unchanged
[148], [243]. As myeloid differentiation requires the induction of C/EBPα
and PU.1 expression, repression of these processes might explain Flt3 ITD-
associated differentiation block. Additionally, anti-apoptotic pathways in-
duced by Flt3 ITD appear to be more divergent than those induced by Flt3
wt [146]. While dephosphorylation of BAD was shown to be sufficient to
induce apoptosis in Flt3 wt expressing cells, additional down-regulation of
Bcl-xL was needed to induce apoptosis in cells expressing Flt3 ITD [146].
The mechanism underlying different signaling properties of Flt3 wt and Flt3
ITD is not known. It might include the length and strength of signaling in-
duced by wild type and mutated receptors, as well as different intracellular
localization of these receptors [198].
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1.4 Src family of tyrosine kinases
1.4.1 Structure of Src family kinases (SFKs)
Domain structure of SFKs
A gene coding for Src (c-Src) was discovered as a cellular counterpart of a
transforming gene in a genome of Rous sarcoma virus (RSV) v-Src [208],
[209], [199]. This finding ultimately led to a number of break-through dis-
coveries including that of an origin of viral oncogenes from normal cellular
genes called proto-oncogenes [217] and protein phosphorylation on tyrosine
residues [54] among many other findings. In contrast to the c-Src protein,
v-Src lacks several amino acids at its C-terminus and contains several point
mutations, which contribute to its transformation potential.
Src is a prototype of a family of nine non-receptor tyrosine kinases, which
now includes Blk, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes and Yrk. These proteins
share a common domain structure (shown in Figure 1.8) and the mechanism
of regulation (described in 1.4.3). Each member contains an N-terminal se-
quence, sometimes referred to as Src homology 4 (SH4) region, followed by
a unique domain, Src homology 3 (SH3) domain, Src homology 2 (SH2) do-
main, a catalytic domain and a short cytoplasmic tail. This region contains
a signal for myristylation (glycine at the position 2) and palmitoylation
(cystein at the position 3). All SFKs are myristylated and most of them
are also palmitoylated (except for Src, p61Hck and Blk). Myristylation is
required for membrane binding of SFKs. Nonmyristylated mutants do not
bind to the membranes and non-myristylated v-Src lacks a transforming po-
tential, but is capable of inducing cellular proliferation [34]. The sequence of
the unique domain is the least conserved among SFKs. The exact function
of this domain is not known. However, in some SFKs the unique domain
was shown to participate in specific protein-protein interactions [222], [72].
For example, Lck specifically interacts with co-receptors of T cell receptor
(TCR), namely CD4 and CD8, by a di-cystein motif found in the unique
domain [222]. Additionally, Src but not other SFKs, are phosphorylated on
serine and threonine residues in the unique domain by Cdc2/cyclin com-
plexes at the M phase of the cell cycle [152], [37]. The SH2 domain is a
protein-protein binding domain that recognizes a phosphorylated tyrosine
residues within a specific consensus sequence [205]. It is involved in the reg-
ulation of the kinase activity of SFKs by associating with the phosphorylated
C-terminal tyrosine residue. It also associates with other phospho-tyrosine-
containing proteins. The SH3 domain is another protein-protein interaction
domain that binds to proline rich (XP-x-XP) motifs [36]. The SH3 domain
is involved in auto-regulation of SFK activity via its interactions with the
SH2-kinase linker region and in association with other signaling proteins.
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Figure 1.8: Domain structure of SFKs. SFKs share a common domain structure, which
includes N-terminal stretch of amino acids, unique domain, SH3, SH2, kinase domain
and C-terminal tail. Auto-phosphorylation site in the A-loop, Tyr 416 (amino acids
numbering for Src), and C-terminal negative regulatory tyrosine, Tyr 527, are shown.
Isoforms of SFKs
Some SFKs are present in more than one isoform. Two isoforms of Fyn show
mutually exclusive patterns of expression: FynT is expressed exclusively in
thymocytes and splenocytes, while another isoform of Fyn is mainly ex-
pressed in the brain [43]. Fyn isoforms arise from an alternative splicing,
which results in the differences of the kinase domain. Specific functions of
these two isoforms of Fyn are not known.
Hck also exists in two isoforms: p59Hck and p61Hck. These isoforms re-
sult from the use of an alternative translation start on a single Hck mRNA.
Translation of p61Hck starts at CTG, 21 codons upstream of an ATG trans-
lation start codon of p59Hck isoform [121]. Hck isoforms differ in their sub-
cellular localization: the smaller p59Hck isoform localized primarily to the
plasma membrane and the larger p61Hck isoform is found in the membrane
and in the cytosol [121]. The difference in the intracellular localization of
Hck isoforms is associated with the different post-translational modification
of these two isoforms. While both isoforms are myristylated, only p59Hck
is palmitoylated [177]. Palmitoylation was shown not only to increase the
affinity for the membrane binding, but also to target Hck to caveolae [177]
or lysosomes [35].
1.4.2 Expression of SFKs in various tissues
In vertebrates SFKs are expressed in various tissues and at least one SFK
is expressed in each cell of the human body. Some SFKs are expressed
ubiquitously (Src, Fyn, Yes and Yrk), while the expression of others is more
restricted, usually to the cells of hematopoietic origin. Patterns of expression
of different SFKs in various tissues are outlined in table 1.1.
1.4.3 Regulation of catalytic activity of SFKs
A kinase fold of SFKs is similar to all other known tyrosine and serine/threonine
protein kinases. It consists of a smaller N lobe and larger C lobe. ATP binds
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SFK Tissue of expression
Blk B cells
Fgr Myeloid cells, B cells
Fyn ubiquitous
Hck Myeloid
Lck T cells, NK cells, brain
Lyn B cell, myeloid cell, NK cells, brain
Src ubiquitous
Yes ubiquitous
Yrk ubiquitous
Table 1.1: Expression of SFKs in various tissues. Predominant tissues of expression for
individual SFKs are shown. (Adopted from [167].)
in the cleft between two lobes and a peptide substrate binds in the extended
conformation across the front end of the nucleotide binding pocket. The
N lobe consists of five-stranded β sheet and an α helix, called αC, while
the C lobe is mostly helical [99]. Conformational changes in αC play a key
role in the regulatory mechanisms of SFK activity [202], [236]. In the active
state of the kinase conserved Glu 310 in αC helix forms an ionic interaction
with the side chain of the conserved Lys 295 in the N lobe. This interaction
coordinates α and β phosphates of ATP. In addition, the A-loop, located in
the center of the catalytic domain, is phosphorylated in the activated kinase
and provides a platform for substrate binding. When not phosphorylated
on Tyr 416, the A-loop collapses into the active site blocking the binding of
ATP and the substrate [195].
Inactive conformation of SFKs is stabilized by a set of intramolecular
interactions. SH2 domain associates with phosphorylated Tyr 527 in the
C-terminal tail of the kinase [202], [236]. This association directs the SH3
domain to interact with a linker connecting the SH2 and kinase domains.
SH3 and the linker bind to the N lobe of the kinase domain and stabilize
αC in the inactive conformation.
Dephosphorylation of the tyrosine residue in the C-terminal tail or bind-
ing of the proteins to the SH2 or SH3 domains disrupt intramolecular in-
teractions and allow the αC to assume an active conformation. Since αC
and the A-loop are structurally linked, the disruption of the intramolecular
interactions also increases phosphorylation of the A-loop [99]. Phosphory-
lation of the A-loop on Tyr 416 is required for the full activation of SFKs.
Upon phosphorylation, the A-loop assumes a conformation which no longer
inhibits substrate and ATP binding. In addition, phosphorylation of the
A-loop results in a reduced affinity of the SH2 and SH3 domains to their
intramolecular ligands and promotes exogenous substrate binding [170], [73].
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Figure 1.9: Regulation of the catalytic activity of SFKs. Intramolecular interactions
between the SH2 domain and phosphorylated Tyr 527 (amino acids numbering for
Src) at the C-terminus and between the SH3 domain and SH2-kinase domain linker
stabilize an inactive conformation of SFKs (a). Full activation of SFKs requires the
disengagement of the intramolecular interactions and phosphorylation of the A-loop
on Tyr 416 (b).
1.4.4 Cellular mechanisms of SFK regulation
Regulation of the SFK activity by molecular displacement
Protein phosphatases in the regulation of SFK activity. Various pro-
tein tyrosine phosphatases have been involved in positive or negative reg-
ulation of the SFK activity by de-phosphorylating inhibitory C-terminal
tyrosine residue or tyrosine residue in the activation loop of the kinase,
respectively. Src activity was shown to be reduced in cells derived from
SHP-1 deficient mice and was restored by over-expression of SHP-1 [204].
Moreover, Src activity was shown to be decreased upon over-expression of a
dominant negative form of SHP-1 [204]. These studies suggest that SHP-1
is involved in positive regulation of Src activity. However, these findings
could not be confirmed by others [66]. Furthermore, some studies suggest
that SHP-1 negatively regulates the activity of SFKs. For example, SHP-
1 was shown to directly de-phosphorylate Lck on tyrosine residues located
in the A-loop and reduce its kinase activity [41]. In addition to direct de-
phosphorylation of SFKs, SHP-1 was also shown to antagonize the action
of Src by de-phosphorylating the substrates of Src [66]. Activity of another
protein tyrosine phoshatase, PTP1B, was shown to be increased in human
breast cancer cell lines with an increased Src activity, suggestsing the posi-
tive influence of PTP1B on the activation of Src [18]. The ability of PTP1B
to de-phosphorylate and activate Src was confirmed in vivo and in vitro [18].
Other protein tyrosine phosphatases can also de-phosphorylate C-terminal
tyrosine residue and activate Src. PTP-α de-phosphorylates and activates
Src in fibroblasts and induces cellular transformation [245]. The hematopoi-
etic cell phosphatase CD45 de-phosphorylates Lck and is considered a major
regulator of Lck and Fyn in T cells [89]. These examples show that the level
of activity of protein tyrosine phosphatases in cells can regulate the level
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of SFK activity. However, further studies are required to understand the
influence of tyrosine phosphatases on SFK activity.
Tyrosine kinases in the regulation of SFK activity. The activation of
SFKs by protein tyrosine phosphatases can be antagonized by the action of
kinases that phosphorylate negative regulatory tyrosine in the C-terminal
tail of SFKs. The C-terminal Src kinase (Csk) is known to promote inacti-
vation of SFKs in this manner [155]. A homolog of Csk, the Csk-homologous
kinase (Chk), which is expressed primarily in hematopoietic cells and in the
brain, was also suggested to possess a similar activity. However, in contrast
to Csk, the function of Chk in the regulation of the catalytic activity of SFK
is not clear. While kinase activity of SFKs is greatly enhanced in Csk knock-
out mice [155], studies with Chk knock-out mice show that Chk does not
affect the activity of Src, Hck and Fgr in the bone marrow cells [80]. On the
other hand, some studies show that Chk can mediate inactivation of Src by
kinase-dependent and by less understood kinase-independent mechanisms
[42]. Restricted function of Chk in comparison with Csk was suggested to
be at least in part due to the inability of the former to be recruited to certain
cellular locations [48].
Regulation of the kinase activity of SFKs by kinases and phosphatases
provides an additional mechanism for self-control of SFK activity. For ex-
ample, Src was suggested to phosphorylate Cbp/PAG, a protein which binds
and recruits Csk to the plasma membrane [17]. This leads to an activation of
the latter and to the subsequent inactivation of SFKs. In a similar manner,
SFKs can induce an activation of protein tyrosine phosphatases. Lck, for
example, phosphorylates SHP-1, which in turn might modulate the catalytic
activity of Lck [122].
Binding of the SH2 and SH3 domain ligands. Various proteins compete
with intramolecular ligands for binding to the SH2 and SH3 domains of
SFKs and thereby induce their activation. So far, no proteins which interact
with phosphorylated C-terminal tyrosine or SH2-kinase linker have been
identified. Examples of SH2 domain-binding proteins include RTKs [6],
[114] and focal adhesion kinase (FAK) [193], [221]. SH3 domain-interacting
proteins include Nef [149] and Sin [5], among others. An engagement of the
SH2 and SH3 domains activates SFKs in response to RTK activation and
integrin signaling [6], [114], [193], [221] [33]. SH2 and SH3 domain binding
proteins not only activate SFKs, but can also serve as the substrates for
SFKs and mediate biological responses of the activated SFKs.
26 Chapter 1. Introduction
Altered mechanisms of SFK expression and protein stability
Another mechanism involved in regulation of SFKs independently of molec-
ular displacement is the control of SFK protein levels. SFKs were shown to
be degraded by the ubiquitin-mediated pathway [85], [160], [79]. An active
form of Src is more sensitive to degradation by the proteosomal machinery
and is therefore less stable than an inactive form [85]. It was suggested
that E3 ubiquitin ligase that binds specifically to the activated Src regu-
lates its degradation. c-Cbl was later identified as an E3 ubiquitin ligase
that binds specifically to the active Src and promotes its destruction via the
proteosomal pathway [109], [240], [191]. Consistent with this, it was shown
that c-Cbl suppresses Hck-mediated cellular transformation [94]. Therefore,
once activated, SFKs induce attenuation of the signal by recruiting proteins
responsible for their own degradation.
Nitric oxide-mediated activation of SFKs
Recent studies identified another mechanism that might be involved in the
activation of SFKs. It was shown that Nitric oxide (NO) released from
NO-generating agents activates Src [4]. The mechanism underlying the ac-
tivation of Src by NO involves phosphorylation of the tyrosine residues in
the activation loop of the kinase as well as formation of disulphide bonds
(S-S). The latter finding is supported by data showing that treatment of
NO-activated Src with reducing agents such as 2-mercaptoethanol (2-ME)
or dithiothreitol (DTT) abolished NO-induced catalytic activity of Src. NO
may mediate S-S bond formation between different Src molecules and in-
crease the probability of trans-phosphorylation. Alternatively, NO-induced
S-S bond formation may mediate conformational changes of Src which would
ultimately lead to an increase in its catalytic activity.
Regulation of SFKs by intracellular localization
SFKs associate with various cellular membranes, including cytoplasmic, per-
inuclear and endosomal membranes. Consistent with their membrane local-
ization, SFKs are involved in biological functions associated with different
cellular membranes [17]. At the plasma membrane, SFKs participate in
the signal transduction from various cell surface receptors and regulate cell
adhesion and migration. At endosomes and Golgi membranes, SFKs most
likely regulate endosomal membrane transport [105], Golgi function [10] and
secretion of proteins [166], [174]. In addition to membrane localization, a
fraction of Src has been shown to localize to the nucleus and nucleolus de-
pending on the phase of the cell cycle and the confluency of cells [47].
Membrane association of SFKs is dependent on its myristylation at the
N-terminal glycine residue. However, myristylation provides only a general
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membrane affinity and additional signals are responsible for targeting of
SFKs to different cellular membranes [175]. For instance, six basic residues
at the N-terminus and other regions of SFKs can participate in membrane
targeting of SFKs. It was shown that a polypeptide derived from these
regions of Src targets a cytoplasmic protein, piruvate kinase, to various cel-
lular membranes [104]. It is possible that phosphorylation of SFKs within
these sites could regulate its intracellular location [104]. Palmytoylation was
also suggested to target SFKs to different membranes [177]. As palmytoy-
lation is a reversible process, it might represent an additional mechanism
involved in the control of the intracellular localization of SFKs. Another
possible mechanism of the regulation of SFKs’ localization is suggested by
studies showing that upon activation Src is translocated from the perinu-
clear region of the cell to the cell periphery. This translocation depends on
the SH3-mediated association of SFKs with the cytoskeleton through Rho
GTPases and other cytoskeleton-associated proteins [64]. Therefore, de-
regulation of these proteins might alter the subcellular localization of SFKs.
The specific functions of SFKs at various intracellular locations are poorly
understood and would require identification of specific substrates of SFKs
at these particular locations.
1.4.5 Functions of SFKs in hematopoietic cells
Hematopoiesis is a process in which a small population of slowly cycling self-
renewing hematopoietic stem cells first undergoes commitment to generate
common lymphoid or myeloid progenitors, which then give rise to the whole
range of increasingly differentiated blood cells with specific functions. Nor-
mal hematopoiesis is tightly regulated by external stimuli, such as secreted
and membrane-associated growth factors, extracellular matrix and cell-cell
contacts.
Several lines of evidence point to the role of SFKs in hematopoiesis.
These include expression profiles of SFK in hematopoietic cells, defects in
hematopoiesis observed in animals with disrupted SFK-encoding genes, the
suppression of growth of hematopoietic cells upon inactivation of SFKs and
the cooperation of SFKs with cell surface receptors involved in hematopoiesis.
In addition, SFKs are involved in specific functions of mature hematopoietic
cells. These points are described in more detail below.
Expression of SFKs in hematopoietic cells
The expression pattern of SFKs suggests their function in hematopoietic
system. Hck, Fgr, Lck and Blk are expressed exclusively and Fyn and Lyn
predominantly in hematopoietic cells. Src, Yes and Yrk are expressed in a
wide variety of tissues including cells of hematopoietic origin.
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SFK T cell B Cell NK Cell Mast cell Monocyte Granulocyte Platelet Erythrocyte
Blk - + - - - - - ?
Fgr - -* - - + + - +
Fyn + + + - + ? + ?
Hck - + - + + + + +
Lck + +a + - - - - ?
Lyn -* + + + + ? + +
Src -* - + + + ? + ?
Yes + - + + ? ? + ?
Yrk - - ? ? + - - -
Table 1.2: Expression pattern of SFKs in hematopoietic cells. * indicates that a SFK is
present in transformed of immortalized cells, but not found routinely in normal cells
of that type. a indicates that SFK expression in the particular cell type is found in
some studies, but not in others. (Adopted from [23] and modified using data for Yrk
expression [141] and on SFK expression in erythrocytes [49].)
In hematopoietic cells, with the exception of Blk, whose expression is
limited to B cells, SFKs are usually expressed in more than one cell type
(outlined in Table 1.2) [23]. Likewise, each hematopoietic cell usually ex-
presses more than one SFK. This expression pattern raises a question of
whether each SFK has a unique function in a cell or a function of one SFK
can be substituted by another family member. Another important observa-
tion is that cell lines derived from a particular type of hematopoietic cells
sometimes express SFKs which are not detected in normal cells of that type.
This observation suggests that immortalization or transformation process
might induce a change in the expression of SFKs [23].
In the myeloid compartment, expression of SFKs is associated with the
later stages of differentiation. For example, expression of Hck and Fgr
increases as cells undergo myeloid differentiation. However, low levels of
mRNA encoding these SFKs are also found in immature myeloid cells [24].
Consistent with their expression in more differentiated cells, mRNA encod-
ing Hck and Fgr is detected in leukemic cells in which differentiation to
granulocyte or monocytic lineages has taken place [233].
Hematological defects associated with genetic disruption of SFKs
Knock-out animals in which genes encoding SFKs are disrupted by homolo-
gous recombination, have specific defects in either development or function
of hematopoietic cells. These findings provide direct evidence for the in-
volvement of SFKs in hematopoiesis.
T cell abnormalities in mice deficient for SFKs. T cells express mainly
Lck and Fyn. Disruption of the genes encoding these SFKs interferes with
normal thymocyte development and functions. Disruption of the Lck gene
results in the suppression of thymocyte development, which manifests in thy-
mus atrophy, reduction in number of immature double-positive (CD4+/CD8+)
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thymocytes and disappearance of mature single positive thymocytes [151].
Lck activity is also required for normal TCR signaling. T cell line Jurkat,
which is defective in the expression of functional Lck is not responsive to
TCR stimulation. However, re-introduction of Lck into these cells restores
TCR specific cellular response [213]. Mice that lack the T-cell-specific iso-
form of Fyn show nearly normal thymocyte development, but their thymo-
cytes are defective in TCR signaling [7], which is restored in mature T cells
[210]. The mechanism underlying the function of Lck and Fyn in T cell
development has been analyzed by various groups [165]. It was shown that
Lck associates with CD4 and CD8, which brings it into the proximity of the
TCR complex. A stabilization of TCR by its interaction with the MHC-
peptide complex and by interaction of CD4 or CD8 with the non-variable
region of MHC results in clustering and activation of Lck. Activated Lck
phophorylates tyrosine residues within immunoreceptor tyrosine-based ac-
tivation motifs (ITAMs) within the TCR signaling complex, which recruits
the Syk family kinase ZAP-70 to the complex via SH2 domain-dependent
interaction. Once in the complex, ZAP-70 is phosphorylated and activated
by Lck, which results in the activation of the T cell specific kinase cascade.
Activation of Fyn follows the activation of Lck and results in the phosphory-
lation of another subset of the intracellular proteins. Fyn can also partially
substitute the function of Lck in peripheral T cells.
B cell abnormalities in mice deficient for SFKs. Blk is a SFK expressed
exclusively in B cells. However, disruption of the gene encoding Blk does not
alter B cell development, in vitro activation of B cells or humoral immune
responses of B cells to T-cell-dependent and independent antigens [219].
On the other hand, animals that lack the Lyn gene have reduced num-
bers of peripheral B cells with a greater proportion of immature cells [39],
develop autoantibodies and glomerulonephritis [91], [159]. B cells derived
from Lyn−/− animals are also defective in B cell receptor (BCR) signal-
ing. B cells from these animals have lower threshold for BCR signaling,
enhanced MAP kinase activation and an increased proliferative response to
BCR engagement [39]. These findings suggest that Lyn negatively regulates
BCR signaling. Negative regulation of BCR signaling by Lyn is associated
with phosphorylation of negative regulatory co-receptors of BCR, such as
FcγRIIB and CD22 [158]. The lack of phosphorylation of these receptors
prevents their association with SHP-1 and SHIP and abrogates suppression
of BCR-mediated responses. However, studies with Lyn knock-in mice that
over-express hyper-active form of Lyn, show that Lyn also plays a positive
role in BCR signaling. Lyn knock-in mice have increased levels of Syk and
PLCγ2 phosphorylation and show increased calcium flux in response to BCR
stimulation [90]. Similar to Lyn deficient mice, these animals also develop
autoantibodies and autoimmune glomerulonephritis [90]. These results sug-
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gest that constant over-activation of Lyn can ultimately overcome negative
signals controlled by Lyn in B cells.
Lyn is not the only SFK that controls B cell development. Studies with
mice lacking Lyn, Fyn and Blk show the importance of these SFKs in pre-B
cell receptor (pre-BCR)-mediated NF-κB activation and B cell development
[189]. Therefore, various SFKs control B cell development and a function of
one SFK can be at least partially substituted by another family member in
these cells.
Abnormalities of myeoloid cells in mice deficient for SFKs. Expres-
sion of Hck, Fgr and Src is drastically increased during myeloid differentia-
tion, suggesting that these proteins might be involved in the differentiation
process. However, no profound defects in myelogenesis are associated with
the disruption of these SFKs. On the other hand, the functions of specialized
cells derived from common myeloid progenitor are affected by disruption of
genes encoding Hck, Fgr and Src.
Hck and Fgr single knock-out animals have no defects in hematopoiesis
[126]. However, macrophages derived from Hck−/− mice have a defect in
phagocytosis [126]. Impairment of phagocytosis is not due to a defect in
FcγR signaling, but most likely involves alterations of some other molecu-
lar events such as phagosome membrane trafficking [126]. Disruption of the
genes encoding Hck and Fgr results in a defect in natural immunity, which
manifests in higher susceptibility of double knock-out animals to infection
with Listeria monocytogenes, a bacterium that can survive intracellularly in
the inactive macrophages [126]. The mechanism underlying this defect is not
understood. The production of cytokines and of NO by macrophages, gener-
ally associated with the clearance of Listeria is not affected [126]. It is possi-
ble that reduced motility and/or reduced integrin signaling observed in these
macrophages might contribute to an increased susceptibility to Listeria in-
fection [214]. Additionally, neutrophils derived from Hck−/−, Fgr−/− mice
are defective in adhesion-dependent production of reactive oxygen species
and degranulation [124] and [150].
Mice lacking a gene encoding Src have a defect in bone destruction -
osteopetrosis [206]. This defect is a result of the inability of osteoclasts to
resorb bone [123], while differentiation of monocytes into osteoblasts and
then into osteoclasts is not affected in Src knock-out animals. The sever-
ity of osteopetrosis in mice lacking genes encoding Src and Hck (Src−/−,
Hck−/−) is higher than in single Src knock-out mice and expression of Hck
in osteoclasts from Src−/− mice is increased [125]. These finding suggest
that Hck can at least partially substitute the function of Src in osteoclasts.
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Several mechanisms have been suggested to explain Src-mediated osteoclast
deficiency. For example, Src could participate in the adhesion of osteoclasts
to extracellular matrix or adhesion-mediated signaling required for bone
resorption [100]. Alternatively, Src-mediated function of osteoclasts could
involve regulation of the secretion of the lysosomal enzymes [168].
As described above, Lyn−/− mice have a phenotype associated with
the defects in B cells. In addition to affecting B cells, disruption of the
Lyn gene also alters myeloid development. With age Lyn−/− mice de-
velop a dramatic increase in the number of myeloid progenitors, as well
as splenomegaly and disseminated monocyte/macrophage tumors [84]. The
same study shows that mice expressing a hyperactivated mutant of Lyn
(Lynup/up), containing a substitution of the C-terminal tyrosine with pheny-
lalanine, are tumor-free [84]. With respect to mechanism underlying Lyn-
dependent myeloid phenotype, it was shown that phosphorylation and activ-
ity of phosphatases SHP-1 and SHP-2 as well as phosphorylation of tyrosine
residues within immunoreceptor tyrosine-based inhibitory motifs (ITIMs)
in inhibitory receptors SIRPα and PIR-B are decreased in Lyn−/− as com-
pared with (Lynup/up) mice [84]. Therefore, a possible mechanism explaining
the negative role of Lyn in myelopoiesis includes activation of certain phos-
phatases and ITIM-dependent inhibitory signaling [84].
In summary, gene knock-out studies suggest that SFKs are involved in
various molecular events required for hematopoiesis and function of mature
hematopoietic cells. While some SFKs are engaged in unique functions of
these cells, often a function of one SFK can be at least partially substituted
by another SFK.
1.4.6 Role of SFKs in leukemogenesis
The function of SFKs in normal hematopoiesis suggests the possibility that
these proteins are also involved in leukemogenesis. A number of recent stud-
ies explored this possibility with respect to different types of leukemia using
genetic knock-out approaches, cell line models and agents inhibiting SFKs.
The most studied types of leukemia with respect to the involvement
of SFKs are those caused by the Bcr-Abl oncogene. Bcr-Abl is associated
with the development of CML and B cell acute lymphoblastic leukemia (B-
ALL). SFKs are activated in myeloid cell lines which over-express Bcr-Abl,
as compared with Bcr-Abl-negative cell lines [44]. Additionally, SFKs are
more active in B-lymphoid cells derived from mice in which B-ALL was in-
duced by infection with recombinant retrovirus containing Bcr-Abl, than in
B cells derived from mice infected with a control retrovirus [95]. Bcr-Abl
also physically associates with SFKs via a complex mechanism [227], [207].
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A number of studies provide evidence for a biological relevance of SFK activ-
ity in Bcr-Abl-induced leukemias. One study shows that dominant negative
mutants of Hck suppress transformation of myeloid cells by Bcr-Abl [120].
In the other study, mice lacking Lyn, Hck and Fgr failed to develop B-ALL,
but not CML upon transplantation of the bone marrow infected with the
recombinant retrovirus containing Bcr-Abl. This data suggest that Lyn,
Hck and Fgr mediate signaling pathways required for the establishment of
Bcr-Abl-induced B-ALL [95]. The latter study also shows that a SFK in-
hibitor, which does not affect Bcr-Abl kinase activity, significantly prolongs
survival of mice with Bcr-Abl-induced B-ALL [95]. Additional evidence for
the involvement of SFKs in the development of CML is presented by a study,
which shows that disruption of Lyn using small interfering RNA (siRNA)
induces apoptosis in primary, and drug-resistant Bcr-Abl-positive leukemic
cells [171]. These findings set the stage for the development of improved
specific therapies for the treatment of Bcr-Abl-positive leukemias based on
the inhibition of SFK activity. However, more detailed analysis is required
to understand the precise molecular events underlying the contribution of
SFKs to the development of Bcr-Abl-positive leukemias.
In addition to CML and B-ALL, SFKs were suggested to be involved in
the development of AML. In one study, blasts from the majority of AML
patients were shown to have increased kinase activities of Lyn and Hck [180].
However, the sample size in this study was too small to provide any statis-
tical significance of the finding. Positive contribution of Lyn to AML devel-
opment is also suggested by the findings that treatment of cells with Lyn
anti-sense oligonucleotide suppresses the growth of myeloid cell line MO7e in
response to granulocyte-macrophage colony stimulating factor (GM-CSF),
and that SFK inhibitor PD166285 decreases the growth of myeloid leukemic
cell lines and blasts [180]. However, besides SFKs, PD166285 also inhibits
other proteins, which could be relevant to the growth of myeloid cells. To-
gether, these finding provide preliminary evidence for the involvement of
SFKs in the development of AML. However, further studies along this line
are required.
Besides positive regulation of leukemogenesis, SFKs can also negatively
regulate the development of hematopoietic malignancies. As described above,
Lyn knock-out animals develop monocyte/macrophage tumors while Lynup/up
animals are tumor-free [84]. Therefore, consistent with positive and negative
function in hematopoiesis, SFKs can either positively or negatively regulate
the development of different types of leukemias.
1.4. Src family of tyrosine kinases 33
1.4.7 SFKs in signal transduction mediated by RTKs
Activation of SFKs downstream of RTKs
Activated RTKs recruit SFKs via their SH2 domains. This leads to a disrup-
tion of intramolecular interaction of SH2 domain with C-terminal tyrosine
and induces activation of SFKs. However, full activation of SFKs in response
to RTK activation requires additional factors such as recruitment of protein
tyrosine phosphatases that activate SFKs and the translocation of SFKs to
the plasma membrane.
Methods used to study the roles of SFKs downstream of RTKs
Four main approaches were used to study the involvement of SFK in RTK-
mediated signaling. First approach includes microinjections or transfections
of SFKs or cDNA encoding these proteins or their their domains or antibod-
ies inactivating SFKs into the cells. Second approach involves the analysis
of signal transduction induced by mutant receptors which do not associate
with SFKs. Third approach takes advantage of cell lines derived from mice
lacking SFKs, and involves the comparison of receptor-induced responses in
these and normal cell lines. Finally, pharmacological inhibitors of SFKs are
often used to determine specific functions of SFKs in RTK signal transduc-
tion. The role of SFKs in RTK-mediated cell growth or motility is usually
analyzed using these approaches.
Examples of SFK-dependent signaling downstream of class III RTKs
SFKs are the key signaling molecules downstream of RTKs of different sub-
families. Examples of SFK-dependent signaling downstream of class III
RTKs are described below.
Role of SFKs downstream of the PDGFR. Among class III RTKs, asso-
ciation with SFKs is the most extensively studied in case of the PDGFR.
Phoshorylation and activation of SFKs in response to the stimulation of
quiescent fibroblasts by PDGF was the first discovery suggesting the role
of SFKs in RTK-mediated signaling [172]. Further studies showed that in
addition to being activated by PDGF stimulation, Src, Yes and Fyn also
associate with the PDGFR following its stimulation by the ligand [114].
Small fraction of Src molecules activated in response to PDGF stimulation
correlates with low stoichiometry of association of Src with the PDGFR and
suggests that activation accompanies complex formation [114]. SFKs bind
to phosphorylated Tyr 579 and Tyr 581 in the JM region of the PDGFR via
their SH2 domains [6], [154].
Following these findings, various groups have attempted to investigate
whether SFKs are required for biological functions mediated by the PDGFR.
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Microinjection studies have revealed that SFKs are required for PDGF-
induced DNA synthesis and entry into the mitosis and that SH2 domain
of SFKs is essential for this function [179]. On the other hand, studies
with the mutant PDGFR that is not able to bind SFKs do not confirm
these data. For example, the substitution of two critical tyrosines in the
JM of the PDGFR (Tyr 579 and Tyr 581) with phenylalanines prevents
the association of the PDGFR with SFKs, but has no effect on mitogenic
signaling and transcription of Myc induced by PDGF stimulation [51]. On
the other hand, PDGF-mediated chemotaxis of cells expressing the mutant
PDGFR is either inhibited or unaffected, depending on the cell type used
[183], [93]. Another study that argues against the involvement of SFKs in
PDGFR-mediated signaling, shows that PDGF-induced phosphorylation of
intracellular proteins, cell cycle progression as well as chemotaxis are not
affected in fibroblasts derived from mice lacking Src, Yes and Fyn [112].
However, a cell line used in this study (SYF) was derived from the knock-
out animals by transformation with the large T antigen of simian virus 40
(SV-40) [112], which might overcome the requirement of SFKs for PDGFR-
mediated mitogenic response [29].
Role of SFKs downstream of the Kit receptor. Similarly to the stim-
ulation of fibroblasts with PDGF, stimulation of human megakaryoblastic
leukemia cells with the Kit receptor ligand, stem cell factor (SCF), leads
to an increase in phosphorylation and kinase activity of Lyn [119]. Lyn
associates specifically with phosporylated fusion protein consisting of the
Glutathione S-transferase (GST) and the JM region of Kit [119]. Similar
to the PDGFR, autophosphorylated tyrosine residues 568, and to a lesser
extent 570, in the JM region of Kit are required for the activation of SFKs
upon stimulation of Kit with SCF [116]. Several studies suggest that SFKs
mediate biological responses of Kit which lead to cell growth and chemo-
taxis. For example, treatment of cells with Lyn anti-sense oligonucleotides
results in a reduced proliferation of cells in response to SCF stimulation
[119]. Moreover, transfection of dominant negative Lyn into normal murine
mast cells and analysis of SCF-induced growth of mast and hematopoietic
progenitor cells derived from Lyn knock-out mice, shows that Lyn is required
for SCF-induced growth and chemotaxis of these cells [162]. On the other
hand, activation of SFKs in porcine aortic endothelial cells (PAE) does not
correlate with SCF-induced DNA synthesis [116].
Role of SFKs downstream of the CSF-1R. CSF-1R is expressed on mono-
cytes and macrophages and supports their proliferation, differentiation and
survival [194]. Stimulation of the CSF-1R over-expressed in the myeloid cell
line M1 results in phosphorylation of Hck, Fyn and Yes [137]. In addition,
following stimulation by the ligand, SFKs are recruited to phoshorylated Tyr
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559 in the JM region of the CSF-1R, and mutation of this tyrosine to Phe
results in a decreased response of cells to CSF-1 with respect to cell growth
and differentiation [137]. In contrast to the data obtained using M1 cells,
over-expression of the CSF-1R Y559F mutant in the murine myeloid 32D
cells results in an increased proliferation in response to CSF-1 as compared
with cells over-expressing wild type CSF-1R [181], which suggests that SFKs
negatively regulate the CSF-1R (described in detail in 1.4.8).
Role of SFKs downstream of the Flt3 receptor. Of the several studies
analyzing the role of SFKs in signaling of class III RTKs, only one investi-
gated the involvement of SFKs in Flt3-mediated signaling [53]. This study
shows that stimulation of the chimeric receptor, which consists of the ex-
tracellular part of the CSF-1R and the transmembrane and cytoplasmic
parts of Flt3, with CSF-1 induces a slight increase in phosphorylation of
Src, but not Fyn. Additionally, this study shows that both Src and Fyn
co-immunoprecipitate with the chimeric receptor. There has been no con-
firmation of these observations with Flt3 or Flt3 ITD reported, and the role
of SFKs in Flt3-mediated signal transduction requires further analysis.
SFK-mediated signaling downstream of RTKs leading to cell growth
Above examples, as well as studies with other RTKs, show that at least in
certain cell types and certain cellular contexts SFKs promote mitogenesis
induced by RTKs. Possible mechanisms of SFK-mediated signaling with
respect to cell growth are described below and summarized in Figure 1.10.
A number of studies suggest that an increase in mRNA encoding a tran-
scription factor Myc is required for SFK-mediated mitogenic response of
RTKs. Over-expression of Myc rescues cells from cell cycle block caused by
over-expression of dominant negative Src [11]. A direct role of Myc down-
stream of SFKs in PDGF-induced mitogenic response is demonstrated in a
study with the specific SFK inhibitor SU6656, which does not inhibit the
PDGFR [19]. Treatment of cells with this inhibitor prevents an increase in
Myc mRNA levels and DNA synthesis following PDGF stimulation. How-
ever, re-introduction of Myc into these cells abrogates the block caused
by SU6656 [19]. How exactly activation of SFKs leads to an increase in
Myc mRNA level is not clear. Some preliminary reports suggest that SFK-
mediated signaling increases the stability of Myc mRNA without inducing its
transcription, and that multiple signaling molecules phosphorylated and/or
activated by SFKs (e.g Abl, Shc, Stat3, Vav2 and Rac) play a role in this
process [28].
Pro-apoptotic transcription factor p53 has also been involved in the mi-
togenic signaling of RTKs mediated by SFKs. Antibodies neutralizing SFKs
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have no effect on mitogenesis induced by PDGF stimulation in cells express-
ing dominant negative form of p53 or derived from p53-null mice [29]. The
role of SFKs in opposing the effects of p53 also explains the fact that cells
over-expressing Large T antigen of SV-40, which inactivates p53, do not re-
quire SFKs for transduction of the mitogenic signal [29]. It is not known if
SFK-mediated inactivation of p53 is coupled to SFK-dependent increase in
Myc mRNA levels.
Besides Myc and p53, other pathways were suggested to be involved
in the downstream signaling of SFKs leading to mitogenesis. For example,
SFKs phosphorylate Shc and FAK, which could recruit adaptor protein Grb2
to the plasma membrane and thereby activate Ras-MAPK pathway, which
is often associated with the mitogenic responses of RTKs. Another possi-
ble mechanism of SFK-mediated mitogenic signaling involves SFK-induced
phosphorylation of PLCγ. PLCγ induces translocation of the Ras exchange
factor RasGRP1 to the Golgi complex and subsequently activates Ras in
the Golgi complex, but not on the plasma membrane [16], [28]. It has been
suggested that Ras-mediated signaling from Golgi contributes to cell pro-
liferation [81]. In addition, SFKs modulate the activity of Rho GTPases,
which, besides their more extensively studied role in the organization of
cytoskeleton, also regulate cell growth [223].
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Figure 1.10: A model of SFK-mediated mitogenic responses downstream of RTKs.
Possible mechanisms of SFK-mediate mitogenic and anti-apoptotic signals down-
stream of RTKs are outlined in a simplified manner. Myc and p53 are required for
SFK-mediated mitogenesis upon PDGFR stimulation. An increase in Myc mRNA
stability depends on various signaling molecules, including Abl, Shc, Stat3, Vav2
and Rac. In addition to Myc and p53, activation of Ras on the Golgi and plasma
membranes, as well as activation of PI3-K signaling pathway, could promote SFK-
mediated mitogenesis downstream of RTKs.
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SFK-mediated signaling downstream of RTKs leading to cytoskeletal
effects
The cytoskeletal effects induced by activated SFKs lead to a decrease in
cell-cell and cell-matrix adhesion and an increase in cell motility [65], [239].
These SFK-mediated effects could promote metastatic and invasive growth
of advanced tumors in which SFKs are activated [239]. However, only a
few studies address the question of SFK-mediated signaling downstream of
RTKs leading to cytoskeletal changes. The results of these studies suggest
that at least under certain circumstances, SFKs are involved in the modu-
lation of cellular migration induced by several RTKs.
An increase in the motility of a cell requires modification of cellular
attachments to the extracellular matrix and disruption of the intracellular
contacts. These processes are regulated by two types of subcellular struc-
tures: focal adhesions and adherent junctions, respectively. SFKs regulate
both of these structures [239]. Although the exact functions of SFKs down-
stream of RTKs with respect to cellular motility are poorly understood, var-
ious molecular mechanisms underlying SFK-dependent cytoskeletal effects
in cells expressing activated SFKs are known. These mechanisms could also
be employed by SFKs in response to their activation by RTKs (outlined in
Figure 1.11).
Src physically associates with and phosphorylates components of focal
adhesions including FAK and p130 Cas [192], [169]. In addition to com-
ponents of focal adhesions, Src can inhibit the functions of Rho which is
involved in the regulation of the formation of stress fibers and turn-over of
focal adhesions [223]. Src-mediated down-regulation of Rho is mediated by
phosphorylation of Rho GTPase activating protein (Rho GAP) [182], which
increases the intrinsic GTPase activity of Rho, converting it into inactive
GDP-bound form. Another cytoskeletal target of Src is cortactin, a protein
involved in the actin dynamics [229]. Src-mediated phosphorylation regu-
lates the activity of cortactin towards the cytoskeleton and thereby might
contribute to the changes in actin dynamics and regulate cellular motility
[96]. Additionally, hyperactive Src encoded by the v-src gene phosphory-
lates R-Ras, a relative of H-Ras involved in maintaining integrin activity.
Mutant R-Ras, which can not be phosphorylated by Src, inhibits v-Src me-
diated decrease in cellular adhesion [246]. This finding suggests a possibility
that Src can act through R-Ras to inhibit cellular adhesion and stimulate
cellular motility.
In adherent junctions, Src stimulates ubiquitination and degradation of
E-Cadherin via E3 Ubiquitin ligase Hakai [67]. E-Cadherin is a component
of adherent junctions that forms homotypic interactions with E-Cadherin
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molecules on neighboring cells, and its disruption leads to the disassem-
bly of adherent junctions and a decrease in cell-cell adhesion. Besides E-
Cadherin, Src phosphorylates p120-catenin, a protein which associates with
E-Cadherin and regulates cell-cell adhesion [136].
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Figure 1.11: A model of SFK-mediated cytoskeletal effects downstream of RTKs.
Possible mechanisms of SFK-mediated cytoskeletal effects downstream of RTKs
are outlined in a simplified manner. SFKs phosphoryalate and modulate the activ-
ity of the components of focal adhesions and proteins that regulate their integrity:
FAK, p130Cas, paxilin, cortactin. SFKs promotes the inactive state of Rho by
activating Rho GAP, thereby contributing to the turn-over of focal adhesions. In
addition to the effects on focal adhesions, SFKs mediate proteasomal degradation of
E-Cadherin, which leads to the disruption of adherent junctions and consequently
intracellular contacts. SFK-mediated effects on focal adhesions and adherent junc-
tion decrease cellular adhesion and stimulate motility.
1.4.8 SFK-mediated modulation of RTKs
SFKs not only serve as signal transduction molecules downstream of RTKs,
but also modulate the activity of RTKs. Therefore the synergy between
SFKs and RTKs is bidirectional. By modulating the activity of RTKs,
SFKs can take part in feed-back mechanisms regulating RTKs or participate
in cross-talk between various RTKs [190] and between RTKs and other cell
surface receptors [237]. The mechanisms of SFK-dependent modulation of
RTKs are described below and are outlined in Figure 1.12.
SFK-mediated phosphorylation of RTKs
As described above, ligand-stimulated auto-phosphorylation of RTKs on ty-
rosine residues is required for their full activation and generation of the bind-
ing sites for various signaling molecules. In addition to auto-phosphorylation,
RTKs such as the insulin growth factor-1 receptor (IGF-1R), EGFR, PDGFR,
and Kit can be phosphorylated by intracellular tyrosine kinases including
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SFKs. These findings are described below.
Src phosphorylation sites vary among different RTKs. In case of the
EGFR, they include Tyr 845 in the A-loop and Tyr 1101 in the C-terminus
of the receptor [15]. In case of the PDGFR and Kit, Src induces phosphory-
lation of a homologous tyrosine residue located in the kinase domain of these
RTKs (Tyr 934 in the PDGFR and Tyr 900 in Kit) [83], [117]. For all three
receptors, Src phosphorylation sites are different from auto-phosphorylation
sites, suggesting a unique role for Src-mediated phosphorylation in receptor
signaling. In contrast, Src phosphorylation sites on the IGF-1R correspond
to auto-phosphorylation sites, implying the role of SFKs in the enhancement
of the ligand-mediated phoshorylation [28]. These findings suggest that in
contexts of different receptors, SFK-mediated phosphorylation might have
different consequences for RTKs signaling.
Src-mediated phosphorylation of the EGFR induces catalytic activity of
this receptor and is required for its full mitogenic response [15]. Similarly,
in case of the PDGFR, Src phosphorylation positively modulates mitogenic
response to PDGF stimulation [83]. However, receptor-mediated signaling
leading to cell motility is reduced when PDGFR is phosphorylated by Src
[83]. In case of the Kit receptor, SFK-mediated phosphorylation creates
binding sites for adaptor protein CrkII, and is also involved in Kit-mediated
cellular response which leads to cellular proliferation [117]. To summarize,
SFK-mediated phosphorylation can positively regulate biological responses
of RTKs leading to cellular proliferation either via an increase in their cat-
alytic activity or by generating binding sites for other signaling molecules.
In addition, SFK-mediated phosphorylation can direct RTK signaling to-
wards a particular pathway and thereby modulate biological responses of
RTKs.
SFK-mediated endocytosis of RTKs
As described in 1.2.4, activated RTKs are removed from the cell surface
by endocytosis. Various studies demonstrate the ability of SFKs to pro-
mote this process. The PDGFR mutant, which is not able to activate SFKs
(PDGFR Y579F), undergoes a reduced rate of the ligand-stimulated endo-
cytosis of the PDGFR, suggesting that SFK positively regulate endocytosis
of the PDGFR [153]. However, another study shows that SFKs suppress
endocytosis of the PDGFRα when cells are not stimulated by PDGF [8].
Internalization of the Kit receptor in lymphoid cells lacking Lyn (DT33) is
impaired as compared with cells expressing Lyn (DT40) [31]. This suggests
that Lyn plays a positive role in the regulation of the Kit endocytosis. Sim-
ilarly, internalization of CSF-1R, which contains a substitution of Tyr 559
with phenylalanine, and therefore defective in the ability to associate with
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SFKs, is decreased [181]. The mechanisms involved in SFK-mediated regula-
tion of receptor endocytosis in these cases are not understood. Some studies
suggest that SFKs modulate the components of the endocytic machinery.
For example, SFKs co-localize with clathrin in platelets and when activated
phosphorylate clathrin’s heavy chain [211], [140]. Furthermore, Src acti-
vated by the EGFR induces phosphorylation and redistribution of clathrin
to the cell periphery, thereby promoting endocytosis of the EGFR [232].
Dynamin is another substrate of Src associated with endocytosis which is
phosphorylated by Src upon EGFR stimulation [3]. Src-mediated dynamin
phosphorylation induces self-assembly of dynamin and increases in its GT-
Pase activity, both of which are required for clathrin-mediated endocytosis
[3]. Some evidence also points to the potential role of SFKs in regulating
the intracellular vesicular transport [105]. However, it is not known whether
this function of SFKs is relevant to the endocytosys of RTKs. Additionally,
SFKs regulate ubiquitination of RTKs, which was shown to mediate endo-
cytic events (see below).
SFK-mediated ubiquitination of RTKs
In addition to phosphorylation, another reversible post-translational mod-
ification of RTKs regulated by SFKs is ubiquitination, an addition of a 76
amino acid peptide ubiquitin. Ubiquitination is mediated by a series of en-
zymatic reactions including activation of ubiquitin by ubiquitin-activating
enzyme, E1, transfer of ubiquitin from E1 to ubiquitin-conjugating enzyme
E2, and finally ligation of ubiquitin to γ-amino group of a Lys in the target
protein by ubiquitin ligase E3. Depending on the attachment of a single
ubiquitin moiety or a chain consisting of multiple ubiquitin polypeptides
branched at internal lysines within ubiquitin, two types of ubiquitinations
are defined: mono-ubiquitination and poly-ubiquitination. Proteins can also
be mono-ubiquitinated at multiple sites (multi-ubiquitination). Unlike poly-
ubiquitination of cytoplasmic and nuclear proteins usually associated with
proteasomal degradation (at least when ubiquitin chains are branched at
internal Lys 48), mono- and multi-ubiquitination of RTKs is involved in
endocytosis of cell surface receptors [78]. However, exact function of ubiqui-
tination in endocytosis is not known. Some studies show that ubiquitination
induces endocytosis, while other studies suggest that the main function of
RTK ubiquitination is the regulation of the endosomal sorting of the inter-
nalized RTKs [138].
Ubiquitin ligases that mediate the transfer of ubiquitin to RTKs are
multi-domain proteins that belong to the Cbl family [138]. In particular, a
protein encoded by proto-oncogene c-cbl, has been extensively studied with
respect to ubiquitination of RTKs [220]. Molecular mechanism of c-Cbl
action includes direct binding to RTKs via its PTB domain as well as re-
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cruitment of ubiquitin-conjugating enzyme, E2, and mediation of ubiquitin
ligase activity by RING finger domain [102], [220]. c-Cbl-mediated ubiqui-
tination of RTKs is generally linked to their endocytosis. SFKs associate
with proline-rich domain of c-Cbl via their SH3 domains [218]. Additionally,
c-Cbl PTB domain specifically binds to phosphorylated tyrosine residue in
the A-loop of SFKs which leads to an induction of ubiquitin ligase activity
of c-Cbl and degradation of SFKs via proteasomal pathway [191]. However,
relationship of SFKs and c-cbl is bi-directional. Active SFKs also phoshory-
lates c-Cbl, which leads to ubiquitination and proteasomal degradation of
the latter [9], [240]. SFK-dependent destruction of c-Cbl was shown to play
a role in RTK-mediated signal transduction. Stimulation of cells by EGF
leads to the activation of SFKs which induces phosphorylation, ubiquiti-
nation and destruction of c-Cbl [9]. Destruction of c-Cbl decreases EGFR
ubiquitination and leads to prolonged EGFR signaling [9]. Similar to the
EGFR, ubquitination of the mutant CSF-1R, which is unable to bind SFKs,
is decreased. This correlates with a reduced level of c-Cbl phosphoryla-
tion and its reduced association with the mutant CSF-1R [181]. In PDGF-
stimulated cells, c-Cbl is also a direct substrate of Src. Treatment of cells
with SFK inhibitor SU6656 inhibits phosphorylation of c-Cbl [19]. However,
it is not clear whether similar to the EGFR, SFK-mediated phosphorylation
of c-Cbl leads to its degradation and subsequent reduction of the PDGFR
ubiquitination. In summary, these studies suggest that RTK-mediated acti-
vation of SFKs can positively regulate RTKs signaling by targeting c-Cbl for
degradation. However, at least in the case of the PDGFR, SFKs can also
positively regulate c-Cbl-mediated degradation of RTKs [184]. Therefore,
further analysis of the interplay between SFK, c-Cbl and ubiquitination of
RTKs is required to understand the role of SFKs in the ubiquitination of
RTKs.
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Figure 1.12: Mechanism of SFK-mediated modulation of RTKs. Possible mechanisms of
of SFK-mediated modulation of RTKs are outlined in a simplified manner. Phos-
phorylation of RTKs by SFKs modulates their signaling leading to mitogenesis
and cytoskeletal effects. Additionally, SFK-mediated phosphorylation of the com-
ponents of the endocytic machinery, including clathrin and dynamin, and possibly
their effects on vesicular trafficking influence endocytosis and membrane sorting
of internalized RTKs. SFKs also reduce ubiquitination of RTKs by phosphory-
lating and promoting degradation of c-Cbl. However, c-Cbl can also target SFKs
for degradation. Ubiquitination status of RTKs mediates their endocytosis and
membrane sorting after receptor internalization.
1.5 Thesis proposal
Flt3 is the most recently discovered member of the class III of RTKs. Its
expression profile and functional analysis, as well as the phenotype of Flt3
knock-out animals suggest a predominantly hematopoietic role. Mutations
of the Flt3 gene are the most common alterations in AML patients. Of
these mutations, internal tandem duplications in the JM region of Flt3 are
the most frequently occurring type. For this reason, Flt3 is an attractive
target for tyrosine kinase inhibitors, and a number of such inhibitors are
currently being tested in clinical trials. However, preliminary data from
these and other studies with tyrosine kinase inhibitors suggest that more
effective therapies require cocktails of inhibitors targeted at multiple mole-
cular lesions underlying the development of a particular malignancy.
A Src kinase family constitutes the largest family of non-receptor tyro-
sine kinases in human cells. Over-expression and over-activation of SFKs
has been associated with the development and progression of various can-
cers, including several types of leukemia. These observations prompted the
development of specific inhibitors of SFKs, which could serve as therapeu-
tic agents against these malignancies. Six out of nine SFKs are expressed
exclusively or predominantly in hematopoietic cells and at least two (Hck
and Lyn) are found to be activated in AML patient samples. SFKs play key
roles in signaling of RTKs, including those of class III. These data suggest
the possibility that SFKs could be involved in Flt3-mediated intracellular
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events and participate in leukemogenesis associated with activation of Flt3.
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2.1 Equipment
• −80oC Freezer, Heraeus, Hanau, Germany
• 0.22 µm sterile filters, Millipore, Bedford, MA, USA
• 40 µm sterile cell strainers, BD Biosciences,
• Automatic pipets, Gilson, Middleton, WI, USA
• Cell counting chambers, Neubauer, Germany
• Cell freezing containers, Nalgene, Neerijse, Belgium
• Centrifuges, Eppendorf, Hamburg
• CO2 Incubators, WTB Binder, Tuttlingen, Germany, Forma Sci-
etific
• Electrophoresis cells and blotting systems, Biorad, Hercules,
CA, USA
• Flow cytometer, Coulter EPICS XL-4, Beckman Coulter GmbH,
Krefeld, Germany
• Heating blocks, Techne, Cambridge, UK
• Laminar flow hoods, BDK, Sonnenbuehl, Germany
• Liquid nitrogen tank, Cryoson, Schoellkrippen, Germany
• Microscopes, Zeiss, Oberkochen, Germany
• Modular Flow cytometer (MoFlo), Cytomation, Fort Collins,
USA
• pH-meter, WTW, Weilheim, Germany
• Spectrophotometer, Eppendorf, Hamburg)
• Sterile cryotube vials, and cell scrapers, Sarstedt, Newton, USA
• Sterile tissue culture plastic pipets, tubes, dishes, flasks and
cell scrapers, Sarstedt, Newton, USA
• Thermocycler, Perkin Elmer, Norwalk, USA
• Vacuum driven disposable filtration systems, Millipore, Bed-
ford, MA, USA
• Vortex, Heidolph, Kelheim, Germany
• Water bath, Koettermann, Haenigsen, Germany
2.2 Reagents
• 2-Mercaptoethanol, Merck, Darmstatdt, Germany
• 30% Acrylamide and 0.8% bisacrylamide stock solution, Roth,
Karlsruhe, Germany
• Acetic Acid 96%, Sigma-Aldrich Chemie GmbH, Steinheim, Ger-
many
• Agarose (electrophoresis grade), Sigma-Aldrich Chemie GmbH,
Steinheim, Germany
• Ammonium Persulfate, Bio-rad, Hercules, CA, USA
• Calcium chloride, Sigma-Aldrich Chemie GmbH, Steinheim, Ger-
many
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• EDTA, Sigma-Aldrich Chemie GmbH, Steinheim, Germany
• Ethanol, Merck, Darmstatdt, Germany
• Ethidium Bromide (10 mg/ml), Sigma-Aldrich Chemie GmbH,
Steinheim, Germany
• Gelatine, Merck, Darmstatdt, Germany
• Glycerol, Merck, Darmstatdt, Germany
• Glycine, Merck, Darmstatdt, Germany
• Isopropanol, Merck, Darmstatdt, Germany
• LB medium, Invitrogen, Karlsruhe, Germahy
• Luria agar, Gibco, Eggenstein, Germany
• Methanol, Merck, Darmstatdt, Germany
• Nonidet P-40, ICN Biomedicals, Aurora, Ohio, USA
• Phosphatase inhibitor cocktail II for tyrosine protein phos-
phatases, Acid and Alkaline Phosphatases, Sigma, Saint Louis,USA
• Ponceau S, Sigma-Aldrich Chemie GmbH, Steinheim, Germany
• Protease inhibitor cocktail, Sigma, Saint Louis, Missouri, USA
• Protein A/G-Agarose, Roche, Mannheim, Germany
• SDS (electrophoresis grade), Merck, Darmstatdt, Germany
• SDS-PAGE loading buffer Roti Load (4X concentrate), Roth,
Karlsruhe, Germany
• SDS-PAGE Molecular Weight Standarts, Broad Range, Bio-
Rad, Hercules, CA, USA
• Silver Nitrate, Merck, Darmstatdt, Germany
• Skim Milk Powder (blotting grade), Roth, Karlsruhe, Germany
• Sodium Orthovanadate, Sigma-Aldrich Chemie GmbH, Steinheim,
Germany
• TEMED, Roth, Karlsruhe, Germany
• Tween 20, Sigma-Aldrich Chemie GmbH, Steinheim, Germany
2.3 Kits and other research products
• Annexin V - PE Apoptosis detection kit, BD Pharmingen, San
Diego, USA
• BCA Protein assay reagent kit, Pierce, Rockford, IL, USA
• DNA isolation and purification kits, Qiagen, Hilden, Germany
• ECLWestern Blotting Detection System, Amersham Biosciences,
Buckinghamshire, England, UK
• Effectene Transfection Reagent, Qiagen, Hilden, Germany
• Gel blotting paper, Schleicher & Schuell, Dassel, Germany
• High performance chemiluminescence film, Amersham Biosciences,
Buckinghamshire, England, UK
• Immobilon-P PVDF Transfer Membrane, Millipore, Bedford,
MA, USA
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• Mycoplasma detection kit for conventional PCR, Minerva Bi-
olabs, Berlin, Germany
• Primers, Metabion, Martinsried, Germany
• QuikChange Site-Directed Mutagenesis Kit, Stratagene, La Jolla,
CA, USA
• Restriction endonucleases and DNA modifying enzymes, New
England Biolabs, Beverly, MA, USA
2.4 Antibodies
• Anti-mouse IgG from sheep, peroxidase conjugated, Amer-
sham Biosciences, Buckinghamshire, England, UK
• Anti-rabbit IgG from goat, peroxidase conjugated, Sigma, St.
Louis, USA
• c-Src (N-16), Santa Cruz Biotechnology, Santa Cruz, CA, USA
• Erk (C-16), Santa Cruz Biotechnology, Santa Cruz, CA, USA
• Flt3 conjugated with PE (clone SF 1.340), Immunotech, Mar-
seille, France
• Flt3 (S-18),Santa Cruz Biotechnology, Santa Cruz, CA, USA
• Fyn, Santa Cruz Biotechnology, Santa Cruz, CA, USA
• Hck, BD Biosciences, San Jose, CA, USA
• IgG1 from mouse, conjugated with PE, Immunotech, Marseille,
France
• Lyn, Santa Cruz Biotechnology, Santa Cruz,
• myc (9E10), Roche, Mannheim, Germany
• phospho-tyrosine (PY99), Santa Cruz Biotechnology, Santa Cruz,
CA, USA
• phospho-Akt, Ser 473, Cell Signaling Technology, Beverly, MA,
• phospho-Erk, Thr 202/Tyr 204 (E10), Cell Signaling, Technol-
ogy, Beverly, MA, USA
• phospho-STAT5, Tyr 694, Cell Signaling Technology, Beverly, MA,
USA
• phospho-Src Family kinases, Tyr 416, Cell Signaling Technology,
Beverly, MA, USA
• STAT 5 (C-17), Santa Cruz Biotechnology, Santa Cruz, CA, USA
2.5 Plasmids
2.5.1 Vectors
• pApuro [113], gift of Dr. Seth Corey, Pitsburgh, USA
• pCDNA3.1/His c© A, Invitrogen, Karlsruhe, Germahy
• pCDNA6A, Invitrogen, Karlsruhe, Germahy
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• pMSCV-IRES-EGFP, gift of Dr. Van Etten, Tufts-New England
Medical Center, Boston, MA, USA
• ecopack, gift of Dr. Van Etten, Tufts-New England Medical Center,
Boston, MA, USA
• MIY, gift of Dr. C. Buske, University of Munich, Germany
• pMSCV neo, Clontech, Palo Alto, USA
• pCDNA3 GFP, gift of Dr. K. Foster, University of Munich, Ger-
many
2.5.2 All other plasmids used for this work
• pApuro Hck wt, gift of Dr. Seth Corey, Pitsburgh, USA
• pCDpuro Hck K269R, gift of Dr. M. Warmuth, University of Mu-
nich, Germany
• pApuro Hck Y501F, gift of Dr. M. Warmuth, University of Munich,
Germany
• pApuro Lyn, gift of Dr. M. Warmuth, University of Munich, Ger-
many
• pApuro Fyn, gift of Dr. M. Warmuth, University of Munich, Ger-
many
• pApuro c-Src, gift of Dr. M. Warmuth, University of Munich, Ger-
many
• pCDpuro Hck K269R R150L, generated by mutagenesis
• pCDpuro Hck K269R W93A , generated by mutagenesis
• pApuro Hck G2A, generated by mutagenesis
• pCDNA3.1/His c© A Hck wt. To produce this plasmid PCR frag-
ment generated using pApuro Hck wt as a template and the following
primers: 5’-GAA TGT GAA TTC ATG GGG TGC ATG AAG TCC
AAG-3’ and 5’-CGG GGT ACC TGG CTG CTG TTG GTA CTG
G-3’, was sub-cloned into EcoRI/KpnI sites of pCDNA3.1/His c© A
vector.
• pCDNA3.1/His c© A Hck K269R. To produce this plasmid PCR
fragment generated using pCDpuro Hck K269R as a template and the
following primers: 5’-GAA TGT GAA TTC ATG GGG TGC ATG
AAG TCC AAG-3’ and 5’-CGG GGT ACC TGG CTG CTG TTG
GTA CTGG-3’, was sub-cloned into EcoRI/KpnI sites of pCDNA3.1/His c©
A vector.
• pCDNA3.1/His c© A Hck K269R R150L. To produce this plas-
mid PCR fragment generated using pCDpuro Hck K269R R150L as a
template and the following primers: 5’-GAA TGT GAA TTC ATG
GGG TGC ATG AAG TCC AAG-3’ and 5’-CGG GGT ACC TGG
CTG CTG TTG GTA CTG G-3’, was sub-cloned into EcoRI/KpnI
sites of pCDNA3.1/His c© A vector.
• pCDNA3.1/His c© A Hck K269R W93A. To produce this plas-
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mid PCR fragment generated using pCDpuro Hck K269R W93A as a
template and the following primers: 5’-GAA TGT GAA TTC ATG
GGG TGC ATG AAG TCC AAG-3’ and 5’-CGG GGT ACC TGG
CTG CTG TTG GTA CTG G-3’, was sub-cloned into EcoRI/KpnI
sites of pCDNA3.1/His c© A vector.
• pCDNA3.1/His c© A Hck G2A. To produce this plasmid PCR frag-
ment generated using pApuro Hck G2A as a template and the following
primers: 5’-GCG AAT TCA TGG CCT GCA TGA AGT CCA AGT
TCC-3’ and 5’-CGG GGT ACC TGG CTG CTG TTG GTA CTG
G-3’, was sub-cloned into EcoRI/KpnI sites of pCDNA3.1/His c© A
vector.
• pCDNA3.1/His c© A c-Src. To produce this plasmid PCR fragment
generated using pApuro c-Src as a template and the following primers:
5’-G GAA TTC ATG GGT AGC AAC AAG AGC-3’ and 5’-CCC
AAG CTT GAG GTT CTC CCC GGG CTG GTA C-3’, was sub-
cloned into EcoRI/HindIII sites of pCDNA3.1/His c© A vector.
• pCDNA3.1/His c© A Lyn. To produce this plasmid PCR fragment
generated using pApuro Lyn as a template and the following primers:
5’-G GAA TTC ATG GGA TGT ATA AAA TCA AA -3’ and 5’-CGG
GGT ACC AGG CTG CTG CTG GTA TTG CCC TTC C-3’, was
sub-cloned into EcoRI/KpnI sites of pCDNA3.1/His c© A vector.
• pCDNA3.1/His c© A Fyn. To produce this plasmid PCR fragment
generated using pApuro Fyn as a template and the following primers:
5’-G GAA TTC ATG GGC TGT GTG CAA TGT-3’ and 5’-CGC
GGA TCC CAG GTT TTC ACC AGG TTG GTA CTG-3’, was sub-
cloned into EcoRI/BamHI sites of pCDNA3.1/His c© A vector.
• pMSCV IRES EGFP Hck wt. To produce this plasmid Hck wt
fragment was sub-cloned from pApuro Hck wt into EcoRI cloning site
of pMSCV IRES EGFP vector.
• pMSCV IRES EGFP Hck K269R. To produce this plasmid Hck
K269R fragment was sub-cloned from pCDpuro Hck K269R into EcoRI
cloning site of pMSCV IRES EGFP vector
• pMSCV IRES EGFP Hck Y501F. To produce this plasmid Hck
Y501F fragment was sub-cloned from pApuro Hck Y501F into EcoRI
cloning site of pMSCV IRES EGFP vector.
• pCDHF3, gift of Dr. Hitoshi Kiyoi, Nagoya University School of
Medicine, Nagoya, Japan
• pCDNA6A hFlt3 wt, gift of Dr. Spiekermann, University of Mu-
nich, Germany (generated by BamHI/PstI sub-cloning of Flt3 wt frag-
ment from pCDHF3 plasmid)
• pCDHFTD, contains a full-length human Flt3 ITD (Mt3) cDNA
cloned from pCDSRα expression vector, gift of Dr. Hitoshi Kiyoi,
Nagoya University School of Medicine, Nagoya, Japan [111]
• pCDNA6A hFlt3 ITD, generated by BamHI/PstI sub-cloning of
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Flt3 ITD fragment from pCDHFTD plasmid, gift of Dr. Spiekermann,
University of Munich,Germany
• pCDNA6A c-kit, gift of Dr. Spiekermann, University of Munich,
Germany
• pCDNA6A hFlt3 K644R, generated by mutagenesis
• pCDNA6A hFlt3 Y589F, generated by mutagenesis
• pCDNA6A hFlt3 Y591F, generated by mutagenesis
• pCDNA6A hFlt3 Y589F, Y591F, generated by mutagenesis
• pCDNA6A hFlt3 Y589F, Y591F, Y597F, Y599F, generated by
mutagenesis
• pCDNA6A hFlt3 K644R, Y589F, Y591F, generated by mutage-
nesis
• pCDNA6A hFlt3 K 644R, Y589F, Y591F, Y597F, Y599F,
generated by mutagenesis
• pCDNA6A hFlt3 ITD K644R, generated by mutagenesis
• pCDNA6A hFlt3 ITD Y589F, generated by mutagenesis
• pCDNA6A hFlt3 ITD Y591F, generated by mutagenesis
• pCDNA6A hFlt3 ITD Y589F, Y591F, generated by mutagenesis
• MIY hFlt3 wt. To produce this plasmid BamHI/PstI fragment en-
coding hFlt3 wt was sub-cloned into HpaI site of MIY vector.
• MIY hFlt3 ITD. To produce this plasmid BamHI/PstI fragment
encoding hFlt3 ITD was sub-cloned into HpaI site of MIY vector.
2.6 Bacterial strains
• DH5α, gift of Dr. A. Obermeier, Sirenade AG, Martinsried, Germany
• XL-1 Blue, Stratagene La Jolla, USA
• XL-10 Gold, Strategene, La Jolla, USA
2.7 Mammalian cell lines
• HEK-293, gift of Dr. H. Buening, Gene Center, Munich, Germany.
This cell was obtained after transformation of human embryonic kid-
ney cells with adenovirus type 5 DNA [74].
Cells were maintained in DMEM supplemented with 10% FBS, 100
Units/ml of penicillin and 0.1 mg/ml of streptamycin. Cells were split
1:5 to 1:7 every 2-3 days using trypsin/EDTA.
• COS-7, DSMZ, Braunschweig, Germany.
This cell line was derived from a simian cell line CV-1 by transforma-
tion with an origin-defective mutant of SV-40.
Cells were maintained in DMEM supplemented with 10% FBS, 100
Units/ml of penicillin and 0.1 mg/ml of streptamycin. Cells were split
1:3 to 1:5 every 2-3 days using trypsin/EDTA.
2.8. Molecular biological techniques 53
• 32D clone 3 (32D cl.3), gift of Dr. Van Etten, Tufts-New England
Medical Center, Boston, MA, USA.
This cell line was established from Friend murine leukemia retrovirus
infected continuous bone marrow culture derived from C3H/HeJ mouse.
Cell growth is strictly dependent on the presence of IL-3 in the culture
medium. Cells were maintained at 0.1-1x106 cells/ml in RPMI supple-
mented with 10% FBS, 10% supernatant of WEHI-3B cells as source
of IL-3, 100 Units/ml of penicillin and 0.1 mg/ml of streptamycin.
• WEHI-3B, DSMZ, Braunschweig, Germany.
This is a macrophage-like cell line derived from a BALB/c mouse
treated for tumor induction. The cells secrete IL-3 into the culture
medium.
Cells were maintained in RPMI supplemented with 10% FBS, 100
Units/ml of penicillin and 0.1mg/ml of streptamycin. For splitting
cells were loosened by incubation in PBS (without Mg2+ or Ca2+)
and detached mechanically using cell scrapers.
• THP-1, gift of Dr. Spiekermann, University of Munich, Germany.
This cell line was established from the peripheral blood of a 1-year old
boy with acute monocytic leukemia at relapse.
Cells were maintained at 0.1-1 X 106 cells/ml in RPMI supplemented
with 10% FBS, 100 Units/ml of penicillin/ml and 0.1 mg/ml of strep-
tamycin. Cells were split 1:2-1:3 every 3-4 days.
• MV4-11, gift of Dr. Spiekermann, University of Munich, Germany.
This cell line was established from peripheral blood of a 10-year old
boy with acute monocytic leukemia. The Flt3 gene in this cell line
contains an ITD mutation.
Cells were maintained in RPMI supplemented with 10% FBS, 100
Units/ml of penicillin and 0.1 mg/ml of streptamycin.
• MM6, gift of Dr. Spiekermann, University of Munich, Germany.
This cell line was established from the peripheral blood of a 64-year
old man with relapsed acute monocytic leukemia.
Cells were maintained at 0.3-1 X106 cells/ml in RPMI supplemented
with 10% FBS, 100 Units/ml of penicillin and 0.1 mg/ml of strep-
tamycin.
2.8 Molecular biological techniques
2.8.1 Introduction of plasmid DNA into bacteria
Exposure of bacterial cells to high concentrations of certain divalent ions
makes a small fraction of cells permeable to foreign DNA by a mechanism
not yet understood. Bacteria that incorporated plasmid DNA, which carries
antibiotic resistance gene, are selected by plating the cells on dishes contain-
ing nutrient agar and appropriate antibiotic. Methods for preparation and
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transformation of competent E.coli used in this work are described below.
Generation of competent bacterial cells
CaCl2 Solution for generation of competent E.coli
60 mM CaCl2
15% Glycerol
10 mM PIPES, pH 7.0
filter sterilized
Overnight bacterial cultures were diluted 1:10 with fresh LB-medium
and grown at 37oC with shaking at 250 rpm until cell density reached an
OD590 of 0.4. Cells were then aliquoted into prechilled 50 ml tubes and
left on ice for 5-10 minutes. Cells were centrifuged for 7 minutes at 1600g,
4oC. Centrifuge was allowed to decelerate without breaks. Supernatant was
poured out, and each cell pellet was resuspended in 10 ml of ice cold CaCl2
solution. Cells were then centrifuged for 5 minutes at 1100g, 40C. Each
cell pellet was resuspended in 10 ml of ice cold CaCl2 solution and left
on ice for 30 minutes. Cells were pelleted down by centrifugation for 5
minutes at 1100g, 4oC. Supernatant was poured out and each cell pellet was
resuspended in 2 ml of ice cold CaCl2 solution. Cells were dispensed into
prechilled sterile 1.5 ml tubes and frozen immediately either at -80oC or in
liquid Nitrogen.
Transformation of competent bacteria
An aliquot containing 50-150 µl of competent bacteria was thawed on ice.
0.5-5 µl of DNA was added to bacteria, and tubes were swirled gently to
mix bacteria and DNA. The mixture was incubated on ice for 30 minutes.
Tubes were then placed into 42oC water bath for 45 seconds. Immediately
afterwards tubes were returned on ice for 2 minutes. 500 µl of LB medium
was added to each tube. Tubes were incubated at 37oC with shaking at
250 rpm for 1 hour. Bacteria was pelleted down by centrifugation at 7000g
and plated on LB plates containing the appropriate antibiotic. Plates were
incubated at 37oC overnight.
2.8.2 Production of recombinant DNA plasmids
Production of DNA fragments of interest and their insertion into the plasmid
DNA is a first step in the generation of multiple copies of a plasmid DNA
(plasmid DNA cloning). The techniques for the generation of recombinant
plasmid DNA used in this work are described below.
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Digestion of plasmid DNA with restriction endonucleases
Restriction endonucleases recognize short DNA sequences and cleave double-
stranded DNA at specific sites within or adjacent to the recognition se-
quence.
Restriction nuclease cleavage was accomplished by incubating the enzyme(s)
with the DNA in the appropriate reaction conditions according to enzyme
manufacturer’s instructions.
De-phosphorylation of 5’-phosphate residues from DNA using calf in-
testine phosphatase (CIP)
When cDNA fragments resulted from cleavage with a single restriction en-
donuclease had to be sub-cloned into a vector linearized using the same
restriction endonuclease, linearized vector DNA was treated with CIP to
remove 5’-phosphate. The presence of 5’-phosphate residue is necessary for
formation of phosphodiester bonds catalyzed by DNA ligases. Therefore,
de-phosphorylation of 5’-phosphate residues prevents ligation of vector on
itself and reduces the amount of false positive colonies obtained after trans-
formation of ligation mixture into the bacteria.
De-phosphorylation of 5’-phosphate residues from DNA was accomplished
by incubating CIP with the DNA in the appropriate reaction conditions
according to enzyme manufacturer’s instructions.
Modification of sticky ends of DNA into blunt ends using T4 DNA poly-
merase
When direct sub-cloning of DNA containing compatible cohesive ends was
not possible, cohesive ends were converted into blunt ends and blunt-end
cloning was used. 3’-recessed DNA ends were filled in and 3’-overhanging
ends were removed using T4 DNA polymeraze, which possess both 5’→3’
DNA polymerase and 3’→5’ exonuclease activities.
DNA was dissolved in 1X T4 DNA Polymerase reaction buffer, supplemented
with 100 mM dNTPs and 50 µg/ml BSA, and incubated with 0.2 units/µl
of T4 DNA polymerase at 12oC for 20 minutes. Reaction was stopped by
incubating the tubes at 75o C for 10 minutes. DNA was then purified using
PCR purification kit (Qiagen).
Ligation using T4 DNA Ligase
T4 DNA Ligase catalyzes the formation of phosphodiester bonds between
juxtaposed 5’-phosphate and and 3’-hydroxyl termini in duplex DNA.
To join restriction fragments having either cohesive or blunt ends, DNA was
dissolved in 1X T4 DNA Ligase reaction buffer (50 mM Tris-HCl, pH 7.5, 10
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mM MgCl2, 10 mM DTT, 1 mM ATP, 25 µ/ml BSA) and incubated with 40
Units/µl (for cohesive end cloning) or 200 Units/µl (for blunt end cloning)
of T4 DNA Ligase at 160C for 3 hours. Ligation mixture was used directly
to transform competent E. coli.
Amplification of DNA fragments by PCR
PCR was used to amplify DNA fragments necessary for production of re-
combinant DNA plasmids. Optimal parameters for the PCR reaction, such
as primer annealing temperature, elongation temperature and time were
chosen individually for each reaction.
Composition of a standard PCR mix is presented below.
Standard PCR mix
1 µM primers, each
0.5 mM dNTPs mixture (each)
10pg - 0.2 µg template DNA
1X 10X Taq Polymerase Reaction Buffer
1 u Taq Polymerase
variable sterile deionized H2O
Purification of DNA fragments after enzymatic reactions
QIAquick PCR Purification kit and QIAquick Gel Extraction kit were used
to purify DNA fragments after enzymatic reactions and agarose gel elec-
trophoresis. In both kits spin-columns with silica membranes are used. At
high concentration of chaotropic salts and optimal pH, DNA adsorbs to sil-
ica membranes while contaminants pass through. DNA is then eluted from
the columns using a buffer with low salt concentration and basic pH.
2.8.3 Site-directed PCR-based mutagenesis
To introduce point mutations into cDNAs, Stratagene’s QuikChange Site-
Directed mutagenesis kit or its components were used. Suprecoiled double
stranded DNA vector and two oligonucleotide primers, which are comple-
mentary to the opposite sites of the vector and contain the desired muta-
tion were used for PCR reaction. During temperature cycling with high
fidelity Pfu Turbo DNA polymerase, mutated plasmids containing stag-
gered nicks were generated. The presence of PCR reaction product was
confirmed by analyzing 10 µl of PCR mixture on the agarose gels. Parental
DNA was digested with DpnI endonuclease, which is specific for metylated
and hemi-metylated DNA. Plasmids produced in dam+ E. coli strains were
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used as template DNA, therefore the parental strands contained methy-
lated adenosine. In contrast the PCR-synthesized daughter strands did
not contain 6-methyl-adenosine and were resistant to cleavage by DpnI.
For DpnI digestion, 1 µl of DpnI endonuclease was added to 40 µl of the
PCR mixture, and restriction was carried out at 37oC for 1 hour. 5 µl
or PCR mixture treated with DpnI was transformed into XL-10 Gold or
DH5α bacterial strains. Clones, containing correct plasmids were identi-
fied by restriction analysis. Presence of only desired mutations was con-
firmed by the sequence analysis of the whole cDNA. Composition of a
PCR mix for site-directed mutagenesis is presented below. Parameters used
for generation of Flt3 and Hck point mutants are described in Table 2.1.
Standard PCR mix for site-directed mutagenesis
1 µM primers, each
200 µM dNTPs mixture (each)
0.1 - 1 µg template DNA
3µl QuikChange Solution
1X 10X Pfu Turbo Reaction Buffer
2.5 u Pfu Turbo DNA polymerase
sterile deionized H2O to 50 µl
cDNAa Mutation Sense and antisense primers Thermocyclingb
Tann tann n
(oC) (sec)
hFlt3 K644R 5’ CAA TCC AGG TTG CCG TCC GAA TGC TGA 60 50 18
AAG AAA AAG CAG ACA GC 3’
3’ GTT AGG TCC AAC GGC AGG CTT ACG ACT
TTC TTT TTC GTC TGT CG 5’
hFlt3 Y589F 5’ G GTG ACC GGC TCC TCA GAT AAT GAG TTC 60 50 18
Y591F TTC TTC GTT GAT TTC AGA G 3’
3’ C CAC TGG CCG AGG AGT CTA TTA CTC AAG
AAG AAG CAA CTA AAG CTC C 5’
hFlt3 Y597F 5’ C GTT GAT TTC AGA GAA TTT GAA TTT GAT 55 50 3
Y589F, Y599F CTC AAA TGG GA 3’ 60 55 17
Y591F 3’ G CAA CTA AAG TCT CTT AAA CTT AAA CTA
GAG TTT ACC CT 5’
Hck R150L 5’ CTG GGC TCC TTC ATG ATC CTG GAT AGC 55 50 4
K269R GAG ACC ACT AAA GG 3’ 60 55 16
3’ GAC CCG AGG AAG TAC TAG GAC CTA TCG
CTC TGG TGA TTT CC 5’
Table 2.1: Parameters used for the generation of Flt3 and Hck point mutants by
PCR-based site-directed mutagenesis. All cycling protocols started by a 3 min.
denaturation step and were concluded by a 7 min. extension step at 68oC. The
individual cycles contained a 50 sec. denaturation step at 95oC and were concluded by
an extension step at 68oC for 21 min.a: templates used for Flt3 and Hck, respectively:
pcDNA6-Flt3wt(ITD) and pCDpuro-Hck. b: Tann: annealing temperature, tann:
time for annealing, n: cycle number.
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2.9 Mammalian cell culture techniques
2.9.1 Transfection of plasmid DNA into mammalian cells
Transfection of plasmid DNA into HEK-293 cells using Calcium Phos-
phate method
In this approach precipitate containing calcium phosphate and DNA is
formed by mixing HEPES buffered saline solution (HBS) with a solution
containing calcium chloride and DNA. The precipitate adheres to the sur-
face of the cells and is taken up by the cells via yet unknown mechanism.
Solutions
HBS buffer
50mM Hepes
280mM NaCl
1.5mM NaP*
filter sterilized
pH is adjusted with NaOH to 7.2
*NaP is 1:1 mixture of equal molar amounts of Na2HPO4 and NaH2PO4.
pH range of HBS solution optimal for transfection is very narrow. There-
fore, 5 aliquots of HBS solution with pH ranging from 6.6 to 7.8 with the
step of 0.3 were prepared and tested using pCDNA3 GFP for the highest
transfection efficiency.
CaCl2 Solution for transfection
250 mM CaCl2 in H2O
filter sterilized
250 mM CaCl2 Solution was prepared shortly before transfection by dilut-
ing 2.5 M CaCl2 stock solution using sterile endotoxin-tested water (Sigma,
USA).
HEK-293 cells were sub-cultured as described in 2.7. The day before
transfection cells were seeded at 1.7 X 106 cells per 6 cm tissue culture
plate. 10 µg of DNA was diluted in 119 µl of 250 mM CaCl2 solution.
Components were mixed by vortexing briefly at low speed. 119 µl of HBS
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solution was then added dropwise to DNA/ CaCl2 mixture and tubes were
vortexed immediately for 3-4 seconds at low speed. Culture medium was
changed to 4 ml of fresh medium and DNA/ CaCl2/ HBS mixture was
added to the cells dropwise within two minutes after addition of HBS buffer.
12-24 hours after the transfection, culture medium was changed to 4 ml of
fresh medium. 36-48 hours after transfections cells were either lysed or
supernatant containing recombinant retrovirus was harvested.
Transfection of COS-7 cells using Effectene Transfection reagent kit
In this method, DNA is condensed by interaction with Enchancer reagent
of the kit in a defined buffer system. Effectene reagent, which is based on
a proprietary non-liposomal lipid, is then used to coat the condensed DNA.
DNA-Effectene complexes fuse with the plasma membrane of tissue culture
cells resulting in both uptake and expression of the DNA.
COS-7 cells were sub-cultured as described in 2.7. The day before trans-
fection cells were split 1:3, which resulted in about 50% confluent cellular
monolayer on the day of the transfection. Right before transfection, medium
was changed to 2 ml of DMEM containing 1.5 g/L of glucose, supplemented
with 10% FBS, 100 Units/ml of penicillin and 0.1 mg/ml of streptamycin.
1-2 µg of DNA was mixed with 100 µl of EC buffer from the kit and 12 µl of
Enchancer. The mixture was vortexed and incubated at room temperature
for 5 minutes. 14 µl of Effectene Reagent was added to the mixture. The
components were mixed by vortexing for 10 seconds. The mixture was then
incubated at room temperature for 10 minutes. 900 µl of DMEM containing
4.0 g/L of glucose, supplemented with 10% FBS, 100 Units/ml of penicillin
and 0.1mg/ml of streptamycin, was added to the mixture. Samples were
mixed carefully and the mixture was added to the cells dropwise. Culture
medium was changed 8-16 hours after the transfection. Cells were lysed 48
hours after the transfection.
2.9.2 Production of recombinant retrovirus using transient trans-
fection of HEK-293 cells
Recombinant replication-incompetent retroviruses have been generated by
co-transfecting HEK-293 cells with the packaging vector (ecopac) and the
retroviral vector (pMSCV neo, pMSCV IRES EGFP, MIY). Packaging vec-
tor carries retroviral gag, pol and env genes that are required for replication
of retrovirus. Retroviral vector carries the gene of interest, Ψ+ packaging
signal and LTRs, which encode most of the viral control elements including
promoter, enchancer, the polyadenylation signal and the integration signal.
HEK-293 cells were co-transfected with ecopac and appropriated retroviral
vector using calcium phosphate method. 10 µg of retroviral vector and 5
µg of ecopac were usually used per transfection of 80-90% confluent cells
in 6 cm dishes. 12 hours after the transfection, medium was changed to 3
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ml of fresh medium. Supernatant, containing recombinant retrovirus was
harvested 36-48 hours after the transfection, aliquoted and stored at - 80oC.
2.9.3 Titering retroviral stocks
Following infection and reverse transcription of the viral genome, integration
of the viral DNA into the host cell DNA takes place. The number of proviral
integrants into the cellular genome depends on the infection efficiency. Ac-
cording to Poisson statistics, the uninfected fraction is equal to e−l, where l
is the mean proviral copy number per cell. Therefore, when 10% of cells are
infected, the mean proviral copy number per cell is -ln(0.9)=0.1. So, most
infected cells have single proviruses. To generate cell lines, in which most
cells have single proviruses, infections efficiency was kept at 10% or lower.
To normalize between different viral stocks, 32D cl.3 cells were infected
with serial dilutions of retrovirus. Infection efficiency was measured 36-48
hours after the infection by FACS analysis of GFP or YFP expression. Dilu-
tions, at which infection efficiency was 10% or less were used for generation
of 32D cl.3-based cell lines.
2.9.4 Infection of mammalian cells with recombinant retroviruses
Infection of 32D cl.3 cells with retorovirus was achieved by incubation of
retrovirus with cells in the presence of polycations (Polybrene).
Polybrene Solution
800 µg/ml of Polybrene in H2O
filter sterilized
Fresh aliquot of the HEK-293 cells’ supernatant, containing appropriate
recombinant retrovirus was thawed in 370C water bath shortly before the
infection. Exponentially or sub-confluently growing cultures of 32D cl.3 cells
were used for infection. 5 X 104 cells per infection were resuspended in 250
µl of RPMI, supplemented with 10%FBS, 10% WEHI-3B supernatant, 100
Units/ml of penicillin and 0.1mg/ml of streptamycin, in 24-well plate. 16
µg/ml (2X final concentration) of polybrene was added to the cells. When
necessary (see 2.9.3), viral stocks were diluted in RPMI supplemented with
10% FBS, 10% WEHI-3B supernatant, 100 Units/ml of penicillin and 0.1
mg/ml of streptamycin. 250 µl of diluted or undiluted viral stock was added
to the cells. Cells were mixed gently and returned to the incubator for 3-5
hours. 1.5 ml of fresh culture medium was then added to the cells. Cells were
incubated for 48 hours at 370C before subsequent analysis or fluorescence-
activated cell sorting.
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For infection of higher numbers of cells, the volumes of all the components
were multiplied accordingly.
2.9.5 Fluorescence-activated cell sorting
Modular Flow cytometer (MoFlo), Cytomation, USA, was used for cell sort-
ing. In flow cytometer equipped for cell sorting, fluorescent light emitted by
each cell is measured and cell suspension is passed through a nozzle, which
forms droplets containing at most single cells. At the time of formation,
each droplet is given an electric charge proportional to the amount of fluo-
rescence in the cell. Droplets containing electric charge which corresponds
to the fluorescence of desired cells are separated by an electric field and col-
lected.
Cells to be sorted were pelleted by centrifugation at 1000g for 5 minutes,
resuspended in the small volume of culture medium to the final concentra-
tion of 5x107 cells/ml. Cell suspension was passed through sterile 40 µl cell
strainers to obtain single cell suspension right before sorting. Immediately
after sorting cells were resuspended in the appropriated culture medium and
returned to the cell culture incubators.
2.9.6 Generation of 32D cl.3 cells expressing Flt3 and Flt3 F692T
using antibiotic selection
Retroviruses encoding Flt3 constructs and neomycin resistance gene were
generated by transient transfection of HEK-293 cells. 32D cl.3 cells were
infected with retroviruses as described. 48 hours after the transfection,
cells were transfered to the medium containing 1 mg/ml of G418. Infected
cells were selected in the presence of G-418 for 1 week until all cells in the
uninfected control have died. Resulted cell lines were sub-cultured in the
presence of 0.5 mg/ml of G-418.
2.9.7 Generation of 32D cl.3-based cell lines expressing Flt3
and Hck constructs using FACS
To generate 32D cl.3 cell lines expressing Flt3 and Hck constructs, cells
were first infected with retrovirus containing Flt3-IRES-EYFP and YFP-
positive cells were sorted as described in 2.9.5. Within a few days after
sorting, sorted cells were infected the second time with retroviruses contain-
ing Hck-IRES-EGFP, and GFP/YFP-positive cells were sorted. Infection
with retrovirusese were performed as described in 2.9.4. Infectiion efficiency
was always kept at 10% or lower. Aliquots of sorted cells were frozen within
a few days after sorting. Cells, which were in culture for no longer than 3
weeks were used for subsequent analysis.
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2.10 Analysis of mammalian cells
2.10.1 Analysis of cells by flow cytometry
Coulter EPICS XL-4 flow cytometer, Beckman Coulter GmbH, Germany,
was used for analysis of cells by flow cytometry. Individual cells expressing
different molecules can be detected by flow cytometry. Expression of pro-
teins can be detected by staining cells with specific antibodies covalently
conjugated with fluorochrome. Alternatively, cells expressing fluorescent
proteins, such as GFP or YFP can be detected directly. When cells are
placed on flow cytometer, a stream of cells is directed through an argon
laser beam that excites fluorochrome to emit light. The emitted light is
then detected by a photomultiplier tube specific for an emission wavelength
of fluorochrome by virtue of a set of optical filters. The signal is amplified in
its own channel and is displayed in a variety of different forms: histogram,
dot blot or contour display.
Analysis of GFP and YFP expression by FACS
5 X 105 cells were pelleted down by centrifugation at 1000g for 2 minutes,
resuspended in 500 µl of fresh culture medium and used directly for flow
cytometry.
Analysis of Flt3 surface expression by FACS
5X105 cells were pelleted down by centrifugation at 1000g for 2 minutes
and washed once with PBS, containing 0.2% FBS. 10 µl of either anti-Flt3
antibody (clone SF 1.340, Immunotech, France) or isotype control antibody
(mouse Ig G1 antibody, Immunotech, France), both covalently conjugated to
phycoerythrin (PE), were added to the cells. Cells were mixed by flicking the
tubes and incubated with the antibodies for 15 minutes at room temperature
in the dark. 4 ml of PBS containing 0.2% FBS was then added to the
cells. Cells were pelleted down by centrifugation at 1000g for 5 minutes,
resuspended in 250 µl of PBS containing 0.2% FBS, and analyzed by flow
cytometry.
2.10.2 Determination of cell viability and numbers
When cells undergo necrosis or are at the late stages of apoptosis (secondary
necrosis), they lose the integrity of the plasma membrane. These cells can
be detected using exclusion dyes such as Trypan Blue. Trypan Blue stains
only those cells, which have lost the membrane integrity, leaving cells with
intact plasma membrane unstained.
10 µl of cell suspension was mixed with 10 µl of Trypan Blue solution and
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counted using cell counting chambers. Cells which were negative for Trypan
Blue staining were considered viable.
Cell growth assay with 32D cl.3 derived cell lines, expressing Flt3 ITD
Cell growth reflects the rates of cell proliferation and apoptosis. Cell growth
was determined by counting viable cells over a period of time.
Cell lines which were in culture for no more than 3 weeks were used for
the assay. Prior to the start of the assay, all cell lines were sub-cultured
as described in 2.7 in the presence of IL-3. Concentration of viable was
determined using Trypan Blue dye staining as described above. Cells were
washed 3 times with culture medium without IL-3, and resuspended in the
culture medium with or without IL-3 to the final concentration of 1 X 104
viable cells/ml. Cells were plated in triplicates in 24 well plates at 1 ml of
cell suspension per well. 72 hours after plating, concentration of viable cells
was determined using Trypan Blue dye staining as described above.
2.10.3 Apoptosis assay using Annexin-V apoptosis detection
kit
Annexin-V is a calcilum-dependent phospholipid binding protein, that has
a great affinity for phosphatidylserine. In normal cells phosphatydilserine
is present in the inner leaflet of the plasma membrane, while outer leaflet
contains mostly neutral phospholipids. However, as cells undergo apopto-
sis, loss of asymmetry in the plasma membrane phospholipids occurs. The
amount of phosphatidylserine in the outer leaflet of the membrane increases.
Therefore, Annexin-V binds to the surface of apoptotic, but not normal cells.
Late stages of apoptosis (secondary necrosis) and necrosis, are accompanied
by the loss of the integrity of the plasma membrane. Annexin-V can enter
such cells and bind phosphatidylserine in the inner inner leaflet of cells. To
discriminate between apoptotic and necrotic cells, staining with the vital
dye 7-Amino-actinomycin (7-AAD) was performed in parallel to Annexin-V
labeling.
Cells were pelleted by centrifugation, washed with PBS and resuspended
in 100 µl of Annexin-V binding buffer at the concentration of 1 X 106
cells/ml. 2.5 µl of Annexin-V conjugated to PE and 2.5 µl of 7-AAD were
added to the cells. Cells were mixed gently and incubated for 15 minutes
at room temperature in the dark. 400 µl of binding buffer was then added
to the cells and cells were analyzed by flow cytometry within 2-3 hours. All
cells which were Annexin-V positive were considered apoptotic.
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Apoptosis assay with 32D cl.3 derived cell lines expressing Flt3 wt
Cell lines which were in culture for no more than 3 weeks were used for
the assay. Prior to the start of the assay, all cell lines were sub-cultured
as described in 2.7 in the presence on IL-3. Concentration of viable cells
was determined using Trypan Blue dye staining as described above. Cells
were washed 3 times with culture medium without IL-3, and resuspended in
culture medium with or without 10% of WEHI-3B supernatant as a source
of IL-3 or 100 ng/ml Flt3 ligand (Promocell, Germany) to the final concen-
tration of 1X105 cells/ml. Cells were plated in triplicates in 24 well plates
at 1 ml of cell suspension per well. Apoptosis was measured 24-48 hours
after plating using Annexin-V apoptosis detection kit as described above.
2.11 Analysis of proteins
2.11.1 Preparation of cellular lysates
During lysis intracellular and membrane proteins are solubilized due to the
presence of detergent and high salt concentration in the lysis buffer. Non-
solubilized proteins are precipitated by centrifugation. Protease inhibitor
cocktail is included in the lysis buffer to prevent proteolysis, phosphotase
inhibitor cocktail - to maintain the phopsphorylation status of phosphopro-
teins, EDTA - to chelate divalent ions that are essential for metalloproteases.
Lysis Buffer
20mM Tris-HCl, pH 8.0
150mM NaCl
10% Glycerol
1% NP-40
10mM EDTA, pH 8.0
filter sterilized
Protease and phosphatase inhibitor coctails were added freshly before cell
lysis at 1:100 vol./vol. dilution.
Preparation of lysates of adherent cells after transient transfection
HEK-293 and COS-7 cells were transfected in 6 cm cell culture dishes as
described 2.9.1. 36-48 hours after transfection, some cells were stimulated
with recombinant human Flt3 ligand (FL). For stimulation, 3 ml of medium
was removed and 1 ml of medium was left in each of 6 cm cell culture
dishes. Fresh aliquot of Flt3 ligand (Promocell, Germany) was thawed up
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shortly before stimulation. Flt3 ligand was added to the cells at the final
concentration of 100 ng/ml. Cells were incubated in the presence of the
ligand for 10 minutes at 370C. Medium was then aspirated, and cell culture
dishes were placed on ice. 450 µl of lysis buffer for HEK-293 cells, and 300
µl of lysis buffer for COS-7 cells, was added to each 6 cm dish. Cells were
detached from the dishes using plastic cell scrapers and transfered to 1.5
ml pre-chilled tubes. Cells were lysed at 4o with constant rocking for 15-30
minutes. Non-solubilized proteins were pellted down by centrifugations at
20000g, 4oC for 10 minutes . Pre-cleared lysates were then transfered to the
new 1.5 ml pre-chilled tubes. Lysates were stored at -80oC and thawed on
ice when necessary.
Preparation of lysates of non-stimulated suspension cells
To prepare lysates of non-stimulated cells suspension cells, exponentially or
sub-confluently growing cell cultures were pelleted down by centrifugation at
1000g for 5 miuntes and culture medium was discarded. Cells were washed
once with ice cold PBS and resuspended in lysis buffer at the concentrations
described in table 2.2. Cellular lysates were prepared further as described
above for adherent cells.
Table 2.2: Concentrations of suspensions cells used for preparation of cellular lysates.
Cell line Cells per 1 ml of lysis buffer
32D cl.3 1 X 108
THP-1
MM6 2 X 107
MV4-11
Preparation of lysates of suspension cells stimulated with Flt3 ligand
Stimulation of 32D cl.3 cells with Flt3 ligand before lysis. Exponen-
tially or sub-confluently growing 32D cl. 3 cells were pelleted down by
centrifugation at 1000g for 5 miuntes and culture medium was discarded.
Cells were washed 3 times with culture medium without IL-3 and resus-
pended in the same volume of culture medium without IL-3 as that of the
discarded medium. Cells were returned to the incubator for about 12 hours.
Cells were then pelleted down by centrifugation at 1000g for 5 miuntes and
resuspended in a small volume of culture medium without IL-3 to the final
concentration of about 2-4 X 107 cells/ml in 15 ml or 50 ml tubes. Flt3 lig-
and (Promocell, Germany) was added to the cells at the final concentration
of 100 ng/ml. Cells were stimulated with the ligand for 10 minutes at 37oC.
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Stimulation of THP-1 cells with Flt3 ligand before lysis. Exponentially
or sub-confluently growing THP-1 cells were pelleted down by centrifuga-
tion at 1000g for 5 miuntes, washed 3 times with culture medium without
FBS and resuspended in the same volume of culture medium supplemented
with 0.5% FBS. Cells were returned to the incubator for about 16 hours.
Cells were then pelleted down by centrifugation at 1000g for 5 miuntes and
resuspended in a small volume of culture medium with 0.5% FBS to the
final concentration of about 4 X 106 cells/ml in 15 ml or 50 ml tubes. Cells
were stimulated with Flt3 ligand (R&D Systems) at the final concentration
of 20 ng/ml for different periods of time at 37oC.
Lysis of stimulated suspension cells. Immediately after stimulation,
tubes containing cell suspensions were filled with ice cold PBS and cells
were pelleted down by centrifugation at 1000g, 4oC for 5 minutes. PBS was
discarded and appropriate amounts of lysis buffer (see table 2.2) were added
to the cells. Cellular lysates were prepared as described above.
2.11.2 Determination of protein concentration in cellular lysates
The BCA Protein Assay Reagent kit, Pierce, USA, was used to measure pro-
tein concentration in cellular lysates. BCA method combines the reduction
of Cu 2+ to Cu 1+ by proteins in an alkaline medium and selective colori-
metric detection of the cuprous cation (Cu 1+) with a reagent containing
bicinchoninic acid (BCA). The purple-colored reaction product of this assay
is formed by the chelation of two molecules of BCA with one cuprous cation.
This complex has a strong absorbance at 562 nm that is nearly linear with
increasing protein concentrations.
2 µl of protein lysates were diluted in 98 µl of water. Protein standards
for calibration were prepared by diluting 0, 5, 15 and 30 µg of bovine serum
albumin (BSA) from 2 mg/ml stock solution in water to the final volume
of 100 µl. Working BCA reagent was prepared freshly by mixing reagent A
(containing bicinchoninic acid, sodium carbonate, sodium bicarbonate and
sodium tartrate in 0.1M sodium hydroxide) and reagent B (containing 4%
cupric sulfate) from the kit at the ratio of 1:50 vol./vol.. 900 µl of working
reagent was added to protein samples diluted in water and components were
mixed by inverting the tubes 3-4 times. Tubes were placed in 65oC water
bath for 5 minutes. Tubes were allowed to cool down at room temperature
for about 10 minutes. 562 nm absorbance of all samples was measured
using spectrophotometer. Standart curve was prepared by plotting standard
absorbance measurements against their protein concentrations. Equation of
a linear fit curve was used to calculate protein concentration in each sample.
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2.11.3 Immunoprecipitation of proteins from cellular lysates
In this approach, specific antibody is added to the cellular lysate to bind
protein of interest. Antibody-protein complexes are then precipitated using
solid-phase matrix. Bacterial proteins A and G which have specific binding
sites for Fc-parts of antibodies, covalently coupled to cross-linked agarose,
are usually used as solid-phase matrix to precipitate protein-antibody com-
plexes.
Cellular lysates containing 0.5-1 mg of total protein were mixed with
about 1 µg of antibody in pre-chilled 1.5 ml tubes on ice. Volumes of the
mixture were adjusted to 200-300 µl to obtain equal protein concentrations
in each sample. Tubes were incubated for 3 hours to overnight at 4oC
with constant rotation. 20-25 µl of Protein A or G coupled agarose was
added to each sample and tubes were incubated for additional 45 minutes
at 4oC with constant rotation. Following incubation with Protein A or G
agarose, immuno-complexes were pelleted by centrifugation at 1000g, 4oC
for 15 seconds and washed 3 times with ice-cold lysis buffer. Each time com-
plexes were collected by centrifugation at 1000g, 4oC for 15 seconds. 5-10
µl of the lysis buffer used for the last wash were left above the agarose pel-
let. 9µl of 4X SDS-PAGE loading buffer (Roti-load, Roth, Germany) were
added to the samples and proteins were denatured by heating to 100oC for
5 mimutes. Samples were cooled down on ice and analyzed immediately
or frozen at -80oC for later analysis. Protein A or G agarose was pelleted
by centrifugation at 1000g for 15 seconds and supernatants, containing im-
munoprecipitated proteins were analyzed by SDS-PAGE.
2.11.4 Separation of proteins by denaturing discontinuous poly-
acrylamide gel electrophoresis
In this approach proteins in the mixture are denatured by heating in the
presence of 2-mercaptoethanol and SDS. Denatured polypeptides bind SDS
and become negatively charged. The amount of bound SDS is almost always
proportional to the molecular weight of a polypeptide, and is independent
of its sequence. Therefore proteins and protein subunits are separated ac-
cording to their size during migration through the pores in the gel matrix
in responce to an electrical field.
Protein samples for electrophoresis were prepared by dissolving a mix-
ture of proteins in SDS-PAGE loading buffer Roti-Load, Roth, Germany,
and heating up the samples at 100oC for 5 minutes.
Separation gels with the following dimensions were used: thickness 1.0
mm, length 7.3 cm and width 8.3 cm.
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Solutions
SDS Electrophoresis Buffer, 5X
0.125M Tris
0.96M Glycine
0.5% SDS
H2O to 1000 ml
Solutions for casting one 8% separating and one stacking gel
Separating gel, 8% Stacking gel
H2O 2.3 ml 1.4 ml
30% Acrylamide 1.3ml 0.33 ml
1.5M Tris (pH 8.8) 1.3ml -
1.5M Tris (pH 6.8) - 0.25 ml
10% SDS 0.05ml 0.02ml
10% APS 0.05 ml 0.02 ml
TEMED 0.003 ml 0.002 ml
Proteins were separated at 120 V until the dye front has left the separa-
tion gel.
2.11.5 Coomassie staining of proteins in gel
Commasie blue dye is a triphenylmethane textile dye, which binds to amino
acids in acidic environment. Excess dye is diffused from gel during prolonged
period of de-staining.
Solutions
Staining solution (Bio-Rad)
0.25% Coomassie Blue R-250
40% Methanol
10% Acetic acid
De-staining solution
40% Methanol
10% Acetic acid
SDS-PAGE gels were placed for 30 minutes in the staining solution.
Gels were then distained in a large excess of de-staining solution until the
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background was satisfactory clear.
2.11.6 Silver staining of proteins in gel
This method of staining proteins in gels is based on the affinity of silver ions
to nucleophilic and aromatic groups. This affinity causes co-localization of
silver ions at the sites of macromolecules in gel. Silver ions are reduced to
metalic silver generating an image of electrophoretic band.
Solutions
Formaldehyde fixing solution
40% Methanol
37% Formaldehyde
0.2 g/L Na2S2O3 (added freshly before use)
Thiosulfate developing solution
30 g/L Na2CO3
4 mg/L Na2S2O3
37% Formaldehyde (added freshly before use)
Silver nitrate solution
0.1% Silver nitrate (prepared freshly before use)
Drying solution
10% Ethanol
4% Glycerol
A gel was placed in a plastic container containing 50 ml of formaldehyde
fixing solution and agitated slowly for 10 minutes on the orbital shaker.
Fixing solution was then poured out and gel was washed twice with water, 5
minutes for each wash. After washing, gel was soaked for 1 minute in 50 ml
of 0.1% Silver nitrate solution. Silver nitrate solution was poured out and
gel was washed for 1 minute with water and then for 30 seconds with a small
volume of thiosulfate developing solution. The gel was then soaked in 50 ml
of thiosulfate developing solution until band intensities were adequate. 5 ml
of 2.3 M citric acid solution per 100 ml of thiosulfate developing solution was
added to the gel for 10 minutes to stop the reaction. Gel was then washed in
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water for 10 minutes and soaked in 50 ml of drying solution for 10 minutes.
For drying, gel was sandwiched between two pieces of wet dialysis membrane
on a glass plate. Edges were clamped with the notebook clamps and the gel
was dried overnight at room temperature.
2.11.7 Transfer of proteins to PVDF-membrane
Proteins separated by SDS-PAGE were transfered to PVDF membrane by
direct electrophoretic transfer. Tank transfer system (Bio-Rad) was used.
Transfer Buffer
250 mM Tris
200 mM Glycine
20% Methanol
PVDF membrane was soaked in methanol for a few minutes and then trans-
fered to a container with transfer buffer. Gel and attached PVDF mem-
brane were sandwiched between two pieces of Whatman 3 MM paper, two
porous pads, soaked in transfer buffer, and two plastic supports. The en-
tire construct was then immersed in an electrophoresis tank, equipped with
platinum electrodes, which contains transfer buffer. PVDF membrane was
placed towards the anode. Transfer was carried out at 100 V for 1-2 hours.
2.11.8 Ponceau S staining of proteins on PVDF-membrane
Staining with Ponceau S was used to provide visiual evidence that elec-
trophoretic transfer of proteins has taken place and to locate molecular
weight markers.
Ponceau S staining solution
0.5g of Ponceau S was dissolved in 1ml of glacial acetic acid
and the volume was adjusted to 100 ml with H2O
PVDF membrane was incubated for 5-10 seconds in Ponceau S staining so-
lution and then washed with water until the protein bands became visible.
2.11.9 Analysis of proteins on PVDF membrane by immuno-
blotting
In this method, specific antibodies are used to identify proteins trasferred
to PVDF membrane. First, membrane is immersed in blocking buffer to
fill all protein binding sites with non-reactive protein. Then membrane is
incubated in a solution containing antibody directed against the antigen(s)
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in the protein to be detected. Primary antibody bound to the protein of in-
terest are recognized by secondary antobody conjugated with horse radisch
peroxidase (HRP). The complex containing the antigen, primary antibody
and secondary antibody- horse radisch peroxidase conjugate is detected
by chemiluminecsent visualization using ECL detection system (Amersham
Biosciences).
Solutions
TBS-T buffer
10 mM Tris-HCl, pH 8.0
150 mM NaCl
0.01% Tween
NET buffer, 10X
1.5M NaCl
0.05M EDTA, pH 8.0
0.5M Tris, pH 7.5
0.5% Triton X-100
Milk blocking solution
5% (w./vol.of non-fat dry milk
dissolved in TBS-T buffer
G-NET blocking solution
2.5 g of gelatine was dissolved in 100 ml
of 10X NET buffer and the mixture was
brought to boiling. The solution was
then mixed using magnetic stir bar until
it became clear. The volume was adjusted
to 1000 ml with water.
PVDF membranes were blocked in the blocking solution either for 1-3
hours at room temperature or overnight at 4oC. G-NET blocking solution
was used with phosphoprotein-specific antibodies and corresponding sec-
ondary antibodies, while milk blocking solution was used with all other
antibodies. After blocking, membranes were transferred to the containers
with primary antibody in 1% milk blocking solution or G-NET solution and
incubated for either 1 hour at room temperature or overnight at 4oC. After
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incubation with primary antibodies, membranes were washed 3-4 times over
20-30 minutes with TBS-T buffer. Washed membranes were transfered to
the containers with secondary antibody-HRP conjugates in 1% milk blocking
solution or G-NET solution and incubated for 30 minutes at room temper-
ature. Blots were then washed 3-4 times over 20-30 minutes with TBS-T
buffer. Excess of TBS-T buffer was drained using tissue paper and 2 ml of
freshly prepared ECL developing solution was added per each blot. Mem-
branes were incubated with ECL solution for 1 minute with slow rocking.
Excess of ECL solution was drained using tissue paper. Membranes were
exposed to Hyperfilm (Amersham Biosciences).
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3.1 Analysis of the specificity of STI-571
The initial goal of the work described in this section was to understandthe specificity of the small molecule inhibitor STI571. However, early
results, which have raised questions as to the role of SFKs in Flt3-mediated
signal transduction, lead to a change the direction of the project.
3.1.1 Single amino acid substitution renders Flt3 sensitive to
STI-571
The small molecule tyrosine kinase inhibitor STI-571 belongs to the 2-
phenylaminopyrimidine class of pharmacophores. STI571 is used as ther-
apeutic agent to treat CML. STI-571 selectively inhibits Abl, Kit, PDGFR
and Arg kinases. Comparison of protein kinase structures and amino acid
alignments of STI571-sensitive and insensitive kinases revealed that three
amino acids surrounding the nucleotide binding site (amino acids at posi-
tions 315, 380 and 382 of Abl) are critical for the sensitivity of a kinase
to STI-571. In general, protein kinases insensitive to STI-571 have bulkier
amino acids at the positions 315 and 380. In support of this, it was shown
that substitution of Thr 315 in Abl for an amino acid with a bulkier side
chain rendered Abl resistant to STI-571. Analysis of the crystal structure of
the catalytic domain of Abl, complexed to a variant of STI-571, also demon-
strates that presence of Thr 315 is a key requirement for inhibition of Abl
by STI-571 [195]. To further understand the high specificity of STI-571, it
was investigated whether the presence in Flt3 of Phe 692 at the position
corresponding to Thr 315 of Abl is the only cause for insensitivity of Flt3
to STI-571.
Phe 692 in Flt3 was substituted with threonine and the sensitivity of the
modified kinase to STI-571 was tested. 32D cell lines expressing Flt3 wt and
Flt3 ITD F692T were generated as described in 2.9.6. Cells were incubated
with STI-571 and the inhibitors of SFKs PP1 and CGP76030 as controls
for 10 minutes. Flt3 was immuno-precipitated using Flt3 specific antibodies
and the phosphorylation status of the receptor was analysed by immuno-
blotting with phospho-tyrosine specific antibodies. As shown in Figure 3.1,
phosphorylation of Flt3 wt or Flt3 ITD was not changed upon incubation
of cells with STI571, confirming insensitivity of Flt3 to inhibition by STI-
571. However, when Phe 692 was substituted by threonine, incubation of
cells with STI-571 led to a significant decrease in Flt3 phosphorylation as
compared with the phosphorylation of Flt3 F692T in the absence of the
inhibitor. This result demonstrates that the presence of phenylalanine in
position 692 causes insensitivity of Flt3 kinase to STI-571 and its substi-
tution by threonine renders Flt3 sensitive to STI-571. Similar results were
also obtained independently by another group [21].
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Substitution of Phe 692 with threonine also led to a decrease in the kinase
activity of Flt3. In contrast to Flt3 ITD, expression of Flt3 ITD F682T in
32D cl. 3 was not sufficient to transform these cells to IL-3-independent
growth (data not shown).
3.1.2 Inhibition of Flt3 phosphorylation by inhibitors of Src ki-
nases.
High specificity of STI-571 is not only affected by the special amino acid
composition in the ATP binding pocket of the sensitive kinases, but also
by their special conformation in the inactive state, to which the compound
specifically binds [195]. For this reason SFKs, which have a high homology
of amino acids essential for the binding of STI-571, are still insensitive to
this inhibitor. SFKs differ from the STI-571-sensitive kinases in the position
of the A-loop, which in the inactive state of the kinase blocks the access of
STI-571 to its binding pocket. A high degree of homology in amino acids
surrounding the nucleotide binding site between SFKs and Abl explains
why most of the SFK inhibitors, including PP1 and CGP76030, also inhibit
STI-571 sensitive kinases such as Abl, PDGFR and Kit. STI-571, PP1 and
CGP76030 share overlapping binding sites in these kinases, as suggested by
studies demonstrating that mutation of Thr 315 makes Abl insensitive not
only to STI-571, but also to PP1 and CGP76030 [228]. Together, these
observations suggest that the presence of phenylalanine in the position cor-
responding to Thr 315 of Abl would be incompatible with sensitivity of a
kinase to SFK inhibitors such as PP1 and CGP76030. Surprisingly though,
Figure 3.1 shows that incubation of 32D cells expressing Flt3 wt or Flt3
ITD with SFK inhibitors PP1 and CGP76030 leads to a decrease in the
phosphorylation of Flt3 regardless of the presence of F692T mutation. This
observation is in contradiction with the assumption mentioned above and
suggest that SFKs phosphorylate Flt3. Stimulated by this finding, the pos-
sibility that SFKs phosphorylate Flt3 and modulate Flt3-mediated signal
transduction was investigated, and the results are presented in the following
sections of this chapter.
3.2 Functional interaction of Hck and Flt3 in HEK-
293 cells
3.2.1 Hck interferes with maturation of Flt3
Detection of mature and immature forms of Flt3 wt and Flt3 ITD in
HEK-293 cells
As described in 1.3.2, Flt3 is N-glycosylated and differentially glycosylated
forms can be detected in cellular lysates byWestern blot analysis. Consistent
with these studies, Figure 3.2 shows that two forms of Flt3 can be detected
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Figure 3.1: Single amino acid substitution renders Flt3 sensitive to inhibition by STI-
571. SFK inhibitors inhibit Flt3 phosphorylation.. 32D cells expressing Flt3
constructs were incubated either in the absence of the inhibitors or in the presence
of 2.5 µM of STI-571, 5 µM of CGP76030 or 50 µM of PP1 for 10 minutes. Flt3
immunoprecipitates were analyzed with either anti-phospho-tyrosine or anti-Flt3
antibodies.
in the lysates of HEK-293 cells by Western blotting. According to previously
published studies (described in detail in 1.3.2), the high molecular weight
form represents mature fully glycosylated Flt3 receptor, which is present
on the cell surface, while a lower molecular weight form corresponds to the
immature receptor that contains high mannose glycosaccharides, which is in-
side the cell. Figure 3.2 also shows that the mature form of Flt3 wt receptor
is predominantly detected in HEK-293 cell lysates, whereas equal amounts
of mature and immature forms are present in the cells expressing Flt3 ITD.
This finding suggests that the presence of an ITD mutation interferes with
maturation of Flt3.
Figure 3.2: Detection of mature and immature forms of Flt3 in HEK-293 cell lysates
by Western blot. Flt3 wt and Flt3 ITD were over-expressed in HEK-293. Flt3
was detected in cellular lysates by immuno-blotting with Flt3 specific antibodies.
Co-expression of kinase active Hck interferes with maturation of Flt3
To analyze interaction of Flt3 with Src kinases, Src kinase Hck was cho-
sen. Expression of Hck is restricted to the cells of myeloid origin and its
expression and activation was found in patients with AML. Therefore, Hck
is likely to be present in the same cell type as Flt3 in normal and malignant
hematopoiesis.
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HEK-293 cells were used as an over-expression system to study the in-
teraction of Flt3 and Hck. Figure 3.3 (a) shows that the mature form of
wild type Flt3 receptor is expressed at a higher level than the immature
form. However, upon co-expression of Flt3 with Hck, the amount of mature
form of the receptor decreases and more of the immature form of receptor
can be detected. Figure 3.3 (b) demonstrates that constitutively active Flt3
containing an ITD mutation is also sensitive to Hck-mediated interference
with maturation. Similar to Flt3, co-expression of Flt3 ITD with Hck leads
to a decrease in the amount of the mature form and to an increase in the
amount of the immature form of the receptor, as compared to Flt3 ITD
expression alone. This finding suggests that co-expression of Hck interferes
with maturation of wild type and the ITD mutant Flt3 receptors resulting
in accumulation of immature receptor inside the cell.
To investigate whether kinase activity of Hck is required for Hck-mediated
interference with maturation of Flt3 receptor, a kinase inactive mutant of
Hck was employed. In the Hck K269R mutant (Hck KR), lysine 269, which
is essential for the positioning of α- and β- phosphate groups of ATP for
catalysis [99], is substituted with Arginine. As a result, Hck K269R is not
capable of binding ATP, while substrate binding is not affected. Figure 3.3
shows that in contrast to Hck wt, co-expression of Hck KR with Flt3 does
not interfere with maturation of the receptor: the relative amounts of mature
and immature forms of Flt3 are unchanged in case of Flt3 co-expression with
Hck KR. Similar to Flt3 wt, kinase activity of Hck is required for interfer-
ence with maturation of Flt3 containing an ITD mutation (Figure 3.3 (b)).
Thus, co-expression of kinase active, but not kinase-inactive, Hck interferes
with maturation of Flt3 wt and Flt3 ITD.
Over-activation and over-expression of Hck promote Hck-mediated
Flt3 maturation block
Both over-activation and over-expression of Src kinases can contribute to
cellular transformation. Hyperactivation of Hck could be achieved by sub-
stitution of the negative-regulatory tyrosine in the C-terminus of the kinase
with phenylalanine. The resulting Hck Y501F mutant (Hck YF) is unable
to form an intramolecular interaction between the C-terminal phosphory-
lated Tyr 501 and the SH2 domain of Hck and is therefore constitutively
active. To analyze the effects of the activity and expression levels of Hck on
the maturation of Flt3, different amounts of wild type, kinase inactive and
constitutively active Hck were co-expressed with Flt3 in HEK-293 cells.
Figure 3.4 (left panel) shows that at high concentrations both wild type
and hyperactive Hck interfere with maturation of Flt3. When high amounts
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Figure 3.3: Co-expression of Hck interferes with maturation of Flt3 wt (a) and Flt3
ITD (b). Flt3 and Hck constructs were expressed in HEK-293 cells as indicated.
Where indicated, cells were stimulated with FL for 10 minutes prior to lysis. Flt3
and Hck were immuno-precipitated from lysates and analyzed by immuno-blotting.
of hyperactive Hck were co-expressed with Flt3, almost no mature form
of Flt3 was detected. Co-expression of similar amounts of wild type Hck
resulted in a decrease, but not disappearance of the mature form of Flt3.
Figure 3.4 (right panel) shows that much lower amounts of hyperactive Hck
were required to interfere with Flt3 maturation, as compared to Hck wt:
while no effect of Hck wt was observed when 0.25 µg of Hck encoding plas-
mids were transfected, Hck YF still strongly inhibited maturation of Flt3.
All together, Figure 3.4 demonstrates that Hck-mediated effect on matura-
tion of Flt3 correlate with the dose of Hck activity.
Association of Hck with its SH2 or SH3 domain binding partners is not
required for Hck-mediated Flt3 maturation block
Many of the biological activities of Src kinases depend on their ability to
physically interact with binding partners via their SH2 and SH3 domains
(described in detail in 1.4.4). To test whether association of Hck with its
binding partners is required for Hck-mediated interference with Flt3 matu-
ration, Hck R150L (Hck RL) and Hck W93A (Hck WA) mutants were used.
The strictly conserved arginine in the SH2 domain of SFKs (Arg 150 in Hck)
is required for the association of the SH2 domains of SFKs with the phos-
phate groups of the phosphorylated tyrosine residues in the SH2 domain
binding partner. Its substitution with leucine leads to the disruption of the
SH2 domain-mediated protein-protein interactions of SFKs [215], [26]. The
conserved tryptophane in the SH3 domains of SFKs (Trp 93 in Hck) forms
part of the ligand binding surface in the fold of the SH3 domain. Its substi-
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Figure 3.4: Interference with maturation of Flt3 by Hck depends on the kinase ac-
tivity and concentration of Hck. Flt3 and Hck constructs were co-expressed in
HEK-293 cells as indicated. Expression of Flt3 and Hck was analyzed by immuno-
blotting of cellular lysates or immuno-precipitated proteins.
tution with alanine results in the disruption of SH3 directed protein-protein
interactions of SFKs [60].
As shown in Figure 3.5, similar to Hck wt, co-expression of Hck R150L
and Hck W93A with Flt3 interferes with maturation of Flt3 receptor. These
results suggest that the binding of SH2 or SH3 domain interacting proteins
is not required for Hck-mediated interference with Flt3 maturation.
Due to the disruption of negative regulatory intramolecular interactions,
kinase activity of Hck RL and Hck WA is higher than that of the wild type
Hck (data not shown). Considering the essential role of Hck kinase activ-
ity for interference with Flt3 maturation, amounts of wild type Hck and
Hck R150L and Hck W93A mutants corresponding to equal kinase activi-
ties should be tested to completely exclude the involvement of SH2 and SH3
domains in Hck-mediated maturation block of Flt3.
Binding of interacting proteins to SH2 or SH3 domain leads to the acti-
vation of Src kinase activity. Therefore, it can not be excluded that under
certain circumstances binding of SH2 or SH3 domain binding partners via
activation of the kinase activity of Hck contributes to Hck-mediated block
in maturation of Flt3.
80 Chapter 3. Results
Figure 3.5: Association of Hck with its SH2 or SH3 domain binding partners is not
required for Hck-induced Flt3 maturation block. Flt3 and Hck constructs
were co-expressed in HEK-293 cells as indicated. Where indicated, cells were stimu-
lated with FL for 10 minutes prior to lysis. Flt3 and Hck were immuno-precipitated
from lysates and analyzed by immuno-blotting.
3.2.2 Hck phosphorylates Flt3
Co-expression of Hck increases phosphorylation level of Flt3
In accordance with previous publications [111], Figure 3.6 demonstrates that
stimulation of wild type Flt3 receptor with Flt3 ligand (FL) results in the
increase of Flt3 phosphorylation (left panel), while Flt3 containing an ITD
mutation is constitutively phosphorylated in a ligand-independent manner
(right panel). Stimulation of the wild type Flt3 receptor with FL leads to
the phosphorylation of predominantly mature form of Flt3, while in case of
Flt3 ITD both mature and immature forms of Flt3 are phosphorylated.
Figure 3.6 shows that co-expression of wild type Hck with Flt3 wt or
Flt3 ITD leads to the increase in phosphorylation of Flt3 regardless of FL
stimulation. In case of the Hck co-expression, both the mature and immature
forms of Flt3 are phosphorylated. In contrast to cells expressing Flt3 wt only,
stimulation of cells co-expressing Flt3 wt and Hck wt with FL did not induce
a further significant increase in phosphorylation of the receptor. In contrast
to Hck wt, co-expression of kinase inactive Hck mutant with Flt3 wt or
Flt3 ITD did not result in the elevated phosphorylation of the receptor and
did not inhibit FL stimulated Flt3 wt phosphorylation. Moreover, the basal
level of tyrosine phosphorylation of Flt3 was decreased when Hck KR was co-
expressed, as compared with Flt3 in the absence of Hck co-expression. This
finding suggests that Hck KR acts as a dominant negative mutant preventing
endogenously expressed SFKs from phosphorylating the Flt3 receptor.
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Figure 3.6: Co-expression of Hck increases phosphorylation of Flt3. Wild type Flt3 (a)
or Flt3 ITD (b) and Hck were co-expressed in HEK-293 cells as indicated. Where
indicated, cells were stimulated with FL for 10 minutes prior to lysis. Flt3 and Hck
were immuno-precipitated from lysates and analyzed by immuno-blotting.
Hck induces phosphorylation of kinase inactive Flt3
The Hck-mediated increase in Flt3 phosphorylation described above could
be explained either by enhancement of autophosphorylation of Flt3 or by
direct phosphorylation of Flt3 by Hck or by another kinase activated by
Hck. To discriminate between these possibilities, a kinase inactive mutant
of Flt3 was employed. Similarly to Hck K269R, Lys644 in the N-lobe of Flt3
kinase domain was substituted by arginine. As shown in Figure 3.7 (a), in
contrast to Flt3 wt, Flt3 K644R was not phosphorylated on tyrosine residues
even upon stimulation with FL. Similarly, Flt3 ITD containing the K644R
mutation (Flt3 ITD KR) was not constitutively phosphorylated compared
to Flt3 ITD (figure 3.7 (b)).
Figure 3.7 demonstrates that co-expression of Flt3 K644R or Flt3 ITD
K644R with kinase active Hck results in a significant increase in phosphory-
lation of the receptor. This finding suggests that Hck phosphorylates Flt3
directly without prior stimulation of the Flt3 kinase activity.
Tyrosine residues in the JM region of Flt3 are the sites for phospho-
rylation by Hck
It was previously demonstrated that SFKs associate with phosphorylated
tyrosine residues in the JM region of class III RTKs [154], [137], [6], [119].
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Figure 3.7: Hck phosphorylates Flt3 wt (a) and Flt3 ITD (b). Flt3 and Hck were co-
expressed in HEK-293 cells as indicated. Where indicated, cells were stimulated
with FL for 10 minutes prior to lysis. Flt3 and Hck were immuno-precipitated from
lysates and analyzed by immuno-blotting.
A similar binding mode is described here for Flt3 (see 3.3). As Src ki-
nase phosphorylation and binding sites often overlap, the possibility that
tyrosines in the JM region of Flt3 could serve as phosphorylation sites for
Hck was investigated.
To analyze whether Hck phosphorylates tyrosine residues in the JM re-
gion of Flt3, all four tyrosines present in this region were substituted with
alanines in the kinase inactive Flt3 receptor. The resulting Flt3 K644R,
Y589F, Y591F, Y597F, Y599F (Flt3 KR 4F) mutant was co-expressed with
different amounts of wild type Hck in HEK-293 cells and the receptor phos-
phorylation level was compared with that of Flt3 KR with all tyrosine
residues present in the JM region. Figure 3.8 demonstrates that compared
to Flt3 KR, phosphorylation of Flt3 KR 4F by Hck was significantly reduced
albeit not completely abolished. Further analysis demonstrates that Hck-
mediated phosphorylation of Flt3 containing mutation of only two tyrosines
in the JM region, Tyr 589 and Tyr 591, is also significantly reduced (data
not shown). This suggests that tyrosine residues in the JM region of Flt3
serve as the the major phosphorylation sites for Hck.
3.2.3 Several SFKs phosphorylate Flt3 and interfere with its
maturation
The Src family of tyrosine kinases comprises nine members with different
patterns of tissue expression in humans. However, expression profiles of
Src family kinases often overlap and several Src kinases with overlapping
3.2. Functional interaction of Hck and Flt3 in HEK-293 cells 83
Figure 3.8: Tyrosine residues in the JM region of Flt3 are the major sites for phos-
phorylation by Hck. Kinase inactive Flt3 with intact JM region (Flt3 KR) and
containing substitutions of four tyrosines in the JM region with Phenylalanines (Flt3
KR 4F) were co-expressed with different amounts of wild type Hck in HEK-293
cells as indicated. Flt3 and Hck were analyzed by immuno-blotting of immuno-
precipitated proteins or of cellular lysates.
functions are usually expressed in the same cell type (described in detail in
1.4.2). To test whether interference with maturation and phosphorylation
of Flt3 is a unique function of Hck or a more general feature of SFKs, two
other Src family members, Lyn and Fyn, were tested. Lyn and Fyn are
expressed in hematopoietic cells and, similar to Hck, their transcripts were
found in bone marrow of healthy donors and AML patients, as well as in all
tested myeloid cell lines (data not shown).
To test whether Lyn and Fyn interfere with Flt3 maturation and phos-
phorylate Flt3, these SFKs were co-expressed with wild type and kinase
inactive Flt3 in HEK-293 cells. Ratios of immature and mature forms
and phoshphorylation of the receptor were analyzed by immuno-blotting
of immuno-precipitated Flt3. Figure 3.9 shows that Lyn and, to a lesser
extent, also Fyn co-expression with Flt3 interferes with Flt3 maturation
(Figure 3.9 (a)). Similar to Hck, Lyn and Fyn also induce phosphorylation
of kinase inactive Flt3 receptor (Figure 3.9 (b)). These results suggest that
other SFKs members besides Hck do also interfere with Flt3 maturation and
induce Flt3 phosphorylation on tyrosine residues.
3.2.4 SFKs phosphorylate the Kit receptor and interfere with
its maturation
RTKs of class III share structural homology and all undergo a maturation
process, with glycosylation being one of the major accompanying chemical
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Figure 3.9: Several SFKs phosphorylate Flt3 and interfere with its maturation. SFKs
were co-expressed with wild-type Flt3 (a) or kinase inactive Flt3 mutant (b) in
HEK-293 cells. Expression and phosphorylation of the proteins were analyzed by
immuno-blotting.
modification. It is therefore likely that cellular mechanisms regulating and
affecting maturation of this class of receptors would be conserved among
different family members. To analyze whether SFK-mediated interference
with maturation and phosphorylation of Flt3 could represent a general phe-
nomenon, effects of Hck, Lyn and Fyn on maturation and phosphorylation
of the class III RTK Kit were investigated.
As shown on Figure 3.10 (a), similar to Flt3, two species of the Kit recep-
tor with lower and higher molecular weights could be detected in HEK-293
cells, representing the immature intracellular and mature cell surface forms
of the receptor, respectively. Similarly to Flt3, the higher molecular weight
form of Kit was expressed to a larger extent than the lower molecular weight
form. Figure 3.10 shows that, by analogy with Flt3, co-expression of Hck
with Kit leads to an increase in the amount of lower molecular weight species
of Kit and a decrease in the amount of the higher molecular weight species.
Figure 3.10 (a) also demonstrates that Hck-mediated interference with c-kit
maturation is dependent on kinase activity of Hck, as co-expression of the
kinase inactive Hck mutant did not induce any changes in the amounts of
immature and mature forms of Kit.
Figure 3.10 (b) shows that similarly to Flt3, co-expression of Lyn and to
a lesser extent Fyn also interfere with maturation and phosphorylate Kit.
However, to discriminate between direct Hck phosphorylation and stimula-
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tion of Kit autophosphorylation activity, phosphorylation of kinase inactive
mutant of Kit by SFKs would have to be analyzed.
These findings suggest that co-expression of SFKs interferes with mat-
uration and can also induce phosphorylation of another member of RTKs
of class III, Kit. Thus, these findings above functional interaction between
Flt3 and Hck appear to be more general and do at least apply to other SFKs
on the one hand and other class III RTKs on the other hand.
Figure 3.10: SFKs phosphorylate the Kit receptor and interfere with its maturation.
Hck interferes with maturation and induces phosphorylation of Kit in a kinase-
dependent manner. Lyn and Fyn also interfere with maturation and phosphorylate
Kit. SFKs and Kit were co-expressed in HEK-293 cells as indicated. Expression
and phosphorylation of proteins were analyzed by immuno-blotting.
3.3 Physical interaction of Hck and Flt3 in HEK-293
cells
Previous publications have demonstrated that SFKs associate with different
members of class III RTKs. A chimeric Flt3 receptor, consisting of an extra-
cellular domain of CSF-1R and transmembrane and cytoplasmic domains of
murine Flt3 receptor, was also shown to co-immunoprecipitate with Src and
Fyn upon CSF-1 stimulation [53]. Results of detailed analysis of physical
association of human Flt3, as well Flt3 ITD with Hck are presented in this
section.
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3.3.1 Flt3 receptor activated by Flt3 ligand or by an ITD-type
mutation recruits Hck via its SH2 domain
Flt3 activated by FL or by an ITD-type mutation associates with kinase
inactive Hck
Firstly, the association of wild type Hck with Flt3 was investigated. Figure
3.11 (a) shows that, regardless of FL stimulation, almost no Flt3 was de-
tected in immuno-precipitates of wild type Hck. The following possibilities
or their combination could explain the lack of detectable association between
Flt3 and wild type Hck: co-expression of Hck prevents Flt3 maturation and
therefore its exposure to the ligand, phosphorylation of Flt3 by Hck does
not create high affinity binding sites for Hck and/or creates high affinity
binding sites for other proteins whose binding to Flt3 is competitive with
Hck. Following these assumptions, a kinase-inactive Hck mutant, Hck KR,
which neither interferes with maturation nor phosphorylates Flt3 (described
in 3.2) should associate with Flt3. Indeed, Figure 3.11 (a) demonstrates that
in contrast to Hck wt, kinase inactive Hck co-immunoprecipitated with Flt3
in the FL-dependent manner. Similar observations were made for Flt3 con-
taining an ITD mutation. Figure 3.11 (b) shows that Flt3 ITD associates
with kinase inactive and not with wild type Hck. However, association of
Flt3 ITD with Hck KR did not depend on FL stimulation, correlating with
the constitutive activation of Flt3 ITD independently of the ligand. These
results suggest that Hck is inducibly recruited to wild type Flt3 stimulated
with FL, as well as to Flt3 containing an ITD mutation.
Association of Flt3 with Hck is mediated by SH2 domain of Hck
Activation of RTKs results in their dimerization and trans-phosphorylation
of receptor monomers. This phosphorylation creates binding sites for SH2
domain-containing proteins. To analyze whether the described association
of Hck and Flt3 is mediated by the SH2 domain of Hck, a R150L mutation
which results in the disruption of SH2 domain directed protein-protein in-
teractions of Hck (described in 3.2.1) was introduced into the kinase inactive
Hck. Association of the resulting double mutant (Hck KR RL) was analyzed
by co-immunoprecipitation. Figure 3.11 (a) demonstrates that in contrast
to Hck KR, almost no Flt3 was detected in immuno-precipitates of Hck KR
RL even after FL stimulation. This result suggests that Hck is recruited to
wild type Flt3 activated by FL via its SH2 domain. Similarly to wild type
Flt3 receptor, Flt3 ITD did not associate with Hck KR RL (Figure 3.11 (b).
These findings suggest that activation of Flt3 by FL stimulation or an ITD
mutation results in the generation of binding sites for the SH2 domain of
Hck.
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Figure 3.11: Flt3 activated either by Flt3 ligand (a) or by an ITD-type mutation (b)
recruits Hck via its SH2 domain. Flt3 and Hck constructs were co-expressed in
HEK-293 cells as indicated. Hck and Flt3 were immuno-precipitated using myc or
Flt3 specific antibodies, respectively. Expression and phosphorylation of proteins
were analyzed by immuno-blotting.
3.3.2 Tyrosines 589 and 591 in the JM region of Flt3 serve as
Hck binding sites.
Studies of class III RTKs have demonstrated that tyrosines in the JM re-
gion of these receptors serve as binding sites for SFKs [154], [137], [6], [119].
Considering the high homology between class III RTKs in the JM region,
similar binding mode of SFKs to Flt3 could be expected.
To test whether tyrosines in the JM domain of Flt3 serve as binding
sites for Hck, Tyr 589 and Tyr 591 were replaced by phenylalanines. In
Flt3 ITD, Tyr 589 and Tyr 591 in the wild type, but not in the duplicated
sequence were substituted with Phenylalanines. Figure 3.12 (a) shows that
FL inducible association of Hck KR with Flt3 Y589F, Y591F was decreased,
as compared with Flt3 wt, but not completely abrogated. Figure 3.12 (b)
demonstrates that similarly to Flt3 wt, less of Flt3 ITD Y589F, Y591F was
detected in Hck KR immuno-precipitates, as compared with Flt3 ITD. These
data suggest that Tyr 589 and Tyr 591 in the JM region of Flt3 serve as
binding sites for Hck, although other binding sites for Hck exist on Flt3.
88 Chapter 3. Results
(a) (b)
Figure 3.12: Tyr 589 and Tyr 591 in the JM region of Flt3 serve as Hck binding
sites.Flt3 and Hck constructs were co-expressed in HEK-293 cells as indicated.
Hck and Flt3 were immuno-precipitated using anti-myc or anti-Flt3 antibodies,
respectively. Proteins were analyzed by immuno-blotting.
Hck associates with Flt3 in intact cells
To test whether association between Hck and Flt3 takes place inside vi-
able cells or after cellular lysis during immuno-precipitation (in vitro), dif-
ferent co-immunoprecipitation conditions were used. Had the association
been taking place in vitro, high concentration of proteins in the immuno-
precipitation reaction (small volume of immuno-precipitation reaction), as
well as longer times of immuno-precipitations would shift the equilibrium to-
wards the associated couples of proteins. Figure 3.13 shows that the amount
of co-immunoprecipitated Flt3 only slightly increases with the increase in
the time of immuno-precipitation. This slight increase most likely reflects
the increase in the amount of the directly immuno-precipitated Hck. In ad-
dition, the ratios of the amounts of co-immunoprecipitated Flt3 to immuno-
precipitated Hck stayed roughly the same when low and high volumes of
reaction were used. These findings suggest that association of Flt3 and
Hck takes place in viable cells before cellular lysis. However, formation of
complexes containing Flt3 and Hck within a very short period of time after
cellular lysis can not be excluded.
3.4 Biological function of Hck in Flt3-mediated cel-
lular responses
To test whether the described functional and physical association of Hck
with Flt3 affects biological responses mediated by the Flt3 receptor, 32D
cl. 3 cell lines which express Flt3 wt or Flt3 ITD and Hck constructs with
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Figure 3.13: Association of Flt3 and Hck takes place in intact cells. Flt3 and Hck
constructs were co-expressed in HEK-293 cells as indicated. Immuno-precipitations
were performed in the indicated volumes for indicated periods of times (additional
45 minutes for incubation with protein A/G agarose are not included). Precipitated
proteins were analyzed by immuno-blotting.
different kinase activities were used. 32D cl. 3 cells are strictly dependent
on the presence of IL-3 for growth. However, as previously described [146],
over-expression of the Flt3 receptor in these cells and its stimulation with
FL leads to sustained survival of the cells in the absence of IL-3. Over-
expression of Flt3 containing an ITD mutation abrogates the requirement
of IL-3 for growth [147] and blocks G-CSF-mediated differentiation of these
cells into monocytes [243]. These characteristics make 32D cl. 3 cells a
commonly used model for studying Flt3-mediated signaling events leading
to resistance to apoptosis and to proliferation.
3.4.1 Expression of Flt3 and Hck in 32D cl.3 cells
To generate 32D cl. 3 cell lines expressing Flt3 and Hck mutants, cells were
infected with recombinant retroviruses containing Flt3 or Hck connected via
IRES sequence to EYFP or EGFP respectively. Retroviruses were gener-
ated by transfection of the appropriate constructs in HEK-293 cells. Titers
of all retroviral stocks were normalized by infecting 32D cl. 3 cells with
several dilutions of retroviruses. To generate 32D cl. 3-based cell lines, in
which most of the cells contain a single copy of provirus, dilutions for which
infection efficiency was 10% or lower were used.
First, cells were infected with EYFP-IRES-Flt3 wt or EYFP-IRES-Flt3
ITD-containing viruses and YFP positive cells were sorted using FACS. YFP
positive cells were then infected the second time with EGFP-IRES-Hck-
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containing viruses and double positive YFP+/GFP+ cells were sorted by
FACS.
Analysis of Flt3 surface expression in 32D cl. 3 cells lines by FACS
To confirm that YFP positive cells indeed express Flt3 on their cell surface,
cells were stained with Flt3 specific antibodies conjugated to phycoerythrin
and analyzed by flow cytometry. Figure 3.14 shows that cells infected with
control EYFP-containing virus do not express Flt3 on their surface (figure
3.14 (a)), while cells infected with retroviruses containing EYFP-IRES-Flt3
wt (Figure 3.14 (b)) and EYFP-IRES-Flt3 ITD (Figure 3.14 (c)) constructs
do express Flt3. Level of Flt3 surface expression is higher in the case of Flt3
wt than in the case of Flt3 ITD. Impaired maturation is likely to account
for the lower Flt3 ITD surface expression in 32D cl. 3 cells compared with
Flt3 wt.
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Figure 3.14: Expression of Flt3 on the surface of 32D cl. 3 cells. Cells infected with
EYFP control virus (a), EYFP-IRES-Flt3 wt-containing virus (b) and EYFP-
IRES-Flt3 ITD-containing virus (c) were stained with Flt3 specific antibodies con-
jugated to phycoerythrin and analyzed by flow cytometry.
Analysis of Flt3 and Hck expression in 32D cl. 3 cells by immuno-
blotting
Expression of Hck and Flt3 constructs in all generated cell lines was also
analyzed by immuno-blotting. Figure 3.15 (a) shows that equal amounts
of Flt3 were detected in cells expressing either Flt3 wt only and in cells
co-expressing Flt3 wt and EGFP or Hck constructs. Similar results were
obtained for cell lines expressing Flt3 ITD (Figure 3.15 (b). These results
suggest that no loss of Flt3 expression took place after second infection and
second sorting steps.
To confirm that all cells express Flt3 ITD after sorting, 32D cl. 3 cell
lines expressing Flt3 ITD were also analyzed after withdrawal of IL-3 for 3
days. Only cells expressing Flt3 ITD are able to grow with IL-3. Therefore,
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presence of Flt3 ITD negative cells in the cell lines before IL-3 withdrawal
would result in the increase in the amount of Flt3 detected by immuno-
blotting from the lysates containing equal amounts of total protein after
cells have been deprived of IL-3 for three days. Figure 3.15 (b) shows that
expression level of Flt3 ITD did not change after IL-3 has been withdrawn
from the culture medium for three days. This result suggests that all cells
in Flt3 ITD expressing cell lines are Flt3 ITD positive.
Figure 3.15 also shows expression levels of Hck constructs in 32D cl. 3
cells. Kinase inactive Hck mutant was expressed at the higher level than
wild type or constitutively active Hck. This is in agreement with previous
publications showing that activated forms of Src are less stable due to their
degradation via the proteosomal pathway [85].
(a) (b)
Figure 3.15: Analysis of Flt3 and Hck expression in 32D cl. 3 cells by immuno-
blotting. 32D cl. 3 cells, expressing indicated proteins were lysed and lysates
containing equal amounts of total protein were analyzed by immuno-blotting. Cells
expressing Flt3 wt were stimulated with FL for 10 minutes where indicated (a).
Cells expressing Flt3 ITD were either sub-cultured in the presence of 10% WEHI-
3B supernatant as source of IL-3 or deprived of IL-3 for 3 days prior to lysis (b).
3.4.2 Hck is not involved in Flt3 signal transduction leading to
cell survival
To investigate whether Hck interferes with anti-apoptotic signalling medi-
ated by Flt3 wt, apoptosis was compared in 32D cl. 3 cells co-expressing
Flt3 wt and EGFP and cells co-expressing Flt3 and wild type, kinase inac-
tive or constitutively active Hck after stimulation with Flt3 ligand.
Influence of retroviral infection on apoptosis in 32D cl. 3 cells
Figure 3.16 shows that in the absence of cytokine stimulation, the percentage
of apoptotic cells infected with retrovirus twice and therefore over-expressing
two proteins (EYFP and EGFP or Flt3 wt and EGFP) was lower than the
percentage of apoptotic cells infected with retrovirus once and therefore over-
expressing only one protein (EYFP or Flt3). This finding suggests that, as
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compared single retrovial infection, double infection of 32D cl. 3 cells with
retrovirus leads to the activation of anti-apoptotic signalling in these cells.
Single infection of 32D cl. 3 cells with higher titers of retrovirus (more than
10% infection efficiency) also resulted in increased cell growth in the absence
of cytokines (data not shown). This effect was especially pronounced when
cells were sub-cultured for more than 2 weeks after sorting or were incubated
in the absence of cytokine for more than 3 days (data not shown). Together
these results suggest that the presence of more than one proviral copy per
cell leads to activation of anti-apoptotic pathways.
Sustained survival of 32D cl. 3 cells expressing Flt3 wt in IL-3 free
medium upon FL stimulation
Figure 3.16 shows that stimulation of Flt3 wt expressing cells with FL re-
duced the proportion of apoptotic cells: about 20% of the cells underwent
apoptosis in the presence of FL, while about 70% of apoptotic cells were de-
tected when no cytokine was added to the medium. In contrast, when cells
expressing EYFP only were analyzed, only a small reduction in the number
of apoptotic cells was detected (about 70% of apoptotic cells in the pres-
ence of FL versus about 80% of apoptotic cells in the absence of cytokines).
This slight effect of FL probably reflects stimulation of endogenously ex-
pressed Flt3 in 32D cl. 3 cells. Stimulation of Flt3 wt expressing cells with
FL could not, however, fully substitute conditioned medium: about 20% of
Flt3 expressing cells underwent apoptosis in the presence of FL, as opposed
to less than 2% in the presence of conditioned medium. In accordance with
previous publications [146], these data demonstrate that Flt3 wt activates
anti-apoptotic signals in 32D cl. 3 cells which leads to their sustained sur-
vival.
Prolonged survival of 32D cl. 3 cells in IL-3 free medium upon co-
expression of the hyperactive Hck
When cells co-expressing EYFP and EGFP were compared with cells co-
expressing EYFP and wild type Hck or kinase inactive Hck, no significant
differences in the percentage of apoptotic cells upon cytokine withdrawal
were detected. In contrast, apoptosis was decreased in cells co-expressing
EYFP and hyperactive Hck mutant after cytokine withdrawal (Figure 3.16).
This result is in accordance with a previous publication [59], and shows that
over-expression of hyperactive Hck mutant in 32D cl. 3 cells prolongs sur-
vival in the absence of IL-3, while over-expression of wild type or inactive
Hck has no effect on apoptosis.
3.4. Biological function of Hck in Flt3-mediated cellular responses 93
Over-expression of Hck does not influence Flt3-mediated signal trans-
duction resulting in resistance to apoptosis
When cells over-expressing Flt3 wt and wild type Hck or Flt3 wt and kinase
inactive Hck were compared with cells over-expressing Flt3 wt and EGFP,
no differences in the percentage of apoptotic cells were observed when cells
were incubated in the presence of FL. In addition, co-expression of wild type
Flt3 and hyperactive Hck did not result in either an additive or a synergistic
effect with respect to reduction of apoptosis. The percentage of apoptotic
cells in case of Flt3 wt and Hck YF co-expression was about the same as in
case of Flt3 wt and EGFP co-expression or EYFP and Hck YF co-expression
upon stimulation with FL. Combined, these observations suggest that Hck
does not influence any signals downstream of Flt3 with respect to apoptosis.
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Figure 3.16: Hck is not involved in Flt3 signal transduction leading to cell survival.
All cell lines were sub-cultured in the presence of IL-3 prior to the start of the assay.
Cells were washed three times with IL-3 free medium and seeded at 1X105 cells/ml
in the medium containing either 10% of WEHI-3B supernatant as source of IL-3
(green), no cytokine (blue) or 100 ng/ml of FL (red). Apoptosis was measured
36 hours after plating using Annexin-V apoptosis detection kit. All Annexin-V
positive cells were considered apoptotic.
3.4.3 Hck is not involved in Flt3 ITD signal transduction lead-
ing to cell growth
To investigate whether Hck influence on Flt3 ITD-mediated cell growth,
growth rates of 32D cl. 3 cells co-expressing Flt3 ITD and GFP were com-
pared with growth rates of cells co-expressing Flt3 ITD and wild type, hy-
peractive or kinase inactive Hck.
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Over-expression of Flt3 ITD strongly reduces IL-3 requirement of 32D
cl.3 cells for growth
In accordance with the previous publications [147], Figure 3.17 shows that
cells over-expressing Flt3 ITD could grow in the absence of IL-3 while cells
over-expressing EYFP could not. Growth rate of cells over-expressing Flt3
ITD was higher in the presence of IL-3 than in the absence of the cytokine
from the medium. Possible explanations of this difference include: lack
of Flt3 ITD expression in some cells, lower expression levels of Flt3 ITD in
some cells, which are not sufficient to confer IL-3-independent growth, coun-
teraction of Flt3 ITD signalling by the action of tumor-suppressor genes in
some cells and, finally, potentiation of Flt3 ITD signalling by IL-3 stimu-
lation. The first possibility could be excluded on the basis of the previous
finding that equal amounts of Flt3 ITD are expressed in cells incubated for
three days in the presence and in the absence of IL-3 (3.4.1 and Figure 3.15).
Over-expression of hyperactive Hck increases growth rate of 32D cl.
3 cells in the absence of cytokine
Figure 3.17 demonstrates that in the absence of IL-3, growth of cells ex-
pressing hyperactive Hck was increased compared to the growth of cells
expressing EGFP, wild type or kinase inactive Hck. The number of cells
expressing Hck YF and EYFP did not change three days after the start of
the assay, as compared to the number of seeded cells. However, if cells were
kept in culture for more than three days, the growth of all double-infected
cells, including cells co-expressing Hck YF and EYFP was increased (data
not shown). Therefore, it is not clear whether hyperactive Hck contributes
to anti-apoptotic signaling only or it also promotes proliferation.
Over-expression of Hck does not affect Flt3 ITD-dependent cell growth
When cells over-expressing Flt3 ITD and wild type, kinase inactive or hyper-
active Hck were compared with cells over-expressing Flt3 ITD and EGFP,
no significant differences in cell growth were observed after IL-3 withdrawal
(Figure 3.17). The lack in the increase in growth rate of cells over-expressing
Flt3 ITD and Hck YF is surprising and could be explained by a subtle neg-
ative effect of Hck YF on Flt3 ITD-mediated cell growth. Combined, these
results suggest that Hck does not play any significant role in Flt3 ITD-
mediated cell growth.
3.5 Interaction of Hck and Flt3 in 32D cl. 3 cells
As described in 3.2, Hck co-expression with Flt3 in HEK-293 cells interferes
with receptor maturation and induces its phosphorylation. In addition, as
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Figure 3.17: Hck is not involved in Flt3 ITD signal transduction leading to cell
growth. All cell lines were sub-cultured in the presence of IL-3 prior to the start
of the assay. Cells were washed three times with IL-3 free medium and seeded at
1 X 104 cells/ml in the medium containing either 10% of WEHI-3B supernatant
as source of IL-3 (green) or no cytokine (blue). Viable cells were counted 3 days
after seeding using Trypan Blue exclusion assay. All Trypan blue negative cells
were considered viable.
described in 3.3, Flt3 physically associates with Hck in the SH2/phospho-
tyrosine-dependent manner. Results presented below describe the analysis
of functional and physical interaction between Hck and Flt3 in 32D cl. 3 cells
and provide a potential explanation for the lack of any detectable biological
effect of Hck on Flt3-mediated cellular responses in 32D cl.3 cell lines.
3.5.1 Hck does not interfere with maturation and does not phos-
phorylate Flt3 in 32D cl. 3 cells
Figures 3.15 and 3.20 show that in contrast to the findings made when us-
ing HEK-293 cell system, co-expression of neither wild type nor hyperactive
Hck mutant with Flt3 in 32D cl. 3 cells interferes with the maturation of
Flt3 or leads to its increased phosphorylation. The following possibilities
could account for the differences observed between the two cell lines: re-
striction of functional interaction of human Hck and Flt3 to cell lines of
human origin (unlike HEK-293, 32D cl. 3 is a murine cell line), high level of
phosphatase activity counteracting the activity of SFKs in 32D cl. 3 cells, as
compared with HEK-293 cells, and/or lower expression levels of Hck in 32D
cl. 3 cells than in HEK-293 cells. The latter possibility is investigated below.
As described in 3.2.1, Hck-mediated interference with Flt3 maturation
depends on kinase activity and expression level of Hck. Therefore, the pos-
sibility that lower expression levels of Hck in 32D cl. 3 cells, as compared
with HEK-293 cells, account for the lack of Hck-mediated Flt3 maturation
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block and phosphorylation was analyzed. Hck expression levels in 32D cl.
3 cells were compared with Hck expression levels in HEK-293 cells in which
maturation of Flt3 was affected to various degrees dependent on Hck ex-
pression levels. Figure 3.18 shows that expression levels of wild type and
hyperactive Hck in 32D cl. 3 cells are lower than those at which maturation
block is still observed in HEK-293 cells. In addition, Figure 3.18 shows that
expression levels of wild type and hyperactive Hck in 32D cl. 3 cells corre-
spond to those in HEK-293 cells, at which almost no Hck-mediated increase
in phosphorylation of wild type Flt3 is observed. These results suggest that
lower Hck expression levels in 32D cl. 3 cells, as compared with HEK-293
cells, account for the lack of both Hck-mediated block in maturation and
increase in phosphorylation of Flt3 in 32D cl. 3 cells. However, contribution
of other factors mentioned above can not be excluded. For example, when
hyperactive Hck is expressed in HEK-293 and 32D cl.3 cells at the similar
levels, phosphorylation of Hck is higher in HEK-293 cells as compared with
32D cl.3 cells (Figure 3.18, lanes 10 and 14). These data suggest the pos-
sibility that in addition to the lower Hck expression levels, activation and
subsequent auto-phosphorylation of Hck might be decreased in 32D cl.3 cells
as compared with HEK-293 cells.
Figure 3.18: Lower Hck expression level could account for the lack of Hck-mediated
block in maturation and increase in phosphorylation of Flt3 in 32D
cl. 3 cells. HEK-293 cells were transfected with different amounts of wild type,
kinase inactive and hyperactive Hck (0.5, 0.25 and 0.5 µg of Hck encoding plasmid
per transfection, as indicated). Equal amounts of proteins from cellular lysates of
HEK-293 and 32D cl. 3 cells were analyzed by immuno-blotting with Hck and Flt3
specific antibodies. Flt3 was immuno-precipitated from cells using Flt3 specific
antibodies and its phosphorylation was analyzed using phospho-tyrosine specific
antibodies.
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3.5.2 Flt3 does not detectably associate with Hck in 32D cl. 3
cells
As described in 3.3, Flt3 inducibly associates with Hck in HEK-293 cells.
To investigate whether Flt3 associates with Hck in 32D cl. 3 cells, cells were
starved in the absence of IL-3 for 12 hours and then stimulated with FL
for 10 minutes to induce Flt3 autophosphorylation. Hck KR was immuno-
precipitated from cellular lysates using Hck specific antibodies. Flt3 was
detected in immuno-precipitates by immunobloting with Flt3 specific and
phospho-tyrosine specific antibodies. As a control, HEK-293 lysates con-
taining equal amounts of protein were used. Figure 3.19 (a) shows that no
Flt3 was detected in Hck immuno-precipitates from 32D cl. 3 cells even
when more sensitive phospho-tyrosine specific antibodies were used for de-
tection. In contrast, Flt3 could be easily detected by both Flt3 and phospho-
tyrosine specific antibodies in Hck KR immuno-precipitates from HEK-293
cell lysates containing equal amount of protein. No Flt3 could be detected
in immuno-precipitates of wild type and hyperactive Hck from 32D cl. 3
lysates either (data not shown). The following possibilities could account
for the lack of association between Hck and Flt3 in 32D cl. 3 cells: 1)
interference of a protein expressed in 32D cl. 3, but not HEK-293 cells,
which binds to Hck or Flt3 competitively preventing Hck-Flt3 interaction,
2) restriction of the interaction of human Hck and Flt3 to the cell lines
of human origin, 3) high activity of phosphatases de-phosphorylating Hck
binding sites on Flt3 in 32D cl. 3 cells as compared with HEK-293 cells, and
4) lower levels of over-expressed Hck in 32D cl. 3 cells than in HEK-293 cells.
To test whether lower levels of Hck KR expression could account for the
lack of association between Hck KR and Flt3 in 32D cl. 3 cells, HEK-293
cells were transfected with lower amounts of Hck KR and Hck KR RL as
a negative control and association of the two proteins was analyzed by co-
immunoprecipitation. Figure 3.19 (b) shows that FL inducible association
between Flt3 and Hck KR could be detected in HEK-293 cells, even when
significantly lower Hck KR amounts were expressed. Considering only a
slight difference in the expression of Hck KR between 32D cl. 3 and HEK-
293 cells, these data suggest that lower Hck KR expression levels in 32D cl.
3 cells do not account for the lack of association between Hck and Flt3 in
these cells.
3.5.3 Hck does not have any effect on Flt3-mediated phospho-
rylation of key signal transducing molecules
Cellular response to Flt3 activation mainly relies on the activation of the
MAPK, PI3K-Akt and STAT-5 signaling pathways [86], [147], [241]. Full
activation of the latter, however, requires aberrant signalling induced by
Flt3 ITD while the activation by wild type Flt3 is not sufficient to induce
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Figure 3.19: Flt3 does not detectably associate with Hck in 32D cl. 3 cells. Lysates
from HEK-293, expressing myc-tagged Hck and Flt3 constructs, and 32D cl. 3 cells,
expressing non-tagged Hck and Flt3 constructs, which contain equal amounts of
proteins were used for immuno-blotting and for co-immunoprecipitation with anti-
Hck antibodies. The lowest band on the bottom panel reflect non-specific reaction
of antibodies (a). Different amounts of Hck (0, 5 and 0.5 µg of Hck encoding
plasmid per transfection, as indicated) were transfected into HEK-293 cells and
co-immunoprecipitations were performed using anti-Hck (myc) antibodies (b).
transcription of STAT-5 target genes [148].
To analyze whether Hck interferes with Flt3-mediated signaling events,
activation of signal transduction molecules was compared in cells co-expressing
Flt3 wt and EGFP and Flt3 wt and wild type, kinase inactive and hyper-
active Hck. Cells were starved in the absence of IL-3 for 12 hours and then
stimulated with Flt3 ligand for 10 minutes. Cellular lysates containing equal
amounts of total protein were analyzed by immuno-blotting with antibod-
ies specific for activation of key signal transduction molecules. To analyze
activation of MAPK-dependent pathway, anti-pErk antibodies, which are
specific for Erk 1/2 phosphorylation on Thr 202 and Tyr 204, were used. To
detect activation of PI3K-dependent pathways, antibodies specific for the
downstream Serine/Threonine kinase Akt, phosphorylated on Ser 473, were
used. STAT-5 activation was analyzed by immuno-blotting of lysates with
antibodies specific for an active form of STAT-5 which is phosphorylated on
Tyr 694.
As shown on Figure 3.20, activation of Erk proteins and Akt was induced
by stimulation of Flt3 wt expressing cells with FL. Activation of STAT-5
was detected in Flt3 wt expressing, but not in control EYFP expressing
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cells. However, in contrast to Erk and Akt, STAT-5 activation was not
dependent on the ligand stimulation. No changes in the activation of Erk,
Akt or STAT-5 were detected in cells co-expressing Flt3 wt and Hck wt,
Hck KR or Hck YF mutants, as compared to cells co-expressing Flt3 wt
and EGFP. This finding suggests that co-expression of Hck does not effect
Flt3-mediated activation of key signal transduction molecules.
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Figure 3.20: Flt3-mediated activation of key signal transducing molecules is not af-
fected by co-expression of Hck in 32D cl. 3 cells. Cells expressing Flt3 wt
and indicated Hck constructs were starved for 12 hours and then stimulated with
FL for 10 minutes where indicated. Flt3 was immuno-precipitated from lysates
and its activation and expression were analyzed by immuno-blotting. Lysates con-
tainining equal amounts of total protein were analyzed by immuno-blotting with
antibodies specific for activation of signaling molecules and corresponding control
antibodies.
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4.1 Hck-mediated interference with maturation of Flt3
4.1.1 Possible mechanisms of Hck interference with Flt3 mat-
uration
SFKs modulate signaling mediated by RTKs in various ways. SFK-mediatedphosphorylation increases the kinase activity of the receptors and gener-
ates binding sites for phospho-tyrosine binding proteins (described in 1.4.8).
In addition, SFKs participate in endocytosis and ubiquitination of RTKs.
This work shows that besides these activities, SFKs interfere with the mat-
uration of class III RTKs in a kinase-dependent manner. While mostly
mature form of the Flt3 RTK is present in HEK-293 cells in the absence
of Hck co-expression or when kinase inactive Hck is co-expressed, predom-
inantly the immature form of the receptor is detected in cells which have
high activity of Hck due to its over-expression or hyperactivation (Figure
3.3). Other studies have shown that the immature form of the receptor
contains high mannose oligosaccharides and is located intracellularly, while
the mature form contains complex oligosaccharides and is present on the cell
surface [131], [139]. Glycoproteins that carry high mannose glycans have not
undergone terminal glycosylation in the Golgi complex and in most cases are
present in the ER or ER-Golgi transition [88]. Therefore relative abundance
of the immature high mannose oligosaccharide-containing receptor suggests
its retention in the ER and/or block of its terminal glycosylation in the Golgi
complex. Similar results are also shown here for the Kit receptor, suggesting
that SFK-mediated block in maturation is not restricted to Flt3, but rather
respresents a general effect of SFK activation on the maturation of class III
RTKs.
The mechanism underlying the SFK-mediated block of Flt3 and other
RTKs’ maturation is not clear. This study shows that in addition to in-
terfering with the maturation of class III RTKs, SFKs also phosphorylate
these receptors. It is possible that SFK-mediated phosphorylation of RTKs
is responsible for the maturation block. In support of this hypothesis, this
work shows that the dose of Hck activity (expression and activation level)
correlates with the strength of interference with maturation and the extent
of Flt3 phosphorylation (Figure 3.18). Moreover, results presented in this
thesis and in other studies show that independently of SFK-mediated effects,
the maturation of Flt3 ITD is impaired as compared with Flt3 wt (described
in 3.2.1, and shown in figures 3.3, 3.6, 3.11, 3.15, [147], [198]). This difference
may also arise from the relatively high basal (ligand-independent) phospho-
rylation level of Flt3 ITD as compared with Flt3 wt (Figure 3.6, [147]).
Another indirect evidence that phosphorylation of RTKs in the secretory
pathway might interfere with their maturation is the impaired maturation
of the constitutively active murine Kit receptor [68]. The latter study shows
that the immature form of the Kit receptor is predominantly observed in
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cells expressing activated Kit containing a substitution of aspartic acid 814
to valine, while a mature form of Kit is predominant in cells expressing wild
type Kit. The work presented in this thesis also shows that SFKs interfere
with the maturation of Kit in a SFK-kinase-dependent manner.
Assuming that SFK-mediated phosphorylation of RTKs interferes with
their maturation, what could be a mechanism that inhibits proper matura-
tion of phosphorylated RTKs? Maturation of N-glycosylated proteins and
their movement along the secretory pathway is controlled by a number of
regulatory mechanisms. First, all proteins in the secretory pathway undergo
a so called primary ER quality control (QC) [56]. Proteins that participate
in primary QC control include ER resident chaperons (e.g the Calnexin-
Calreticulin cycle, BiP) and folding factors (e.g ERp57). These factors assist
in protein folding and retain or dispatch misfolded proteins for destruction
into the cytosol [56]. Binding of the immature proteins to these factors
prevents their forward transport to the Golgi complex [57]. One possibility
is that phosphorylation of RTKs at this stage interferes with their proper
folding, which leads to an increased binding of the receptors to one of the
factors participating in the primary ER QC and therefore to their retention
in the ER. It is not clear, however, how phosphorylation which takes place
on the cytosolic side of the ER membrane could cause the folding defect that
is sensed by the residing in the ER lumen chaperons. Phosphorylation could
either result in conformational changes in the lumenal part of the receptor
or, alternatively, transmembrane ER chaperones could recognize the confor-
mational changes in the cytosolic part of the receptors. Another possibility
is that phosphorylation of RTKs in the secretory pathway does not affect
their folding, but instead inhibits the inclusion of protein into the ER exit
sites or another step in the exit of proteins from the ER.
Besides direct phosphorylation of RTKs, other mechanism could con-
tribute to the retention of RTKs in the secretory pathway when active Src
kinases are present in the cell. For example, a number of studies point to
the role of SFKs in membrane trafficking. Src associates with proteins in the
synaptic vesicles [63], [101] and is involved in the secretion of catecholamine
by bovine adrenal chromaffin cells [58]. Additionally, a recent study suggests
that SFKs are required for the the integrity of the Golgi complex [10]. In
this respect it would be interesting to know if active SFKs interfere with the
maturation of other transmembrane or secreted proteins which can not be
phosphorylated in the SFK-dependent manner.
104 Chapter 4. Discussion
4.1.2 Biological relevance of Hck-mediated interference with
Flt3 maturation
The data presented in this work show that co-expression of kinase inactive
Hck does not potentiate the maturation of RTKs, even in case of already
maturation-impaired Flt3 ITD receptor. The lack of a dominant negative
effect of the kinase inactive Hck with respect to maturation of Flt3 (Flt3
ITD) is surprising because this mutant does induce a dominant negative
effect with respect to phosphorylation of Flt3. It is possible that, while the
activity of the endogenous SFKs in HEK-293 cells is sufficient to induce
phosphorylation of Flt3, and therefore can be blocked by co-expression of
dominant negative kinase-inactive Hck, endogenous SFKs do not interfere
with maturation of the receptor because a certain threshold of SFK activity
level (above the endogenous level) has to be reached to affect maturation of
Flt3.
If SFKs interfere with the maturation of class III RTKs only when they
are over-expressed or hyperactivated, is this process relevant to a physiologi-
cal situation? Further work is required to answer this question. Cells derived
from Src knock out animals or agents that specifically block the expression
or the kinase activity of SFKs could be used to analyze the maturation and
the biological responses of class III RTKs. SFK-mediated interference with
the maturation of glycoproteins could contribute to the transformation of
cells by over-expression or over-activation of SFKs. SFK activity is associ-
ated with advanced stages of metastatic tumors [239] and activated SFKs
contribute to the metastatic spread of carcinoma cells [25]. It is known that
cell surface carbohydrates affect tumor cell interaction with endothelial cells
and extracellular matrix during metastatic cell growth. Therefore, the SFK-
mediated influence on maturation of glycosylated proteins could be a general
mechanism that contributes to Src-mediated cancer progression. However,
further research is required to test this hypothesis.
4.2 Phosphorylation of Flt3 by Hck
4.2.1 Hck-dependent phosphorylation of Flt3 and Hck associ-
ation with Flt3
This work shows that Hck directly phosphorylates Flt3. As autophospho-
rylated Flt3 also binds Hck via its SH2 domain, it is possible that Hck
binding to Flt3 activates Hck and results in additional phosphorylation of
Flt3 by Hck. It might be technically difficult to prove this point, though.
Hck that can not engage in SH2-dependent protein-protein interactions due
to a point mutation in the SH2 domain (Hck RL) still phosphorylates Flt3.
However, this Hck mutant should be more active than the wild type Hck, so
the absence of an increased phosphorylation of Flt3 by Hck RL (Figure 3.11)
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suggests that binding of Hck to Flt3 promotes the phosphorylation of Flt3 by
Hck. Kinase inactive Hck reduces the basal phosphorylation of Flt3 wt and
ITD obviously acting in a dominant negative fashion. This finding suggests
that endogenous SFKs phosphorylate Flt3. It is surprising, however, that
the kinase inactive Hck reduces a basal level of Flt3 phosphorylation even
when it can not participate in SH2 domain-dependent interactions (Hck KR
RL). Therefore it is possible that in the absence of ligand stimulation, Hck
activated independently of binding to Flt3 or any other SFK-SH2 domain
binding partner(s) also phosphorylates Flt3. One interesting possibility em-
anating from this is that SFKs activated by one receptor can modulate the
signaling by another receptor and therefore participate in cross-talk between
different receptors in a cell.
4.2.2 Consequences of Hck-mediated phosphorylation of Flt3
Flt3 is not the only RTK that serves as a substrate for SFKs. As described
in 1.4.8, SFKs phosphorylate EFGR, PDGRF and IGF-1R to name only
a few, and SFK-mediated phosphorylation can modulate signaling events
downstream of these RTKs and/or increase their catalytic activity. So, what
are the possible consequences of SFK-dependent phosphorylation of Flt3?
This work shows that SFKs phosphorylate Flt3 on tyrosine residues located
in the JM region, including Tyr 589 and Tyr 591. As described in 1.3.4,
phosphorylation of these two tyrosine residues plays a critical role in the
autoinhibition of the catalytic activity of Flt3 by the JM region. The crys-
tal structure of autoinhibitted Flt3 suggests that phosphorylation of one of
these tyrosine residues releases a part of the JM from its binding site within
the catalytic domain of Flt3 and relieves an autoinhibition imposed by the
JM region [75]. In light of this model, Hck-mediated phosphorylation of
Flt3 on Tyr 589 and 591 should promote the activation state of Flt3 and
positively regulate Flt3 signaling. Substitution of the tyrosines in the JM
region of Flt3 by phenylalanines does not completely abolish Hck-mediated
phosphorylation of Flt3 suggesting that Hck phosphorylates Flt3 on addi-
tional tyrosine residues outside of the JM region. The determination of
Hck phosphorylation and autophosphorylation sites of Flt3 and their role in
Flt3-mediated signaling should help to clarify the function of Hck-mediated
phosphorylation of Flt3. As described above, phosphorylation of Flt3 by
Hck in the secretory pathway might cause retention of Flt3 in the secretoty
pathway and block its maturation. This suggests that Hck-mediated phos-
phorylation might have different consequences depending on the localization
of Flt3.
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4.3 Association of Flt3 and Hck
4.3.1 Mechanism of recruitment of Hck to Flt3
This work shows that in addition to phosphorylating tyrosine residues in
the JM region of Flt3, Hck also binds to these tyrosine residues in a SH2-
dependent manner. However, Hck-mediated phosphorylation of Flt3 is not
sufficient for Flt3-Hck association because Flt3 does not bind strongly to Hck
wt that induces its phosphorylation and blocks maturation of the receptor.
It appears that auto-phosphorylation, but not Hck-mediated phosphoryla-
tion of Flt3 creates high affinity binding sites for Hck. In this respect the
interference by Hck with receptor maturation and plasma membrane expo-
sure and the consequence that FL can not bind such intracellularly retained
Flt3 and induce its autophosphorylation might be a reason for the largely
reduced association of Hck wt with Flt3 as compared with the association
of Flt3 with kinase-inactive Hck KR. In line with this is the finding that
the substitution of Tyr 589 and Tyr 591 by phenylalanines decreases the
binding of Flt3 to Hck, but does not abrogate it completely, suggesting
that besides Tyr 589 and Tyr 591 Hck also binds to other sites on auto-
phosphorylated receptor. However, this hypothesis does not explain why
Flt3 ITD which is auto-phosphorylated in the absence of ligand stimulation,
before its final transport to the plasma membrane, does not bind to kinase
active Hck. However, Flt3 ITD’s auto-phosphorylation pattern may differ
from the ligand-induced auto-phosphorylation of Flt3 wt. Additional fac-
tors may contribute to the weakness of the association between Hck and Flt3
when the latter is phosphorylated by Hck and is impaired in its maturation.
For example, membrane localization of both proteins might be required for a
stable interaction. Furthermore, Hck-induced phosphorylation of Flt3 could
create high affinity binding sites for other phospho-tyrosine binding proteins,
whose binding interferes with the binding of Hck to Flt3.
4.3.2 Consequences of Hck recruitment to Flt3
Whatever the reason is, it is clear that auto-phosphorylated Flt3 localized
in the plasma membrane recruits Hck via its SH2 domain. This scenario
most likely takes place only when the activity of SFKs in the cell is rela-
tively low. Under these conditions maturation of Flt3 is not impaired and
its phosphorylation is mostly a consequence of auto-phosphorylation.
Binding of tyrosine-phosphorylated proteins to SFKs leads to their acti-
vation due to the disruption of intramolecular interactions, though activa-
tion of Hck or other SFKs upon stimulation of Flt3 was not proven directly.
However, SFKs were shown to be activated when recruited to other class III
RTKs, strongly suggesting that recruitment to Flt3 would also lead to the
activation of SFKs. Further studies are required to determine activation of
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SFKs downstream of Flt3 and analyze the substrates phosphorylated by the
active SFKs upon their recruitment to Flt3. This work shows that besides
their commonly accepted role in promotion of signaling of RTKs, activated
SFKs might have an additional function of interfering with the maturation
of the receptors which may prevent their own binding to these receptors.
4.4 Interaction of Flt3 with Hck in different cell lines
To understand the biological role of functional and physical interaction of
Hck with Flt3, 32D cl. 3 cell lines co-expressing Flt3 wt (Flt3 ITD) with
kinase inactive, wild type and hyperactive Hck were used in this study. De-
spite a strong effect of Hck on the maturation of Flt3 in HEK-293 cells,
over-expression of either wild type Hck or the hyperactive Hck mutant does
not detectably interfere with the maturation of Flt3 in 32D cl.3 cells. The
data presented in this work suggest that the lower Hck expression levels in
32D cl. 3 cells, as compared with HEK-293 cells, account for the lack of
Hck-mediated interference with Flt3 maturation in 32D cl. 3 cells. This
result is in accordance with the hypothesis that relatively high activity of
SFKs in the cell is required to interfere with the maturation of Flt3 (see
above). Relatively low Hck expression level may also account for the lack of
phosphorylation of Flt3 by Hck in 32D cl. 3 cells. It is surprising though,
that rather high levels of kinase inactive Hck in 32D cl.3 cells did not have
a dominant negative effect on Flt3 phosphorylation in 32D cl.3 cells (Figure
3.18).
Another factor that could account for the lack of Hck-mediated inter-
ference with Flt3 maturation and its phosphorylation by Hck in 32D cl.3
cells involves decreased activity of Hck in 32D cl.3 cells as compared with
HEK-293 cells. In line with this hypothesis is the finding that Hck phospho-
rylation, which usually reflects an increase in the kinase activity, is decreased
in 32D cl.3 cells as compared with HEK-293 cells.
In contrast to the lack of functional interaction between Hck and Flt3,
the lack of association is not likely to be due to the lower Hck expression level
in 32D cl. 3 cells. It is possible that due to a different pool of pre-existing
signaling molecules in 32D cl. 3 cells, Hck binding sites on Flt3 are occupied
by other proteins that bind Flt3 with higher affinity. Additionally, the
activity of phosphatases that de-phosphorylate phospho-tyrosines involved
in Hck binding could be significantly higher in 32D cl.3 than in HEK-293
cells.
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4.5 Concluding remarks
In conclusion, the work presented in this thesis shows that SFKs interfere
with the maturation of Flt3 in a kinase-dependent manner. SFKs also inter-
fere with the maturation Kit, suggesting that this function of SFKs generally
applies to class III RTKs. This work also shows that SFKs phosphorylate
Flt3 and Kit. In case of Flt3, tyrosine residues in the JM region are the
major phosphorylation sites for Hck. According to the crystal structure of
auto-inhibited Flt3, phosphorylation of these sites promotes an active con-
formation of Flt3 by relief of auto-inhibition imposed by the JM region.
It is very likely that SFK-mediated phosphorylation is a reason for the
impaired maturation of Flt3. Further along that line, another group has
recently shown that premature auto-phosphorylation of Flt3 in Flt3 ITD
impairs its maturation and tyrosine phosphatase SHP-1 promotes matu-
ration of the receptor [198]. In accordance with these findings, this work
suggests a regulatory role of SFKs in the control of receptor maturation me-
diated by phosphorylation of the latter. This is the first study that involves
SFKs in the maturation process of class III RTKs.
This work confirms the finding that SFKs associate with the cytoplasmic
part of Flt3 upon auto-phosphorylation of the receptor. However, in con-
trast an earlier study [53], which used chimeric receptor, this work shows
that Flt3 wt as well as Flt3 ITD, associated with the development of AML,
recruit SFKs. Additionally, this work identifies Tyr 589 and Tyr 591 in the
JM region of Flt3 as the binding sites for a Src kinase Hck. This finding
correlates with the binding mode of SFKs to other class III RTKs, which
also recruit SFKs to tyrosines located in their JM regions.
It would be very interesting to understand the mechanism underlying
SFK-mediated interference with the maturation of RTKs and to further
investigate the biological relevance of this novel function of SFKs.
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Abbreviations
The standard IUPAC nucleotide and amino acid codes were used
2-ME 2-mercaptoethanol
A-loop Activation loop
AML Acute myeloid leukemia
AP Assembly particle
APC Antigen presenting cell
APL Acute promyelocytic leukemia
APS Ammonium-persulfate
ATP Adenosine triphosphate
B-ALL B cell acute lymphoblastic leukemia
BCA Bicinchoninic acid
BCR B cell receptor
Blk B lymphoid kinase
BSA Bovine serum albumine
CaMK Calmodulin-sensitive kinase
CCV Clathrin-coated vesicle
cDNA Complementary deoxyribonucleic acid
Chk Csk-homologous kinase
CIP Calf intestine phosphatase
CML Chronic myeloid leukemia
CNX Calnexin
CRT Calreticulin
CSF-1R Colony stimulation factor-1 receptor
Csk C-terminal Src kinase
DC Dendritic cell
DG Diacylglycerol
DMEM Dulbecco’s modified Eagles medium
DNA Deoxyribonucleic acid
DTT Dithiotreithol
ECL Enhanced chemiluminescence
EDTA Ethylenediamine-tetra acetic acid
EGFP Enhanced green fluorescent protein
ER Endoplasmic reticulum
134 Abbreviations
Erk Extracellular regulated kinase
FACS Fluorescence-activated cell sorting
FAK Focal adhesion kinase
FBS Fetal Bovine Serum
FGFR Fibroblast growth factor receptor
Fgr Gardner-Rasheed feline sarcoma
FL Fms like tyrosine kinase-3 ligand
Flt3 Fms like tyrosine kinase-3
Fyn Fgr/Yes-related novel gene product
GAP GTPase-activating protein
GDP Guanosine 5’-Diphosphate
GFP Green fluorescent protein
GST Glutathione S-transferase
GTP Guanosine 5’-Triphosphate
Hck Hematopoietic cell kinase
HEK Human embryonic kidney
HRP Horse radish peroxidase
Ig Immunoglobulin
IGF-1R Insulin growth factor-1 receptor
IL Interleukin
Inst Inositol
IRES Internal ribosomal entry site
ITAM Immunoreceptor tyrosine-based activation motif
ITD Internal tandem duplication
ITIM Immunoreceptor tyrosine-based inhibitory motifs
IUPAC International Union of Pure and Applied Chemistry
JAK Janus kinase
JM Juxtamembrane
LB Luria-Bertani
Lck Lymphocyte-specific protein tyrosine kinase
Lyn Lck/Yes related novel tyrosine kinase
M-CSF Macrophage colony stimulating factor
MAPK Mitogen-activated protein kinase
MDS Myelodysplastic syndrome
mRNA Messenger ribonucleic acid
MVB Multivesicular body
NADPH Nicotinamide adenine dinucleotide phosphate
NK Natural killer
NO Nitric oxide
PAGE Polyacrylamid gel electrophoresis
PCR Polymerase chain reaction
PDGFR Platelet-derived growth factor receptor
PE Phycoerythrin
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PH Pleckstrin homology
PI3-K Phosphatidylinositol 3-kinase
PKB Protein kinase B
PKC Protein kinase C
PLC Phospholipase C
PML Promyelocytic leukemia
PtdInst Phophoinositol
PTP Protein tyrosine phosphatase
RAR Retinoic acid receptor
RNA Ribonucleic acid
RPMI Roswell Park Memorial Institute medium
RTK Receptor tyrosine kinase
SCF Stem cell factor
SDS Sodium dodecyl sulfate
SFK Src family kinase
SH Src homology
SHIP SH2 domain containing inositol polyphosphate 5-phosphatase
SHP SH2 domain phosphatase
siRNA Small interfering ribonucleic acid
Src Raus sarcoma virus proto-oncogene product
STAT Signal transducers and activators of transcription
SV-40 Simian virus 40
TCR T cell receptor
TEMED N,N,N’,N’-Tetra-methylethylenediamine
TKD Tyrosine kinase domain
TM Transmembrane
UDP Uridine diphosphate
wt Wild type
Yes Yamaguchi 73 and Esh avian sarcoma
YFP Yellow fluorescent protein
Yrk Yes-related kinase
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